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Introduction and thesis outline
The number of elderly individuals is expected to rise substantially in the 
coming years, both in developed and less-developed countries. Besides 
improved birth control, a dramatic increase in life expectancy is responsible 
for this rapid aging of the global population [1]. Although the increase in 
life span is an important biomedical and social success, it also poses a 
substantial burden on the health care systems, as the increased life span 
does not keep pace with an increase in health span [1]. Indeed, aging is 
an important risk factor for infections, cardiovascular disease, cancer and 
autoimmunity. Strategies to improve human health span and to minimize 
morbidity during the last phase of life will therefore be a key challenge 
in the decades to come.
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Aging of the immune system
Aging has a profound impact on all organ systems of the human body, including 
the immune system [2]. Current evidence indicates that aging-related changes 
of the immune system contribute to the enhanced risks for infections, cancer, 
autoimmunity and cardiovascular diseases in the elderly [3-8]. In particular the 
balance between inflammatory and anti-inflammatory immune responses seems 
to be important to preserve health in the elderly [9]. This balance, however, may 
become disturbed in the elderly, as both the innate and adaptive arms of the 
immune system are affected by aging.
Aging-associated changes of the innate immune 
system
Neutrophils, monocytes/macrophages, dendritic cells and natural killer cells 
are all part of the innate immune system. The innate immune system not only 
represents the first-line of defence against microbes and malignant cells, but 
also plays an important role in the development of autoimmune diseases [10]. 
Although innate immune cells are largely retained in the elderly, their functions 
change substantially with age [11]. Unfortunately, harmful functions of the innate 
immune system become more prominent in the elderly [12], whereas its anti-
microbial functions deteriorate [13]. For example, neutrophils in aged individuals 
lose their potential to migrate efficiently towards microbes. Inefficiently migrating 
neutrophils in aged subjects promote tissue damage and systemic inflammation 
on their way via premature secretion of their granular content [14]. In addition, 
monocytes/macrophages of aged individuals produce more pro-inflammatory 
cytokines than those of young individuals [15]. Overall, an aging-associated 
increase in chronic, low-grade inflammation, termed ‘inflammaging’ [16], seems 
to contribute to the development of autoimmune diseases in the elderly [7,16], 
while directly compromising anti-microbial immunity [13].
Aging-associated changes of the adaptive immune 
system
The adaptive immune system, which is comprised of T and B cells, provides 
highly effective, antigen-specific immunity against microbes and malignant cells. 
An important characteristic of the adaptive immune system is the development 
of antigen-specific memory upon the first exposure to antigens. Such memory 
develops as naive T or B cells differentiate into memory and effector cells. 
Human adults have typically acquired memory against a wide variety of 
pathogens. However, the development of immune responses and immunological 
memory upon novel antigenic challenges, seems to occur less efficiently in the 
elderly, as indicated by poor vaccine responses [17]. In contrast, inappropriate 
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activation and differentiation of auto-reactive T and B cells seems to increase 
with age, as suggested by increased prevalence of auto-antibodies and T-cell 
driven autoimmune diseases in the elderly [18,19].
Impact of aging on naive T cell homeostasis
T cells provide help (i.e. CD4+ T cells) to other immune cells or directly kill 
(i.e. CD8+ T cells) virally-infected host cells and cancer cells. As T cells require 
activation via their specific T cell receptor, a large and diverse naive T cell 
repertoire is required to deal with a wide variety of microbial and cancer antigens 
[20]. Current data indicate that the naive T cell repertoire is created early in 
life, when substantial thymic output is present [21]. After the second decade of 
life, however, thymic involution occurs and thymic output hardly contributes to 
the maintenance of the naive T cell repertoire. Instead, homeostatic proliferation 
and long-term survival of existing naive T cells is required to maintain the 
naive T cell repertoire later in life [21]. Animal studies indicate that peripheral 
maintenance of naive T cells requires low affinity recognition of self-peptide/major 
histocompatibility complexes and homeostatic cytokines such as interleukin-7 (IL-7) 
[22]. Indeed, IL-7 also promotes the homeostatic proliferation of naive T cells 
in humans, as indicated by therapeutic trials with IL-7 [23]. Other homeostatic 
cytokines, such as interleukin-2 (IL-2) and interleukin-15 (IL-15) are currently 
thought less important for the homeostasis of naive T cells [22]. In addition, 
aging-associated loss of CD31 on naive T cells is considered evidence that human 
naive T cells require T cell receptor engagement for their survival [24]. This line 
of reasoning is further supported by recent data showing that clonal expansion 
of the naive T cell repertoire occurs in aged humans [25]. Intriguingly, naive 
CD4+ T cells are much better maintained in elderly humans than naive CD8+ 
T cells [26]. Detailed mechanistic explanations for this difference are currently 
lacking. A recent study indicated that naive CD4+ T cell numbers in humans are 
predominantly influenced by (unknown) genetic factors, whereas naive CD8+ T cell 
numbers are mostly determined by environmental factors, such as infections [27]. 
Investigating the mechanisms that influence the maintenance of naive T cells 
will help us understand why elderly individuals are susceptible to infections and 
cancer on one hand, and autoimmunity on the other hand. 
Impact of aging on T helper cells and regulatory T cells
When naive T cells recognize their specific antigen in the presence of co-
stimulatory signals (i.e. CD28 engagement by CD80 or CD86), these cells undergo 
activation, proliferation and eventually differentiation into memory and effector 
T cells. Naive CD4+ T cells can differentiate into distinct subsets of T helper 
(Th) cells, such as interferon-J (IFN-J) producing Th1 cells, interleukin-4 (IL-4) 
producing Th2 cells and interleukin-17 (IL-17) producing Th17 cells [28]. This 
polarization process highly depends on the presence of polarizing cytokines 
during the activation of naive CD4+ T cells (Figure 1). In addition, accumulating 
13
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Figure 1. Development of distinct T cell lineages in humans. The effect of polarizing 
cytokines on the development of distinct CD4+ T cell populations is shown. 
evidence indicates that substantial plasticity between these Th subsets exists 
[29]. For instance, Th17 cells can differentiate into Th1 cells when exposed 
to Th1 polarizing cytokines [30]. Although Th cells are important in the host 
defence against different types of microbes, inappropriate activity of these cells 
may contribute to a break of tolerance and ultimately autoimmune diseases 
(Th1, Th2, Th17) and allergies (Th2) [28]. Various studies have shown that Th1 
14
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and Th2 cells are retained with age [31,32]. However, conflicting data have been 
reported with regard to Th17 cells, as both an aging-associated increase and 
decrease of Th17 cells has been reported [33,34].
Regulatory T (Treg) cells represent another specialized population of CD4+ 
T cells (Figure 1). Treg cells suppress the activation, proliferation and effector 
functions of other immune cells [35]. As such, Treg cells represent an important 
constraint on immune responses and inflammation [36]. Currently, two types 
of regulatory T cells are recognised: thymus-derived (natural) Treg cells and 
peripherally-derived (induced) Treg cells [37]. Unfortunately, markers distinguishing 
these two populations of Treg cells are so far lacking. The most important Treg 
cell marker FOXP3 is expressed by both thymus-derived Treg cells and peripherally-
derived Treg cells [35]. Ample evidence indicates that Treg cells increase with 
age [38,39]. Although an increase in Treg cells could be an important adaptation 
against ‘inflammaging’ in the elderly, data from animal studies indicate that 
this adaption develops at the expense of antimicrobial and antitumor responses 
[40-42]. So far, only limited data support this latter notion in humans [43].
Impact of aging on cytotoxic CD8+ T cells
CD8+ T cells are critical in the host defence against viruses and cancer. Upon 
activation, naive CD8+ T cells differentiate into effector-memory CD8+ T cells, 
which directly kill target cells through the release of perforin and granzymes. 
Furthermore, these effector-memory CD8+ T cells produce substantial amounts 
of pro-inflammatory cytokines such as INF-J and TNF-D [44]. For many years, 
aging-associated expansion of differentiated CD8+ T cells was thought to directly 
compromise the naive T cell pool by progressively taking more and more 
‘immunological space’ from naive T cells. Recent studies, however, strongly argue 
against this notion, as absolute numbers of effector-memory CD8+ T cells do not 
expand during adulthood [26,45]. However, latent infection with cytomegalovirus 
(CMV) is associated with an absolute increase in effector-memory CD8+ T cells. 
These virus-specific effector-memory CD8+ T cell may comprise a substantial portion 
of the circulating CD8+ T cell pool in order to restrain CMV reactivation [46,47]. 
Impact of aging on B cells
Historically, B cells were seen as precursor cells for antibody-producing plasma 
cells. This function of B cells is decreased in the elderly, as indicated by a 
poor ability to raise humoral immune responses upon vaccination [17]. During 
the last decade, awareness has grown for B cell functions not directly related 
to their antibody producing capacity. B cells present antigens to T cells and 
can modulate immune responses via secretion of pro-inflammatory (IL-6, TNF-D) 
and anti-inflammatory (IL-10, TGF-E) cytokines (Figure 2) [48]. Currently, a 
strong debate is taking place on whether production of these cytokines defines 
distinct lineages of B cells (i.e. effector B cells and regulatory B cells) or just 
15
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represents a temporary ability that B cells acquire during particular stages of 
differentiation. Enhanced production of pro-inflammatory cytokines by B cells 
has been linked to development of multiple sclerosis and rheumatoid arthritis 
(RA) [49,50], while defective IL-10 production has been observed in systemic 
lupus erythematosus [51]. Interestingly, a recent study indicates that the in vitro 
capacity of B cells to differentiate into IL-10 producing B cells declines with age 
[19]. This decreased ability to produce IL-10 is associated with a steady increase 
in serum autoantibody levels in the elderly. So far, it is unclear whether this 
decrease in IL-10 production only represents an in vitro phenomenon, or that 
aging affects the actual number of IL-10 producing B cells in vivo. Furthermore, 
it remains to be elucidated whether or not aging affects the capacity of B cells 
to produce pro-inflammatory cytokines.
Aging-associated autoimmunity
Aging is associated with development of autoimmunity [18]. The prevalence 
of autoantibodies, such as rheumatoid factors and anti-nuclear antibodies, 
increases with age [52,53]. Common autoimmune diseases, such as giant cell 
arteritis (GCA), polymyalgia rheumatica (PMR) and RA primarily affect the elderly. 
Interestingly, these aging-associated autoimmune diseases not only share a 
predilection for elderly individuals [54,55], but also a genetic background. HLA-DR4 
is the strongest genetic risk factor for both GCA and RA. In addition, HLA-DR4 
has been identified as a risk for PMR in some studies. Notably, most of the 
association between HLA-DR4 and these diseases can be explained by sequences 
Figure 2. Effector and regulatory B cells. Pro-inflammatory effector B cells stimulate 
T cells via secretion of TNF-D and IL-6. Anti-inflammatory regulatory B cells suppress 
T cells via secretion of IL-10 and TGF-E. 
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encoding for amino-acids at the peptide binding grooves of HLA-DR4, which is 
important for antigen presentation to CD4+ T cells [56-58]. In accordance with 
this association, CD4+ T cells play an important role in the pathogenesis of 
GCA and RA [54,55]. Some evidence indicates that T cells may also contribute 
to the development of PMR [59,60]. 
Several processes could explain the development of T-cell driven autoimmune 
diseases in the elderly. Firstly, it is possible that the involuted thymus still 
produces very small amounts of new T cells that are highly auto-reactive. 
Indeed, recent evidence indicates that thymic involution is associated with 
failing negative selection [61]. Secondly, it is possible that auto-reactive T cells 
causing aging-associated autoimmune diseases are actually produced early in 
life and maintained until these diseases are eventually triggered by unknown 
factors. Mechanisms promoting the lifelong maintenance of these T cells would 
therefore be critical for the development of autoimmune diseases later in life. 
Thirdly, it is possible that aging shifts the balance from anti-inflammatory 
immune responses towards pro-inflammatory responses. More specifically, pro-
inflammatory Th cells may predominate over anti-inflammatory Treg cells in the 
CD4+ T cell compartment of elderly individuals. In addition, this imbalance may 
perhaps also be present among other leukocyte populations, such as the B cell 
compartment, as outline above. 
Giant cell arteritis and polymyalgia rheumatica
GCA is a systemic vasculitis affecting large and medium-sized arteries [55]. 
Besides general symptoms of systemic inflammation (such as weight loss and 
fever), GCA patients can develop localized symptoms related to arterial stenosis 
caused by arterial wall inflammation and remodelling: e.g. headache, blindness, 
jaw claudication and stroke. PMR is a closely related rheumatic disease that 
frequently co-occurs with GCA [55]. PMR is associated with synovitis, enthesitis 
and bursitis. PMR patients typically develop pain and stiffness of the shoulders, 
hips and back. An important role for dendritic cells, macrophages and T cells 
has been reported in GCA and PMR [62]. Although cytokine production by B cells 
is implicated in the development of various autoimmune diseases, little is known 
about the contribution of B cells to the pathogenesis of GCA and PMR. Furthermore, 
traditional biomarkers for GCA and PMR, i.e. the erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP) are not always increased during active disease 
in GCA and PMR patients at diagnosis [63,64]. Novel biomarkers for active GCA 
and PMR are therefore awaited. Candidate biomarkers for GCA and PMR would 
not only include pro-inflammatory cytokines in the serum, but also the activation 
state of circulating T cells. Although tremendous progress has been made in the 
discovery of targeted treatments in other autoimmune diseases, corticosteroids 
have remained the only validated treatment for GCA and PMR since the 1950s 
[55]. Unfortunately, corticosteroids are associated with substantial side effects in 
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elderly patients [65]. Thus, identification of novel targets for treatment in GCA 
and PMR patients is needed.
Aim and outline of the thesis
Age is an important risk factor for the development of autoimmune diseases in the 
elderly [18]. This thesis explores aging-associated changes of the adaptive immune 
system and aims to elucidate why aged subjects are susceptible to autoimmune 
disease. Aging-associated autoimmune diseases, such as GCA, PMR and RA are 
considered T cell driven diseases [54,62]. As thymic output dramatically drops 
early in life [21], we postulated that the prolonged maintenance of the naive 
T cell repertoire, associated with ageing, is a critical factor in the development 
of autoimmune diseases in the elderly. 
In chapter 2 important risk factors for aging-associated autoimmunity, i.e. 
HLA-DR4 positivity and female gender were studied in relation to maintenance of 
the naive CD4+ T cell repertoire in aged individuals. In addition, we investigated 
the differential impact of aging and latent CMV infection on distinct CD4+ and 
CD8+ T cell differentiation subsets. 
Chapter 3 provides a mechanistic explanation why the naive CD4+ T cell 
repertoire is significantly better retained in the elderly than the naive CD8+ 
T cell repertoire. More specifically, low affinity T cell receptor stimulation and 
interleukin-2 are identified as factors promoting the maintenance of naive CD4+ 
T cells, but not naive CD8+ T cells. 
Chapter 4 describes the impact of age and CMV on the human T cell receptor 
repertoire. To that end, economic statistics were introduced to measure inequality 
in TCR-VE distribution among well-defined CD4+ and CD8+ T cell differentiation 
subsets. Furthermore, we delineated the effects of vaccination on the naive CD4+ 
and CD8+ T cell repertoire. 
Although a well-maintained balance between pro-inflammatory Th cells and 
anti-inflammatory Treg cells may be critical to preserve health in the elderly 
[66], comprehensive studies investigating the impact of aging on this balance are 
currently lacking. Chapter 5 therefore elucidates how aging affects the balance 
between Th cells and Treg cells, and whether this balance may influence vaccine 
responses in the elderly. 
As accumulating evidence indicates that B cells modulate immune responses 
via secretion of cytokines [48], chapter 6 studies the impact of aging on the 
potential of B cells to produce pro-inflammatory or anti-inflammatory cytokines. 
In addition, B cell cytokine production is studied in relation to the presence of 
autoantibodies in the elderly.  
So far, B cells have received little attention in studies on GCA and PMR. 
In chapter 7, we describe for the first time profound disturbances of B cell 
homeostasis in GCA and PMR patients. Furthermore, the distribution of pro-
inflammatory and anti-inflammatory B cells is explored in these patients. 
18
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Chapters 8 and 9 of this thesis are dedicated to identifying novel biomarkers 
for disease activity in GCA and PMR patients. In chapter 8, we study the 
expression of activation, proliferation and differentiation markers by T cells of 
GCA and PMR patients. In addition, we explored the ability of these markers to 
detect active GCA and PMR. Chapter 9 explores the diagnostic accuracy of 26 
distinct serum proteins as biomarkers for active disease in GCA and PMR patients. 
Finally, chapter 10 provides a summary and discussion of the findings in 
this thesis. 
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Summary
Common autoimmune diseases, such as rheumatoid arthritis and giant 
cell arteritis, primarily affect elderly individuals and have a predilection 
for HLA-DR4 positive females. The development of these CD4 T-cell driven 
autoimmune diseases likely requires lifelong maintenance of auto-reactive 
T cells, as thymic output already drops early in life. Understanding the 
factors that promote the peripheral maintenance of the T cell repertoire 
will therefore help to understand how T-cell driven autoimmune diseases 
develop in the elderly. In a cross-sectional cohort, we observed that age, 
cytomegalovirus (CMV), gender and HLA-DR4 influence the maintenance 
of distinct T cell differentiation subsets. Aging by itself was associated 
with an increase in central memory CD4 T cells and a decrease of naive 
CD8 T cells. CMV seropositive individuals demonstrated increased numbers 
of effector memory CD4 T cells, as well as various memory CD8 T cell 
populations. The risk factors for aging-associated autoimmunity, i.e. female 
sex and HLA-DR4 positivity, were associated with enhanced maintenance 
of the naive CD4 T cell pool in elderly subjects. In addition, synergistic 
effects of female sex and HLA-DR4 positivity on the maintenance of naive 
CD4 T cell numbers were observed. These findings support the notion that 
maintenance of a large T cell repertoire may be required for development 
of T cell-driven autoimmune diseases in the elderly. Furthermore, our 
findings may provide a novel explanation why HLA-DR4 positive females 
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Introduction
Maintenance of a large T cell repertoire is critical for effective immunity in aged 
humans. Indeed, perturbations in the homeostasis of T cells are associated 
with poor vaccine responses and increased risks for infections in the elderly 
[1, 2]. However, maintenance of a large T cell repertoire may also facilitate the 
development of T cell-driven autoimmune diseases in the elderly [3]. Notably, 
the most common autoimmune diseases, such as rheumatoid arthritis and giant 
cell arteritis, primarily affect aged individuals [4]. As thymic output dramatically 
drops after the second decade of life [5], it is likely that auto-reactive T cells are 
maintained over a longer period of time before these cells cause autoimmune 
disease in the elderly. Studying the factors that influence T cell maintenance 
may therefore be important to understand the development of autoimmune 
disease later in life. 
Both heritable and non-heritable factors may influence the numbers of 
circulating CD4 and CD8 T cells [6]. Two well-studied factors that influence the 
number of circulating CD4 and CD8 T cells are aging and latent infection with 
human cytomegalovirus (CMV). In essence, aging is associated with a strong 
decline in naive CD8 T cells, whereas naive CD4 T cells and memory CD4 
and CD8 T cells are barely affected [7-9]. On the other hand, CMV infection 
drives the expansion of virus-specific memory CD4 and CD8 T cells, which 
may represent a substantial part of the circulating memory T cell pool in CMV 
infected individuals [10-15]. 
Gender is another factor that may influence the number of circulating T cells. 
Women are known to possess higher numbers of circulating CD4 T cells than 
men, whereas no gender difference has been observed for CD8 T cells [16-18]. 
So far, it is unclear which CD4 T cell differentiation subsets are affected by 
gender. This would be interesting to know, as CD4 T cell-driven autoimmune 
diseases, such as rheumatoid arthritis and giant cell arteritis, primarily affect 
women [19, 20].
A mostly unexplored factor that could influence the homeostasis of CD4 and CD8 
T cells is HLA-type. HLA genes are highly polymorphic and distinct HLA-molecules 
substantially vary in their ability to present specific antigens to T cells. Antigen 
presentation to T cells is not only important in anti-microbial immune responses 
[21], but also in the physiological homeostasis of T cells [22, 23]. HLA-DR4 is of 
particular interest in this context, as the presence of this HLA-type is not only 
associated with premature immune-aging [24], but also with development of CD4 
T cell-dependent autoimmune diseases in the elderly [19, 20, 25]. 
In the current study, we investigated the impact of age, CMV, gender and 
HLA-DR4 on the maintenance of distinct CD4 T and CD8 T cell differentiation 
subsets in cohort of healthy individuals. Our findings link important risks factors 
for aging-associated autoimmunity, i.e. female sex and HLA-DR4 positivity, to 
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Materials and Methods
Study subjects and samples
Peripheral blood was collected from 100 healthy individuals (age 19-92). Part of the 
study participants were described previously [26]. Study participants underwent medical 
examination, blood testing (general blood count, renal and liver function, glucose, ESR) 
and urinalysis. None of the subjects had a history of recent infection or vaccination, 
malignancy, autoimmune disease, chronic liver or kidney disease, alcohol or drug abuse, 
diabetes mellitus, current pregnancy or immunosuppressive therapy. Clinical and laboratory 
data are provided in Supplemental Table 1. Written informed consent was obtained from 
all study participants and the study was approved by the Medical Ethical Committee of 
the UMCG. All procedures were in accordance with the Declaration of Helsinki. 
Flow cytometry
Whole blood samples were stained with the following monoclonal antibodies: CD3-efluor605, 
CD4-efluor450, (all eBioscience) CD45RO-FITC, CCR7-PE-Cy7, CD8-APC-H7 (BD Biosciences). 
Stained samples were treated with BD Lysing Solution (BD Biosciences) according to 
instructions of the manufacturer and washed with PBS + 1% bovine serum albumin. 
Samples were measured on a LSR-II (BD) and analyzed with Kaluza Analysis Software 
(Beckman Coulter). In addition, absolute numbers of CD3, CD4 and CD8 T cells, CD19 
B cells and CD16/CD56 NK cells were determined according to the MultiTest TruCount 
method (BD), as described by the manufacturer. Data were acquired on a FACSCanto-II 
(BD) and analysed with FACSCanto Clinical Software (BD).
Measurement of CMV-specific IgG
96-well ELISA plates (Greiner) were coated overnight with lysates of CMV-infected fibroblasts. 
Lysates of non-infected fibroblasts were used as negative controls. Following the coating, 
dilutions of serum samples were incubated for 1 hour. Goat anti-human IgG was added 
and incubated for 1 hour. Samples were incubated with phosphatase for 15 minutes and 
the reaction was stopped with NaOH. The plates were scanned on a Versamax reader 
(Molecular Devices). A pool of sera from 3 CMV seropositive individuals with known 
concentrations of CMV IgG was used to quantify CMV IgG in the tested samples.
HLA-typing
DNA was isolated from peripheral blood granulocyte pellets after density centrifugation 
with Lymphoprep (Axis-Shield). HLA-DRB1*04 genotype was analysed by a polymerase chain 
reaction-based sequence-specific oligonucleotide probe hybridization (PCR-SSOP) approach 
with commercial kits (Gen-Probe) and Luminex xMAP technology (Luminex Corp.). These 
assays were performed according to instructions of the manufacturer in a laboratory 
accredited by the European Federation for Immunogenetics. HLA genotype was ascertained 
according to the manufacturer’s instructions using the software of the manufacturer and 
additionally by the SCORE software, as previously described [27]. 
Statistics
The Mann Whitney U test was used to compare individuals grouped according to CMV 
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rank correlation coefficient. Univariate and multivariable linear regression analysis were 
used to investigate the impact of age, gender, and CMV serostatus on numbers of CD4 
and CD8 T cell differentiation subsets. Only variables with p < 0.3 in the univariate linear 
regression analyses were used in the multivariate linear regression analysis. Non-normally 
distributed outcome variables were transformed (log or square root). These analyses were 
also used to explore whether the HLA-DR4 type is associated with CD4 T cell differentiation 
subsets in aged humans. Analysis were performed with SPSS 20.0 Software and GraphPad 
Prism 5.0. P-values less than 0.05 were considered significant.
Results
Characteristics of study subjects
Subjects’ characteristics are shown in Supplemental Table 1. The age groups 
demonstrated a similar distribution of gender and CMV serostatus. Furthermore, 
biochemical and immune parameters did not differ significantly between the 
age groups. 
Effect of age on circulating CD4 and CD8 T cell differentiation 
subsets
Absolute numbers of CD4 and CD8 T cells were determined in the peripheral 
blood of the healthy individuals (age 19-92). CD4 T cell numbers did not 
significantly change with age, whereas the absolute number of CD8 T cells 
declined (Fig. 1A). Consequently, the ratio between CD4 and CD8 T cells increased 
with age (Fig. 1B). Next, CD4 and CD8 T cells were further divided into naive 
(TNaive), central memory (TCM), effector memory (TEM) and terminally differentiated 
memory (TTD) cells, based on CD45RO and CCR7 expression (Supplemental Fig. 1). 
Absolute numbers of CD4 TNaive cells slightly decreased with age, whereas CD4 
TCM cells showed a modest increase (Fig. 1C). Aging did not affect the absolute 
numbers of circulating CD4 TEM and TTD cells. While CD8 TNaive cells profoundly 
decreased with age, absolute numbers of CD8 TCM, TEM and TTD cells were stable 
(Fig. 1D). Thus, aging imposes different effects on distinct CD4 and CD8 T cell 
differentiation subsets. 
Effect of CMV on circulating CD4 and CD8 T cell differentiation 
subsets
Subsequently, we determined the impact of CMV infection on total numbers 
of circulating CD4 and CD8 T cells. Total CD4 T cell counts were comparable 
in CMV seropositive (CMV+) and seronegative (CMV-) individuals (Fig. 2A). In 
contrast, CMV+ individuals demonstrated higher numbers of CD8 T cells than 
CMV- individuals. Consequently, CMV+ individuals showed lower CD4/CD8 ratios 
than CMV- individuals (Fig. 2B). We next compared absolute numbers of CD4 and 
CD8 T cell differentiation subsets between CMV+ and CMV- individuals. Whereas 
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Absolute numbers of CD4 and CD8 T cells, (B) the CD4/CD8 ratio, (C) absolute numbers 
of CD4 T cell differentiation subsets and (D) absolute numbers of CD8 T cell differentiation 
subsets in the peripheral blood of 100 healthy individuals of different ages (19-92). T cell 
differentiation subsets were identified by expression of CD45RO and CCR7: TNaive (CD45RO-
CCR7+), TCM (CD45RO+CCR7+), TEM (CD45RO+CCR7-) and TTD (CD45RO-CCR7-). Correlations 
were determined with Spearman’s correlation coefficient. Spearman’s rho and p values 
are shown in the respective graphs.
CMV- donors, the number of CD4 TEM cells was increased in CMV+ individuals 
(Fig. 2C). CMV+ individuals also showed higher numbers of CD8 TCM, CD8 TEM 
and CD8 TTD cells than CMV- individuals (Fig. 2D). In contrast, CMV infection did 
not affect the size of the CD8 TNaive compartment, as the absolute number of 
these cells was similar in CMV+ and CMV- individuals. Thus, CMV infection was 
associated with expansion of memory T cell subsets, while TNaive cell numbers 
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Effect of gender on circulating CD4 and CD8 T cell differentiation 
subsets
To determine whether gender influences the number of circulating T cells, we 
compared absolute numbers of CD4 and CD8 T cells between male and female 
donors. Male donors demonstrated substantially lower numbers of circulating 
CD4 T cells than female donors (Fig. 3A). In contrast, we observed no differences 
between CD8 T cell numbers in men and women. Although CD4/CD8 T cell ratios 
tended to be slightly lower in male donors than female donors, this difference 
did not reach statistical significance (Fig. 3A-B). Notably, the age of male and 
female donors was similar. The higher number of circulating CD4 T cells in 
female donors could be attributed to higher numbers of circulating CD4 TNaive 
cells in women (Fig. 3C). Numbers of other CD4 and CD8 T cell differentiation 
subsets were similar in male and female donors. 
Figure 2. Effect of CMV on absolute numbers of T cell differentiation subsets. (A) 
Absolute numbers of CD4 and CD8 T cells, (B) the CD4/CD8 ratio, (C) absolute numbers 
of CD4 T cell differentiation subsets and (D) absolute numbers of CD8 T cell differentiation 
subsets in the peripheral blood of 53 CMV seropositive (CMV+) and 47 CMV seronegative 
(CMV-) individuals. Median age for CMV+ donors was 63 (range 19-84) and for CMV- donors 
63 (range 20-92). Statistical significance by Mann Whitney U test is indicated as * p < 
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Figure 3. Effect of gender on absolute numbers of T cell differentiation subsets. (A) 
Absolute numbers of CD4 and CD8 T cells, (B) the CD4/CD8 ratio, (C) absolute numbers of 
CD4 T cell differentiation subsets and (D) absolute numbers of CD8 T cell differentiation 
subsets in the peripheral blood of 72 female donors and 28 male donors. Median age 
for female donors was 63 (range 19-92) and for male donors 63 (range 20-82). Statistical 
significance by Mann Whitney U test is indicated as * p < 0.05.
Independent effects of age, CMV and gender on circulating T cell 
differentiation subsets
To determine whether age, CMV and gender independently influence the numbers 
of circulating CD4 and CD8 T cell differentiation subsets, we next performed 
multivariate linear regression analyses (Table 1). Age was an independent 
predictor for the numbers of CD4 TCM and CD8 TNaive cells. CMV serostatus was 
an independent predictor for the numbers of CD4 TEM, CD8 TCM, CD8 TEM and CD8 
TTD cells. CMV serostatus almost reached statistical significance as a predictor 
for CD4 TTD cell numbers. In this multivariate linear regression analysis, gender 
was not only an independent predictor for CD4 TNaive cell numbers, but also for 
CD8 TNaive cell numbers. Although only part of the variance in numbers of CD4 
and CD8 T cell differentiation subsets was accounted for in our models, these 
findings demonstrate that age, CMV and gender exert independent effects on 
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Effects of HLA-DR4 on CD4 TNaive cell maintenance in elderly individuals
Recent data indicate that genetic factors strongly influence the number of 
circulating CD4 TNaive cells in humans [6]. We hypothesised that HLA-type could 
represent such a genetic factor, as peptide presentation by HLA-molecules is 
important for the homeostasis of TNaive cells [22, 23]. In this context, HLA-DR4 may 
be of particular interest, as HLA-DR4 has been linked to premature senescence 
Table 1. Univariate and multivariate linear regression analysis for absolute numbers 






B (95% CI) p-value
Multivariate analysis 
B (95% CI) p-value
CD4 TNaive 
(109/L)
Age (years) -0.002 (-0.004 – 0.001) 0.147 -0.002 (-0.004 – 0.001) a 0.178
CMV status -0.052 (-0.116 – 0.038) 0.230 -0.064 (-0.125 – 0.041) a 0.194
Gender -0.088 (-0.152 – 0.003) 0.057 -0.107 (-0.162 – -0.002) a 0.047
CD4 TCM 
(109/L)
Age (years) 0.002 (0.001-0.004) 0.002 0.002 (0.001 – 0.003) b 0.002
CMV status 0.038 (-0.018 – 0.105) 0.197 0.026 (-0.014 – 0.085) b 0.249
Gender -0.028 (-0.083 – 0.039) 0.382 †
CD4 TEM 
(109/L)
Age (years) 0.000 (-0.001 – 0.002) 0.613 †
CMV status 0.062 (0.020 – 0.114) 0.002 0.061 (0.019 – 0.115) c 0.002
Gender -0.029 (-0.063 – 0.017) 0.189 -0.022 (-0.049 – 0.020) c 0.266
CD4 TTD 
(109/L)
Age (years) 0.000 (0.000 – 0.000) 0.863 †
CMV status 0.003 (0.000 – 0.009) 0.079 (-)
Gender -0.002 (-0.003 – 0.002) 0.316 †
CD8 TNaive 
(109/L)
Age (years) -0.005 (-0.005 – -0.004) 0.000 -0.005 (-0.005 – -0.005) d 0.000
CMV status 0.000 (-0.020 – 0.031) 0.994 †
Gender -0.023 (-0.040 – 0.005) 0.100 -0.041 (-0.068 – -0.006) d 0.026
CD8 TCM 
(109/L)
Age (years) 0.000 (0.000 – 0.000) 0.846 †
CMV status 0.005 (0.001 – 0.013) 0.010 (-)
Gender 0.001 (-0.002 – 0.008) 0.599 †
CD8 TEM 
(109/L)
Age (years) 0.000 (-0.001 – 0.001) 0.698 †
CMV status 0.053 (0.016 – 0.101) 0.003 (-)
Gender 0.003 (-0.033 – 0.050) 0.874 †
CD8 TTD 
(109/L)
Age (years) 0.000 (0.000 – 0.001) 0.926 †
CMV status 0.065 (0.028 – 0.134) 0.000 (-)
Gender 0.002 (-0.019 – 0.050) 0.878 †
Gender: 0 = female, 1 = male. CMV: status 0 = seronegative, 1 = seropositive. a model R2 = 0.073. b model R2 = 0.110. 
c model R2 = 0.106. d model R2 = 0.582. † not tested in multivariate analysis due to p > 0.3 in univariate regression 
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of leukocytes [24] and the development of aging-associated autoimmune diseases 
[25]. Therefore, we analysed a subgroup of 53 elderly individuals (median age 
68, range 58-84) for presence of the HLA-DR4 type. 
In total, 19 out of 53 donors were HLA-DR4 positive (HLA-DR4+). Interestingly, 
HLA-DR4+ individuals demonstrated higher numbers of CD4 TNaive cells than 
HLA-DR4 negative (HLA-DR4-) individuals (Fig. 4A). In addition, the presence 
of HLA-DR4 was also associated with higher numbers of CD4 TTD cells. In 
contrast, HLA-DR4+ and HLA-DR4- individuals showed similar numbers of CD4 
TCM and CD4 TEM cells, as well as CD8 T cell differentiation subsets (Fig. 4A-B). 
When assessing the joint effects of gender and HLA-DR4, we observed that 
HLA-DR4+ women demonstrated the highest numbers of circulating CD4 TNaive 
cells among the elderly subjects studied (Fig. 4C). Moreover, after adjustment 
for age, gender, and CMV serostatus in multivariable linear regression analysis, 
the presence of HLA-DR4 proved to be an independent predictor of higher 
CD4 TNaive cell numbers (Table 2). Taken together, our findings indicate that 
presence of HLA-DR4 is associated with enhanced maintenance of CD4 TNaive 
cells in the elderly.
Figure 4. T cell numbers in HLA-DR4+ and HLA-DR4- 
individuals. (A) Absolute numbers of CD4 T cell 
differentiation subsets and (B) CD8 T cell differentiation 
subsets in the peripheral blood of 19 HLA-DR4 positive 
(HLA-DR4+) and 34 HLA-DR4 negative (HLA-DR4-) individuals. 
Median age for HLA-DR4+ donors was 68 (range 59-82) 
and for HLA-DR4- donors 69 (range 58-84). (C) Absolute 
numbers of CD4 TNaive cells in HLA-DR4+ women (n = 12), 
HLA-DR4+ men (n = 7), HLA-DR4- women (n = 26) and 
HLA-DR4- men (n = 8). Boxplot and whiskers are drawn 
according to Tukey method. Statistical significance by Mann 
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Table 2. Univariate and multivariate linear regression analysis for absolute numbers 





Univariate analysis         
B (95% CI) p-value
Multivariate analysis   
B (95% CI) p-value
CD4 TNaive 
(109/L)
Age (years) -0.016 (-0.017 – -0.002) 0.033 -0.015 (-0.017 – -0.002) 0.031 a
CMV status -0.109 (-0.176 – 0.009) 0.066 -0.227 (-0.225 – -0.052) 0.021 a
Gender -0.081 (-0.164 – 0.056) 0.208 -0.236 (-0.239 - -0.030) 0.033 a
HLA-DR4 0.134 (0.009 – 0.308) 0.033 0.328 (0.062 – 0.780) 0.005 a
CMV status: 0 = seronegative, 1 = seropositive. Gender: 0 = female, 1 = male. HLA-DR4: 0 = 1 HLA-DR4 negative, 
1 = HLA-DR4 positive. a model R2 = 0.297. 
Discussion
Maintenance of a large T cell repertoire may facilitate the development of 
autoimmune diseases in the elderly [3]. In the current study, we investigated the 
impact of multiple factors on the maintenance of well-defined T cell populations. 
We observed that age, CMV and gender independently influence the maintenance 
of distinct CD4 and CD8 T cell differentiation subsets in adult humans. Moreover, 
we obtained evidence that HLA-DR4 is associated with increased maintenance 
of CD4 TNaive cells in the elderly. 
Age primarily affected the absolute numbers of circulating CD8 TNaive and CD4 
TCM cells and only showed a very modest effect on the number of CD4 TNaive 
cells. The remarkable preservation of CD4 TNaive cells in aged humans indicates 
that these cells are well maintained in the periphery. We recently observed 
that low affinity TCR-engagement induces upregulation of the IL-2 receptor and 
promotes IL-2 dependent post-thymic maintenance of CD4 TNaive cells, but not 
of CD8 TNaive cells [28]. Of interest, it has been proposed that TCR-dependent 
homeostasis of T cells promotes the selection of auto-reactive T cells over time, 
and results in autoimmune disease later in life [29]. Earlier studies indicated that 
circulating memory CD8 T cells increase at the expense of naive CD8 T cells in 
aged individuals, presumably via occupation of ‘immunological space’. This notion, 
however, was based on studies enumerating percentages of T cell subsets rather 
than absolute numbers. In accordance with two recent studies [7, 8], we here 
provide evidence against the ‘immunological space’ concept: although absolute 
numbers of CD8 TNaive cells decline with age, absolute numbers of memory CD8 
T cells do not expand. The substantial, aging-associated loss of CD8 TNaive cells 
may impair immune responses in the elderly [30]. 
Latent CMV infection has profound effects on the human T cell repertoire 
[10, 15] and CMV-specific memory T cells may comprise a substantial part of the 
circulating T cell pool in CMV+ individuals [10-14]. In our study, CMV infection 
in otherwise healthy individuals was associated with the expansion of CD4 TEM 
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we show that absolute numbers of CD4 and CD8 TNaive cells are not substantially 
affected by CMV. Nevertheless, we observed a slight negative effect of age on 
CD4 TNaive cell numbers, when our analysis was restricted to aged subjects. 
These discrepant findings may be explained by an aging-associated decrease 
of CD4 TNaive cells that was recently observed in CMV+ individuals, but not in 
CMV- individuals [7]. 
Gender represents a genetic factor that may explain the numerical variations 
in circulating T cells. Ample evidence indicates that women possess higher 
numbers of circulating CD4 T cells in comparison to men, whereas numbers of 
CD8 T cells are not influenced by gender [16, 17]. We here confirm and extend 
these findings. So far, little was known about the influence of gender on well-
defined CD4 and CD8 T cell differentiation subsets. In the current study, we 
show that female gender is associated with enhanced maintenance of CD4 TNaive 
cells and to a lesser extent CD8 TNaive cells. No gender effects were observed 
for memory CD4 and CD8 T cell subsets. Differences in TNaive cell homeostasis 
between men and women may be at least partly explained by effects of sex 
hormones on the immune system [18]. The enhanced maintenance of TNaive cells 
in women is interesting, as women are in general less susceptible to infections 
than men, while being more prone to develop autoimmune diseases [18]. 
We here identify HLA-DR4 as a heritable factor associated with enhanced 
maintenance of CD4 TNaive cells in elderly individuals. HLA-molecules not only 
present microbial peptides to T cells during infections [21], but also promote the 
homeostatic proliferation of T cells by low-affinity presentation of self-peptides 
[22, 23]. Interestingly, we observed that the HLA-DR4 type was associated with 
higher numbers of CD4 TNaive cells in elderly donors. Previous studies have shown 
that CD4 T cells of HLA-DR4+ healthy individuals demonstrate a higher replicative 
history [24]. As self-peptide/HLA driven homeostasis may promote the selection 
of auto-reactive T cells [29], our results could indicate that the HLA-DR4 type 
in particular is associated with maintenance of auto-reactive CD4 TNaive cells in 
adult humans. Interestingly, aberrant presentation of self-peptides by HLA-DR4 
is thought to promote the development of autoimmune diseases in the elderly 
[25]. The combined effects of female gender and HLA-DR4 on the peripheral 
maintenance of CD4 TNaive is of special interest, as HLA-DR4+ women in particular 
are prone to develop CD4 T cell-dependent autoimmune diseases at old age 
[19, 20]. It remains to be established if aged subjects carrying HLA-DRB1*0401 
and *0404 suballeles, which are associated with development of autoimmune 
diseases [25], also show enhanced maintenance of the CD4 TNaive cell pool. 
Conclusions
In the current study, we show that age, CMV, gender and HLA-DR4 independently 
influence the maintenance of circulating T cell differentiation subsets in humans. 
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associated autoimmune disease, are associated with enhanced maintenance 
of the CD4 TNaive cell pool in the elderly. Our findings may provide a novel 
explanation why HLA-DR4+ females are susceptible for developing CD4 T cell-
mediated autoimmune diseases later in life. 
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No. 25 19 56 100
Age, yrs, mean ± SD 27 ± 6 55 ± 5 70 ± 7 57 ± 19
No. Male (%) 7 (28) 5 (26) 16 (29) 28 (28)
No. CMV seropositive (%) 13 (52) 10 (53) 30 (54) 53 (53)
Hemoglobin, mmol/L, mean ± SDa 8.5 ± 0.6 8.6 ± 0.8 8.8 ± 0.6 8.7 ± 0.7
Leukocyte count, 109/L, mean ± SDa 5.0 ± 1.5 5.5 ± 1.5 5.9 ± 1.5 5.7 ± 1.5
Thrombocyte count, 109/L, mean ± SDa 259 ± 70 240 ± 50 231 ± 51 237 ± 55
ESR, mm/hr, mean ± SDa 7 ± 5 9 ± 5 10 ± 6 9 ± 6
T cell count, 109/L, mean ± SD 1.44 ± 0.54 1.41 ± 0.45 1.33 ± 0.46 1.37 ± 0.48
NK cell count, 109/L, mean ± SD 0.27 ± 0.15 0.29 ± 0.18 0.30 ± 0.15 0.29 ± 0.15
B cell count, 109/L, mean ± SD 0.25 ± 0.15 0.24 ± 0.12 0.21 ± 0.13 0.23 ± 0.13
Creatinine, μmol/L, mean ± SDa 68 ± 11 72 ± 11 71 ± 13 71 ± 12
ASAT, U/L, mean ± SDa 23 ± 4 26 ± 6 25 ± 6 25 ± 6
ALAT, U/L, mean ± SDa 17 ± 4 22 ± 6 22 ± 8 22 ± 7
No. = number. ESR = erythrocyte sedimentation rate. ASAT = aspartate aminotransferase. ALAT = alanine 
transaminase. SD = standard deviation. a performed in 12/25 young individuals, 18/19 intermediate age individuals 
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Supplemental Figure 1. Flow cytometric gating for CD4 and CD8 T cell differentiation 
subsets. Representative flow cytometric staining for CD45RO and CCR7 is shown for 
CD4 T cells (A) and CD8 T cells (B). Based CD45RO and CCR7 expression the following 
T cell differentiation subsets were identified: naive T cells (TNaive; CD45RO-CCR7+), central 
memory T cells (TCM; CD45RO+CCR7+), effector memory T cells (TEM; CD45RO+CCR7-) and 
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Summary
Insight into the maintenance of naive T cells is essential to understand 
defective immune responses in the context of aging and other immune 
compromised states. In humans, naive CD4+ T cells, in contrast to CD8+ 
T cells, are remarkably well retained with aging. Here, we show that low-
affinity TCR engagement is the main driving force behind the emergence 
and accumulation of naive-like CD4+ T cells with enhanced sensitivity to 
IL-2 in aged humans. In vitro, we show that these CD45RA+CD25dimCD4+ 
ʶ˅ˇˎˎ˕˅˃ːˆˇ˘ˇˎˑ˒ˈ˔ˑˏ˅ˑː˘ˇː˖ˋˑː˃ˎː˃ˋ˘ˇʥʦʔʗ˵ʥʦʖʍʶ˅ˇˎˎ˕˗˒ˑː
CD3 cross-linking alone, in the absence of costimulation, rather than via 
stimulation by the homeostatic cytokines IL-2, IL-7, or IL-15. In vivo, TCR 
engagement likely occurs in secondary lymphoid organs as these cells 
were detected in lymph nodes and spleen where they showed signs of 
recent activation. CD45RA+CD25dimCD4+ T cells expressed a broad TCRVE 
repertoire and could readily differentiate into functional T helper cells. 
Strikingly, no expansion of CD45RA+CD25dimCD8+ T cells was detected 
with aging, thereby implying that maintenance of naive CD4+ T cells is 
uniquely regulated. Our data provide novel insight into the homeostasis 
of naive T cells and may guide the development of therapies to preserve 
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Introduction
A broad naive T cell repertoire is essential for optimal immunity against novel 
antigenic challenges (Nikolich-Zugich et al., 2004; Goronzy et al., 2007; Blackman 
& Woodland, 2011). Contractions of the T cell repertoire have been linked to 
poor immunity in the context of aging, stem cell transplantation, cancer, and HIV 
infection (Gorochov et al., 1998; Maury et al., 2001; Saurwein-Teissl et al., 2002; 
Baum et al., 2012; Manuel et al., 2012). To develop strategies for preserving and 
restoring the naive T cell repertoire, insight into the basic mechanisms driving 
naive T cell homeostasis is critical.
So far, most knowledge on the homeostasis of naive T cells is derived from 
mouse studies (Surh & Sprent, 2008). Mechanisms of naive T cell maintenance, 
however, differ substantially in mice and men (den Braber et al., 2012). Whereas 
thymic output in mice is sustained on to high age, thymic involution drastically 
reduces T cell replenishment in adult humans (den Braber et al., 2012). Maintenance 
of the naive T cell pool in humans therefore relies on low-grade proliferation and 
long-term survival of already existing naive T cells in the periphery (Bains et al., 
2009; den Braber et al., 2012). Furthermore, a clear difference has been noted 
between the maintenance of naive CD4+ and CD8+ T cells in humans (Goronzy 
et al., 2007). Whereas circulating numbers of naive CD8+ T cells decline with 
age, naive CD4+ T cells are remarkably well retained (Wertheimer et al., 2014). 
So far, little is known about the mechanisms underlying this difference.
Two types of signals are thought to drive the peripheral homeostasis of naive 
CD4+ T cells in humans (Kohler & Thiel, 2009). The first are T-cell receptor 
(TCR)-derived signals, as evidenced by an increase in naive CD4+ T cells lacking 
CD31 in aged humans (Kimmig et al., 2002). CD31 (PECAM-1) is expressed by 
recent thymic emigrant naive CD4+ T cells (CD31+ naive CD4+ T cells) but is 
lost upon TCR-derived signaling only (Kohler et al., 2005; Azevedo et al., 2009). 
In addition, homeostatic cytokines can promote the maintenance of naive CD4+ 
T cells. IL-7 promotes the expansion and survival of human, naive CD4+ T cells 
(Sportes et al., 2008). Other cytokines such as IL-2 and IL-15 have long been 
thought less important for the homeostasis of naive CD4+ T cells (Rochman 
et al., 2009).
Recently, a novel population of naive CD4+ T cells expressing the IL-2RD 
chain (CD25) was observed in peripheral blood of aged humans (Pekalski et al., 
2013). These naive CD4+ T cells were characterized by an enhanced response 
to IL-2 and were thought to develop after IL-7 stimulation (Pekalski et al., 2013). 
Yet, important questions regarding the origin and functional relevance of these 
cells remain to be answered. Here, we performed an extensive phenotypical 
and functional analysis of aging-associated CD25-expressing naive CD4+ T cells. 
Furthermore, the effects of TCR stimulation and homeostatic cytokines on the 
in vitro development of CD25-expressing naive CD4+ T cells were evaluated. 




aintenance of naive CD4+ T cells by TCR engagem
ent and IL-2
different types of human, lymphoid tissues were analysed. Finally, we assessed 
the functionality of CD25-expressing naive CD4+ T cells in aged humans.
Results
Maintenance of naive CD4+ T cells but not naive CD8+ T cells in 
aged humans
We first assessed the numbers of naive CD4+ and CD8+ T cells in peripheral 
blood of healthy adults of different ages. Donors were divided according to CMV 
serostatus, as CMV infection may influence naive T-cell numbers (Wertheimer 
et al., 2014). Naive CD4+ and CD8+ T cells were identified as CD45RO-CCR7+ 
cells (Fig. 1A), co-expressing CD45RA and CD27 (data not shown). As recently 
reported (Wertheimer et al., 2014), the proportions and absolute numbers of 
naive CD8+ T cells correlated inversely with age in both CMV-seropositive and 
CMV-seronegative individuals (Figs 1B and S1). In contrast, the proportions and 
absolute numbers of naive CD4+ T cells only demonstrated an aging-associated 
decrease in CMV-seropositive, but not in CMV-seronegative, individuals. Thus, 
aging by itself is associated with a loss of naive CD8+ T cells, but not naive 
CD4+ T cells.
Figure 1. Maintenance of naive CD4+ T cells and loss of naive CD8+ T cells in 
aged humans. (A) Representative flow cytometric staining of naive (CD45RO-CCR7+) CD4+ 
and CD8+ T cells in a young and aged individual. The percentage of naive cells among 
CD4+ and CD8+ T cells is shown. (B) Proportions of naive CD4+ and CD8+ T cells as a 
function of age in 52 CMV-seropositive and 39 CMV-seronegative healthy, adult humans. 
Donor ages ranged between 20 and 92. Correlations were tested with Spearman’s rank 
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CD45RA+CD25dimCD4+ T cells accumulate in the circulation of aged 
humans
Next, we sought to confirm that aging is associated with an increase in CD25-
expressing naive CD4+ T cells (Pekalski et al., 2013). Therefore, a CD45RA/CD25-
based gating strategy allowing delineation of functionally distinct populations of 
naive and memory CD4+ T cells was applied (Miyara et al., 2009). Naive CD25-CD4+ 
T cells and naive CD25int regulatory T (Treg) cells were readily detected in peripheral 
blood of adult humans (Fig. 2A) (Miyara et al., 2009). The proportions of both cell 
Figure 2. Accumulation of CD45RA+CD25dimCD4+ T cells in peripheral blood of 
aged humans. (A) Flow cytometric gating strategy for analysis of CD45RA and CD25 
defined subsets in peripheral blood, as reported by Miyara et al. (Miyara et al., 2009). 
Representative flow cytometry plots are shown for a young and an aged individual. (B) 
Proportions of circulating naive CD25-CD4 T cells, (C) naive CD25int regulatory T (Treg) 
cells, and (D) CD45RA+CD25dimCD4+ T cells in 63 healthy, adult humans of different ages. 
(E) Absolute numbers of CD45RA+CD25dimCD4+ T cells in 58 individuals of different ages. 
(F) Representative staining for CD45RA and CD25 in naive CD45RO-CD27+CD8+ T cells of 
a young and aged individual. (G) Proportions of circulating naive CD45RA+CD25dimCD8+ 
T cells in 44 healthy, adult humans of different ages. Correlations were assessed with 
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populations, however, gradually decreased with age (Fig. 2B and C). Interestingly, 
the aging-associated increase in CD25-expressing naive CD4+ T cells could be 
entirely attributed to the development of CD45RA+CD25dimCD4+ T cells. Not only 
the proportions but also the absolute numbers of CD45RA+CD25dimCD4+ T cells 
increased with age (Fig. 2D and E). CD45RA+CD25dimCD4+ T cells accumulated 
in aged humans irrespective of gender and CMV serostatus (Fig. S2). Although 
some dim expression of CD25 was observed among CD45RA+CD8+ T cells (Fig. 
2F), CD45RA+CD25dimCD8+ T cells did not accumulate in the peripheral blood 
of aged humans (Fig. 2G). Thus, the expansion of CD45RA+CD25dim cells with 
aging was restricted to the CD4+ T cell compartment.
CD45RA+CD25dimCD4+ T cells display a naive phenotype
Additional phenotypical analysis showed that CD45RA+CD25dimCD4+ T cells 
were not late-stage memory T cells that re-express CD45RA and lack CD27 and 
CD28 (Fig. S3A). Like naive CD25- cells, CD45RA+CD25dimCD4+ T cells showed 
high expression of CCR7 and limited expression of CXCR3 and CCR6 (Fig. S3B). 
These findings indicated that CD45RA+CD25dimCD4+ T cells are indeed naive 
CD4+ T cells. Furthermore, CD45RA+CD25dimCD4+ T cells could produce some 
IL-2, but not IFN-J, IL-4, or IL-17, upon short-term stimulation with PMA and 
calcium ionophore (Fig. S3C). This cytokine profile was similar to that of naive 
CD25-CD4+ T cells. CD45RA+CD25dimCD4+ T cells also lacked expression of 
Treg cell markers FOXP3, Helios, and IL-10, as well as the activation marker 
CD69 (Fig. S3D and E). Thus, CD45RA+CD25dimCD4+ T cells represented naive 
CD4+ T cells rather than Treg cells or recently activated T cells.
CD45RA+CD25dimCD4+ T cells show signs of prior TCR engagement
Although peripheral blood CD45RA+CD25dimCD4+ T cells lacked expression of 
CD69, we found evidence for prior in vivo activation of these cells. Already in 
our first analysis (Fig. 2A), a somewhat lower per-cell expression level of CD45RA 
was noted on CD45RA+CD25dimCD4+ T cells than on naive CD25-CD4+ T cells. 
CD45RA to CD45RO transgression typically occurs upon TCR stimulation of naive 
T cells (Kristensson et al., 1992; Geginat et al., 2001). Analysis of CD45 isoforms 
confirmed the reduced per-cell expression of CD45RA, and slightly enhanced 
expression of CD45RO, on CD45RA+CD25dimCD4+ T cells when compared to 
naive CD25-CD4+ T cells (Fig. 3A and data not shown). Although the CD45RO 
expression on CD45RA+CD25dimCD4+ T cells was markedly lower than on memory 
CD4+ T cells, we also observed that around 20% of CD45RA+CD25dimCD4+ 
T cells demonstrated a CD45RAintCD45ROint phenotype vs. only 10% of naive 
CD25-CD4+ T cells (Fig. 3B). These data imply prior in vivo TCR engagement of 
CD45RA+CD25dimCD4+ T cells.
Next, we sought to obtain in vitro evidence that TCR-derived signals drive the 
development of CD45RA+CD25dimCD4+ T cells. Indeed, CD45RA+CD25dim cells 
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only (Fig. 3C). These in vitro CD45RA+CD25dimCD4+ T cells also demonstrated 
slightly modulated expression of CD45 isoforms (Fig. 3D). In contrast, combined 
CD3/CD28 cross-linking largely resulted in complete differentiation of naive 
CD25-CD4+ T cells into CD45RA-CD45RO+ memory cells and high CD25 expression 
(Fig. 3C and D). Neither IL-2 (Fig. 3C) nor IL-15 (data not shown) induced CD25 
Figure 3. CD45RA+CD25dimCD4+ T cells show signs of prior TCR engagement. (A) 
Flow cytometric staining for CD45RA in CD45RA+CD25dim and naive CD25- CD4+ T cells 
(left panel) and mean fluorescence intensity (MFI) of CD45RA in naive CD25-CD4+ T cells, 
CD45RA+CD25dim CD4+ T cells, naive CD25int regulatory T cells, and memory (Mem) 
CD4+ T cells of 15 aged individuals. (B) Gating for CD45RAintCD45ROint CD4+ T cells 
(left panel) and proportions of these cells in the 3 CD45RA+CD4+ T-cell subsets of aged 
individuals. (C) Development of CD45RA+CD25dim cells from naive CD25-CD4+ T cells 
and (D) expression of CD45 isoforms upon 6 days of culture with plate-bound anti-CD3 
˃ː˖ˋ˄ˑˆˋˇ˕ʊ˒ˎ˃˖ˇ˅ ˑ˃˖ˇˆ˃ ˖ʓ˹ ˉˏ ʮ˵ ʓʋʏ˒ ˎ˃˖ˇʐ˄ˑ˗ːˆ˃ ː˖ˋʐʥʦʕ˃ ː˖ˋ˄ˑˆˋˇ˕ʑ˕ˑˎ˗˄ˎˇ˃ ː˖ˋʐʥʦʔʚ
˃ː˖ˋ˄ˑˆˋˇ˕ʊʒʎʓ˹ ˉˏ ʮ˵ ʓʋʏ˔ ˇ˅ˑˏ˄ˋː˃ː˖ˊ ˗ˏ˃ːʊ˔ˊʋʫʮʐʔʊʓʒʒʷ ˏ ʮ˵ ʓʋʏˑ ˔˔ ˊʫʮʐʙʊʓʒː ˉˏ ʮ˵ ʓʋʎ
Data are representative for experiments with three different donors. Statistical significance 
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expression on CD25- naive CD4+ T cells. IL-7 readily induced CD25 expression on 
naive CD25-CD4+ T cells (Fig. 3C), as previously reported (Cimbro et al., 2012; 
Pekalski et al., 2013). However, the per-cell CD25 expression of IL-7 stimulated cells 
was higher than typically observed for ex vivo analysed CD45RA+CD25dimCD4+ 
T cells. Furthermore, IL-7 did not modulate CD45 isoform expression (Fig. 3D). 
These combined data indicate that CD45RA+CD25dimCD4+ T cells develop from 
naive CD25-CD4+ T cells upon TCR stimulation only.
CD45RA+CD25dimCD4+ T cells also reside in the CD31+ naive CD4+ 
T cell pool
Next, we assessed the relation between CD45RA+CD25dimCD4+ T cells and the 
previously reported population of CD31- central naive CD4+ T cells (Kohler et al., 
2005). In accordance with the notion of prior TCR engagement, CD45RA+CD25dimCD4+ 
T cells demonstrated less CD31 expression than naive CD25-CD4+ T cells (Fig. S4A 
and B). Consequently, a substantial proportion of CD45RA+CD25dimCD4+ T cells 
were found in the CD31- central naive CD4+ T cell population (Fig. S4C). However, 
a significant proportion of CD45RA+CD25dimCD4+ T cells were also found among 
the CD31+ recent thymic emigrant naive CD4+ T cell population. The presence 
of these cells within the CD31+ naive CD4+ T cell fraction was not surprising, 
as we found that CD31 is only gradually lost upon CD3/CD28 cross-linking of 
CD31+ naive CD4+ T cells (Fig. S4D). Thus, the expression of CD25 reveals further 
heterogeneity among naive, human CD4+ T cells.
CD45RA+CD25dimCD4+ T cells develop in secondary lymphoid tissues
As naive CD4+ T cells continuously circulate through lymphoid organs to 
encounter antigens, we hypothesized that CD45RA+CD25dimCD4+ T cells would 
develop in these organs. Analysis of mononuclear cells from human bone marrow, 
spleen, liver-draining lymph nodes, and inguinal lymph nodes obtained from 
young and intermediate age donors (median age 42, range 14–62) showed that 
naive CD25-CD4+ T cells, CD45RA+CD25dimCD4+ T cells, and memory CD4+ 
T cells were all present in these tissues (Fig. 4A). No correlation between tissue 
CD45RA+CD25dimCD4+ T cells and age was observed, possibly due to the limited 
number of samples available. Next, we analysed the expression of CD69, an 
activation marker that is induced on naive CD4+ T cells after TCR stimulation 
rather than cytokine stimulation (Simms & Ellis, 1996; Cimbro et al., 2012). 
Whereas T cells hardly expressed CD69 in peripheral blood and bone marrow, we 
observed prominent expression of CD69 on T cells in secondary lymphoid organs 
(Fig. 4B). The percentage of CD69-expressing cells was highest among memory 
CD4+ T cells in lymph nodes and spleen, whereas only few naive CD25-CD4+ 
T cells expressed CD69 in these secondary lymphoid organs. Interestingly, a 
substantial part of CD45RA+CD25dimCD4+ T cells in lymph nodes and spleen 
showed expression of CD69. This suggests that TCR-derived signals drive the 
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Evidence for low-affinity TCR engagement of CD45RA+CD25dimCD4+ 
T cells
Current evidence from animal studies implies that low-affinity TCR engagement by 
peptide/MHC complexes promotes the homeostatic maintenance of naive T cells 
(Surh & Sprent, 2008). Therefore, we next hypothesized that CD45RA+CD25dimCD4+ 
T cells have undergone low-affinity TCR engagement in vivo. An accepted method 
to study the strength of TCR and peptide/MHC interactions is measurement 
of CD3 9 chain phosphorylation levels (Mandl et al., 2013). As this procedure 
requires immediate analysis of T cell samples, it is incompatible with the currently 
employed T cell sorting strategy. Therefore, we decided to analyse expression 
levels of the inhibitory receptor CD5, which reflects prior TCR signalling strength 
(Mandl et al., 2013). In line with the notion of low-affinity TCR stimulation, 
CD45RA+CD25dimCD4+ T cells expressed low levels of CD5 (median MFI 54, range 
48-98) which were substantially lower than in memory CD4+ T cells (median 
MFI 67, range 55-121) and comparable to that of naive CD25-CD4+ T cells 
(median MFI 54, range 12-101), as shown in Fig. S5. The combined data suggest 
that CD45RA+CD25dimCD4+ T cells develop upon low-affinity TCR–peptide/MHC 
interaction in vivo.
Figure 4. CD45RA+CD25dimCD4+ T cells develop in secondary lymphoid tissues. 
(A) Naive CD25-, CD45RA+CD25dim, and memory CD4+ T cells were enumerated by flow 
cytometry in mononuclear cell fractions isolated from peripheral blood (PB) and paired bone 
marrow (BM) samples, and from non-paired liver-draining lymph node (liLN), inguinal lymph 
node (inLN), and spleen (SPL) samples. (B) Expression of the activation marker CD69 by 
naive CD25-, CD45RA+CD25dim, and memory CD4+ T cells in peripheral blood and lymphoid 
tissues. Statistical significance was tested with Wilcoxon signed-rank test or Mann–Whitney 
U-test. Statistical significance vs. peripheral blood is indicated as **P < 0.01, ***P < 0.001. 
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CD45RA+CD25dimCD4+ T cells display increased sensitivity to IL-2
Common J-chain cytokines such as IL-2, IL-7, and IL-15 may support the maintenance 
of T cells by promoting STAT5-dependent proliferation and survival (Rochman et 
al., 2009). In addition to the IL-2RD chain (CD25), CD45RA+CD25dimCD4+ T cells 
also expressed slightly more IL-2/IL-15RE chain (CD122) than naive CD25-CD4+ 
T cells (Figs 5A and S6A). In contrast, expression of the common J-chain (CD132), 
IL-7RD chain (CD127), and IL-15RD chain was similar in CD45RA+CD25dimCD4+ 
T cells and naive CD25-CD4+ T cells. Based on these findings, we predicted that 
CD45RA+CD25dimCD4+ T cells would be more responsive to IL-2 and perhaps 
IL-15 when compared to naive CD25-CD4+ T cells. CD45RA+CD25dimCD4+ 
T cells indeed were more sensitive to IL-2 than naive CD25-CD4+ T cells, 
as shown by more IL-2 induced STAT5 phosphorylation (Figs 5B and S6B). 
CD45RA+CD25dimCD4+ T cells were also slightly more sensitive to IL-15 than 
Figure 5. Increased sensitivity for IL-2 in CD45RA+CD25dim CD4+ T cells. (A) 
Percentages of cells expressing CD122 (IL-2RE chain, n = 9), CD127 (n = 7), and the IL-15RD 
chain (n = 9), and the mean fluorescence intensity (MFI) for CD132 (n = 13) in naive 
CD25-, CD45RA+CD25dim, and memory CD4+ T cells. For CD132, the MFI is shown, as all 
CD4+ T cells expressed CD132. (B) MFI for pSTAT5 in naive CD25-, CD45RA+CD25dim, and 
memory CD4+ T cells in response to increasing concentrations of recombinant human 
IL-2 (rhIL-2), IL-7 (rhIL-7), and IL-15 (rhIL-15). Mean values from experiments with cells from 
three donors are shown. Percentage of Ki-67-expressing cells (right panel) among naive 
CD25-, CD45RA+CD25dim and memory CD4+ T cells of 29 healthy aged individuals. Bars 
and whiskers represent mean with SEM. Statistical significance is indicated as **P < 0.01, 
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naive CD25-CD4+ T cells. In contrast, IL-7 induced similar STAT5 phosphorylation 
in CD45RA+CD25dimCD4+ T cells and naive CD25-CD4+ T cells. As additional 
sensitivity to IL-2 and IL-15 may provide extra signals to undergo proliferation 
(Rochman et al., 2009), we next compared the expression of the proliferation 
marker Ki-67 in CD45RA+CD25dimCD4+ T cells and naive CD25-CD4+ T cells. 
As expected, the percentage of proliferating cells was slightly higher among 
directly analyzed ex vivo CD45RA+CD25dimCD4+ T cells than naive CD25-CD4+ 
T cells (Fig. 5B).
CD45RA+CD25dimCD4+ T cells represent a broad and functional 
reservoir of naive T cells
As a broad TCR repertoire is essential for optimal immunity, we next studied the 
TCR repertoire of CD45RA+CD25dimCD4+ T cells. Although CD45RA+CD25dimCD4+ 
T cells showed subtle differences in TCR VE usage when compared to naive 
CD25-CD4+ T cells, CD45RA+CD25dimCD4+ T cells still demonstrated a broad 
TCR VE repertoire (Fig. 6A).
Subsequently, we tested the ability of CD45RA+CD25dimCD4+ T cells 
to differentiate into memory T cells. CD45RA+CD25dimCD4+ T cells readily 
differentiated into CD45RO+ memory cells upon in vitro CD3/CD28 stimulation 
(Fig. S7). As CD45RA+CD25dimCD4+ T cells were not blocked in their development, 
we assessed whether CD45RA+CD25dimCD4+ T cells were capable of acquiring T 
helper (Th) cell effector functions. When cultured under Th1-polarizing conditions, 
CD45RA+CD25dimCD4+ T cells differentiated into IFN-J+T-bet+ T helper 1 (Th1) 
cells (Fig. 6B). The Th1-polarizing potential of CD45RA+CD25dimCD4+ T cells 
was similar to that of naive CD25-CD4+ T cells. CD45RA+CD25dimCD4+ T cells 
and naive CD25-CD4+ T cells also showed a similar ability to differentiate into 
GATA3+CRTH2+ T helper 2 (Th2) cells (De Fanis et al., 2007) under Th2-polarizing 
conditions (Fig. 6C). In aggregate, our data show that CD45RA+CD25dimCD4+ 
T cells constitute a broad and functional reservoir of naive-like CD4+ T cells 
in aged humans.
Discussion
Here, we report on a unique mechanism of post-thymic maintenance of human 
naive CD4 T cells, which was not observed for naive CD8 T cells. We found 
that a robust population of naive CD4 T cells with evidence of prior in vivo TCR 
engagement develops as a function of age in healthy individuals. We show that 
this subset, defined by increased CD25 expression, likely develops in secondary 
lymphoid organs as a result of low-affinity TCR engagement and is further 
maintained by IL-2. Thus, as thymic output wanes, IL-2 becomes an important 
homeostatic cytokine for the peripheral maintenance of naive CD4+ T cells 
in aged humans. We conclude that these CD25 expressing cells represent an 
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ent and IL-2 Figure 6. CD45RA+CD25dim CD4+ T cells constitute a broad and functional reservoir of naive T cells. (A) Analysis of TCR VE usage in naive CD25- and CD45RA+CD25dim CD4+ 
T cells of 9 aged individuals. (B) Representative T-bet and IFN-J staining in CD45RA+CD25dim 
CD4+ T cells (left panel) and percentages of T-bet+IFN-J+ Th1 cells among naive CD25- and 
CD45RA+CD25dim CD4+ T cells of 3 aged individuals (right panel) after 6 days of culture 
˙ˋ˖ˊ˃ ː˖ˋʐʥʦʕʑʥʦʔʚʐ˅ˑ˃˖ˇˆ˄ ˇ˃ˆ˕˙ ˋ˖ˊʑ˙ˋ˖ˊˑ˗˖ʫʮʐʓʔʍʫʮʐʓʚʊˇ˃˅ˊʓʒː ˉˏ ʮ˵ ʓʋ˃ ːˆː ˇ˗˖˔˃ˎˋ˜ˋːˉ
anti-IL-4 antibodies. Cells were restimulated with PMA and Ca2+ ionophore in the presence 
of brefeldin A for 4 h on the final day. (C) Representative GATA-3 and CRTH2 staining in 
CD45RA+CD25dim CD4+ T cells (left panel) and percentages of GATA-3+CRTH2+ Th2 cells 
among naive CD25- and CD45RA+CD25dim CD4+ T cells of 3 aged individuals (right panel) 
˃ˈ˖ˇ˔ʘˆ˃˛˅˗ˎ˖˗˔ˇ˙ˋ˖ˊ˃ː˖ˋʐʥʦʕʑʥʦʔʚʐ˅ˑ˃˖ˇˆ˄ˇ˃ˆ˕˙ˋ˖ˊʑ˙ˋ˖ˊˑ˗˖ʫʮʐʖʊʔʗːˉˏʮ˵ ʓʋ˃ːˆ
anti-IFN-J antibodies. Statistical significance is indicated as * p < 0.05 and ** p < 0.01, by 
Wilcoxon signed rank test.
Recently, increased proportions of CD25-expressing naive CD4+ T cells were 
observed in aged individuals (Pekalski et al., 2013). We here extend these findings 
using a state-of-the-art flow cytometry strategy (Miyara et al., 2009, 2011) 
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blood of aged humans. A major advantage of our strategy is the possibility to 
delineate the aging-associated CD45RA+CD25dimCD4+ T cells from conventional 
naive CD25-CD4+ T cells and naive CD25int Treg cells. We precluded that 
CD45RA+CD25dimCD4+ T cells are late-stage memory CD4+ T cells that re-
express CD45RA (Akbar & Henson, 2011; Di Mitri et al., 2011) and also confirmed 
their naive phenotype by analysing differentiation markers, homing receptors, 
and intracellular cytokine production. Although the proportional increase in 
CD45RA+CD25dimCD4+ T cells could merely result from the decrease in the 
other naive CD4+ T cell fractions, we also found that the absolute number of 
CD45RA+CD25dimCD4+ T cells increased with age. Our study is therefore the 
first to show that aging is associated with a genuine increase in CD25-expressing 
naive CD4+ T cells.
Recently, the accumulation of CD25-expressing naive CD4+ T cells was 
explained by IL-7-mediated expansion of these cells (Pekalski et al., 2013). We now 
provide evidence that CD45RA+CD25dimCD4+ T cells primarily develop from naive 
CD25-CD4+ T cells upon low-affinity TCR engagement. CD45RA+CD25dimCD4+ 
T cells showed a slight shift in CD45 isoform expression (i.e., from CD5RA to 
CD45RO) and less CD31 expression in comparison with naive CD25-CD4+ T cells. 
Changes in expression of CD45 isoforms and CD31 on naive CD4+ T cells occur 
after TCR engagement rather than IL-7 stimulation (Kohler et al., 2005; Cimbro 
et al., 2012). Furthermore, typical CD45RA+CD25dimCD4+ T cells developed in 
vitro from naive CD25-CD4+ T cells after stimulation with anti-CD3 antibodies 
only. Although we confirmed that IL-7 can induce CD25 expression on naive 
CD25-CD4+ T cells, the per-cell expression of CD25 was much higher than 
typically observed on directly ex vivo analysed CD45RA+CD25dimCD4+ T cells. 
Furthermore, IL-7 did not modulate CD45 isoform expression. An important role 
for IL-7 in the development of CD45RA+CD25dimCD4+ T cells in aged humans 
also seems unlikely, as IL-7 levels decline with age (Kang et al., 2004; Banerjee 
et al., 2011). Taken together, our data imply that TCR-derived signals rather than 
IL-7 drive the development of CD45RA+CD25dimCD4+ T cells in humans.
CD45RA+CD25dimCD4+ T cells likely receive TCR-derived signals in secondary 
lymphoid tissues. CD45RA+CD25dimCD4+ T cells showed substantial expression 
of the activation marker CD69 in human lymph nodes and spleen, but not in the 
peripheral blood and bone marrow. Importantly, CD69 is induced on naive T cells 
after TCR stimulation, but not cytokine stimulation (Simms & Ellis, 1996; Cimbro 
et al., 2012). Recently, regulatory T cells and conventional memory T cells were 
reported to express CD69 in secondary lymphoid tissues (Peters et al., 2013; 
Sathaliyawala et al., 2013). Although commonly used as an activation marker, 
CD69 may actually play a role in retention of activated T cells in lymphoid tissues 
via downmodulation of the sphingosine-1-phosphate receptor-1 (Shiow et al., 
2006). This could explain the absence of CD69-expressing CD45RA+CD25dimCD4+ 
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The exact nature of the peptide/MHC complexes involved in the development 
of human CD45RA+CD25dimCD4+ T cells remains unclear. Animal studies indicate 
that endogenous peptides may be involved in this process. Depriving mouse naive 
T cells of self-peptide/MHC complexes typically leads to naive T cell apoptosis 
(Sprent & Surh, 2011). Non-self (i.e., microbial)-peptides are unlikely to play an 
important role in the maintenance of the naive CD4+ T cell repertoire, as such 
peptides are usually offered to T cells in the presence of costimulatory signals. 
TCR triggering in the presence of costimulation typically leads to full memory 
T cell differentiation, as also demonstrated in the current study. Although we 
confirmed that CMV may have a profound impact on the maintenance of the 
naive CD4+ T cell pool (Wertheimer et al., 2014), we here precluded CMV as a 
driving force behind the accumulation of CD45RA+CD25dimCD4+ T cells.
Our study reveals further heterogeneity within the human naive CD4+ T cell 
pool. Previously, the naive CD4+ T cell compartment was mainly classified into 
non-primed CD31+ thymic naive cells and primed CD31- central naive cells (Kimmig 
et al., 2002). Although CD45RA+CD25dimCD4+ T cells were abundant in the 
CD31- naive population, we also observed CD45RA+CD25dimCD4+ T cells in the 
CD31+ naive population. The presence of CD45RA+CD25dimCD4+ T cells within the 
supposedly non-TCR-engaged CD31+ naive population was not surprising, as our 
data demonstrated that CD31 is only gradually lost upon CD3/CD28 stimulation. 
The latter finding is in accordance with Demeure et al. who showed that T cells 
loose CD31 only after multiple rounds of CD3/IL-2 stimulation (Demeure et al., 
1996). Thus, in addition to the surface marker CD31 (Kohler & Thiel, 2009), the 
expression of CD25 allows for the identification of naive-like CD4+ T cells with 
a history of prior TCR engagement.
Whereas primarily IL-7 is considered important for the homeostasis of naive 
T cells (Rochman et al., 2009), CD45RA+CD25dimCD4+ T cells showed enhanced 
sensitivity to IL-2, and to some extent IL-15. IL-2 and IL-15 are also involved in the 
homeostasis of memory T cells and regulatory T cells (Rochman et al., 2009). 
Cytokines such as IL-2 and IL-15 can induce STAT5-dependent proliferation in 
T cells (Rochman et al., 2009). Interestingly, circulating CD45RA+CD25dimCD4+ 
T cells demonstrated a slightly higher proliferation rate than naive CD25-CD4+ 
T cells. The latter finding may be relevant as naive CD4+ T cells are long-lived 
cells that may undergo slow but substantial homeostatic proliferation over a 
longer period of time (den Braber et al., 2012). As serum levels of IL-2 and IL-15 
are retained in the elderly (Kang et al., 2004; Gangemi et al., 2005; Banerjee et 
al., 2011; Kim et al., 2011), the enhanced sensitivity for IL-2 (and IL-15) may be 
an important adaptation of naive CD4+ T cells to the changing cytokine milieu 
in aged humans (Fig. S8).
CD45RA+CD25dim cells did not accumulate within the naive CD8+ T-cell 
compartment of aged humans. The absence of naive CD45RA+CD25dimCD8+ 
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naive CD8+ T cells. However, several reports have shown that IL-2 imposes 
strong stimulatory effects on naive CD8+ T cells (Cho et al., 2007, 2013; 
Kamimura & Bevan, 2007). IL-2 not only promotes the proliferation of naive 
CD8+ T cells, but can also drive the differentiation into memory cells (Cho 
et al., 2007; Kamimura & Bevan, 2007). Therefore, the absence of naive 
CD45RA+CD25dim CD8+ T cells and the pronounced decline in naive CD8+ 
T cells in aged humans could be related to the relatively low threshold of 
naive CD8+ T cells to convert into memory cells. Indeed, aging is associated 
with a substantial shift from naive CD8+ T cells toward central and effector 
memory cells (Wertheimer et al., 2014).
Our data imply that CD45RA+CD25dimCD4+ T cells may contribute to immunity 
in aged humans. CD45RA+CD25dimCD4+ T cells represent a broad and functional 
reservoir of naive CD4+ T cells in aged humans. CD45RA+CD25dimCD4+ T cells 
showed broad TCR VE usage and a similar ability to differentiate into Th1 and 
Th2 cells as naive CD25-CD4+ T cells. Importantly, our in vitro experiments show 
that CD45RA+CD25dimCD4+ T cells can be generated from naive CD25-CD4+ 
T cells. Furthermore, prior studies with IL-2 therapy have shown that non-regulatory 
CD25-expressing naive CD4+ T cells can be expanded by intermittent IL-2 therapy 
(Natarajan et al., 2002; Sereti et al., 2002, 2004). Enhancing circulating numbers 
of CD45RA+CD25dimCD4+ T cells could therefore be an interesting strategy for 
preserving or restoring immunity in aged humans.
In conclusion, our study shows that TCR engagement drives the emergence 
and accumulation of CD25-expressing naive CD4+ T cells in healthy aged humans. 
These cells, which likely develop in secondary lymphoid tissues, represent a 
broad and functional reservoir of naive CD4+ T cells in aged humans. Our 
study provides new insight into the homeostasis of human, naive CD4+ T cells 
and justifies further studies into CD4+ T cell expanding treatments to promote 
immunity in aged and immune compromised humans.
Experimental procedures
Donor samples and study approval
In a cross-sectional study, blood samples were obtained from 91 healthy individuals 
(age 20–92). Health was assessed by a health assessment questionnaire, a physical 
examination, and blood tests. Only a slight elevation in blood pressure and the use of 
antihypertensive treatment were accepted. Also, clinical and laboratory data attesting 
to the donors’ overall health were assessed. In addition, blood/bone marrow samples 
were obtained from 8 healthy stem cell donors, before mobilization with G-CSF, spleen 
samples from 9 deceased kidney donors, liver-draining lymph nodes from 7 deceased 
liver donors, and inguinal lymph nodes from 5 kidney transplant recipients at the time of 
transplantation (not treated with immunosuppressive drugs prior to lymph node excision). 
Single cell suspensions were obtained from tissues as previously described (Peters et al., 
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Lymphoprep (Axis-Shield and Nycomed Pharma). Written informed consent was obtained 
from all study participants or their representatives, and the study was approved by medical 
ethical committees at the participating study centers.
Flow cytometry
Isolated mononuclear cells or whole blood samples were stained with the following 
fluorochrome-conjugated monoclonal antibodies: CD4-PcP, CD8-APC-H7, CD31-PE, CD45RA-
FITC, CD25-PE, CD45RO-PE-Cy7, CD45RO-FITC, CCR7-PcP-Cy5.5, TCRJG-BV421, pSTAT5-PE-Cy7, 
Ki-67-PcP-Cy5.5, Tbet-PE, CXCR3-PE-Cy5, CD69-APC-Cy7, CCR4-PE-Cy7, CD5-APC, CRTH2-PE, 
GATA3-APC, CD5-APC (all BD), CD4-ECD, CD4-PC7, CD69-PC5, CD69-ECD, Beta Mark TCR 
V E kit (all Beckman Coulter, Woerden, The Netherlands), CD122-PE, CD132-PE, CCR6-
PcP-Cy5.5, IL-2-AF700, IL-4-PE, IFN-J-PcP-Cy5.5, FOXP3-AF647, Helios-AF488 (all Biolegend, 
Uithoorn, The Netherlands), CD4-ef450, CD25-APC, CD25-PE, CD45RA-PE, CD45RA-ef605, 
HLA-DR-APC-ef780, IL-17-AF488, CD27-AF700, CD28-PcP-cy5.5 (all eBioscience, Vienna, 
Austria). In case of whole blood staining, samples were lysed with BD FACS lysing solution. 
Samples were measured on a LSR-II (BD) or FC500 (Beckman Coulter) and analysed with 
Kaluza Analysis Software (Beckman Coulter). Absolute numbers of CD4+ and CD8+ T cells 
were determined according to the BD MultiTest TruCount method, as described by the 
manufacturer. TruCount measurements were taken on a FACS Canto-II (BD) and analysed 
with FACSCanto Clinical Software (BD).
Intracellular cytokine and transcription factor staining
Whole blood samples were diluted 1:1 with RPMI and stimulated with PMA and Ca2+ ionophore 
A23187 in the presence of brefeldin A (Sigma-Aldrich, Zwijndrecht, The Netherlands) for 
4 h. After red blood cell lysis with ammonium chloride, cells were fixed and permeabilized 
with a Foxp3 Staining Buffer Set (eBioscience) followed by intracellular staining.
Phosphorylated STAT5 staining
Peripheral blood mononuclear cells (PBMCs) were stimulated with indicated concentrations 
of recombinant human (rh) IL-2, rhIL-7, or rhIL-15 (all Peprotech) during 15 min, directly 
followed by fixation with Cytofix Buffer (BD) for 10 min at 37 °C. Subsequently, the cells 
were treated with Perm Buffer III (BD) for 30 min on ice and stained for pSTAT5.
Cell culture
Naive T cells fractions of interest were sorted on a MoFlo Astrios sorter (Beckman Coulter). 
For assessment of CD31 loss, sorted CD31+ naive CD4+ T cells were stained with 5 μm 
proliferation dye CFSE. The cells were cultured for 6 days in 96-well flat-bottomed plates 
in RPMI1640 with 10% human pooled serum (HPS) and gentamycin. Cells were stimulated 
with CD3/CD28-coated beads (Life Technologies, Paisley, UK) at a cell to bead ratio of 1:1. 
For induction of CD45RA+CD25dimCD4+ T cells, sorted naive CD45RO-CCR7+CD25- CD4+ 
T cells were cultured for 6 days in the presence of plate-bound anti-CD3 antibodies (wells 
˅ˑ˃˖ˇˆ˃˖˅ˑː˅ˇː˖˔˃˖ˋˑːˑˈʓ˹ˉˏʮ˵ ʓʋ˙ˋ˖ˊʑ˙ˋ˖ˊˑ˗˖˕ˑˎ˗˄ˎˇ˃ː˖ˋʐʥʦʔʚ˃ː˖ˋ˄ˑˆˋˇ˕ʊʒʎʓ
˹ˉˏʮ˵ ʓʋʏˑ˔˙ˋ˖ˊˋːˆˋ˅˃˖ˇˆ˅ˑː˅ˇː˖˔˃˖ˋˑː˕ˑˈ˔ˊʫʮʐʔˑ˔˔ˊʫʮʐʙʎʨˑ˔˒ˑˎ˃˔ˋ˜ˋːˉˇ˚˒ˇ˔ˋˏˇː˖˕ʏ
sorted CD45RA+CD25- and CD45RA+CD25dim CD4+ T cells were cultured with CD3/
CD28-coated beads at a cell to bead ratio of 1:1 in the presence or absence of rhIL-12 
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˔ˊʫʮʐʖʊʔʗːˉˏʮ˵ ʓʋ˃ːˆ˃ː˖ˋʐʫʨʰʐJˏʣ˄ʊʓʒːˉˏʮ˵ ʓʋˈˑ˔ʶˊʔ˕ˍˇ˙ˋːˉʎʶˊˇ˔ˇ˅ˑˏ˄ˋː˃ː˖
human cytokines were purchased from Peprotech and blocking antibodies from BD. After 
4 days, the medium was refreshed and all cytokines and blocking antibodies were added 
again. After 6 days, the cells were restimulated for 4 h with PMA and calcium ionophore 
in the presence of brefeldin A.
CMV-specific antibodies
Serum levels of CMV-specific IgG were determined with an in-house ELISA. 96-well ELISA 
plates (Greiner) were coated with lysates of CMV-infected fibroblasts overnight. Lysates of 
non-infected fibroblasts were used as negative controls. Following the coating, dilutions of 
serum samples were incubated for 1 h. Goat anti-human IgG was added and incubated for 
1 h. Samples were incubated with phosphatase for 15 min, and the reaction was stopped 
with NaOH. The plates were scanned on a Versamax reader (Molecular Devices). A pool 
of sera from 3 CMV-seropositive individuals with known concentrations of CMV-specific 
IgG was used to quantify CMV IgG in the tested samples.
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Supplemental Figure 1. Maintenance of naive CD4+ T cells and loss of naive CD8+ 
T cells in aged humans. Absolute numbers of (A) naive CD4+ and (B) naïve CD8+ 
T cells as a function of age in 52 CMV-seropositive (CMV+) and 39 CMV-seronegative 
(CMV-) healthy, adult humans. Donor ages ranged between 20 and 92. Correlations were 
tested with Spearman’s rank correlation coefficient and p values are shown in the legend 
of the graphs.
Supplemental Figure 2. Accumulation of CD45RA+CD25dimCD4+ T cells in peripheral 
blood of aged humans is not driven by sex or CMV serostatus. (A) Proportions 
of CD45RA+CD25dimCD4+ T cells in young (<40yr) and aged (>60yr) male and female 
individuals. (B) Proportions of CD45RA+CD25dimCD4+ T cells in CMV-seropositive (CMV+) 
aged individuals and age-matched, CMV-seronegative (CMV-) individuals. *** indicates 
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Supplemental Figure 3. Circulating CD45RA+CD25dimCD4+ T cells demonstrate 
a naive-like phenotype. Naive CD25-CD4+ T cells, CD45RA+CD25dimCD4+ T cells, 
naive CD25int regulatory T cells and memory (Mem) CD4+ T cells or memory CD25high 
regulatory T cells of aged individuals were assessed for expression of (A) CD27 and 
CD28, (B) homing receptors, (C) intracellular cytokines, (D) regulatory T cell markers and 
(E) the early activation marker CD69. Results are expressed as the percentage of cells 
expressing the specific markers. Intracellular cytokine production was studied after 4 hour 
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Supplemental Figure 4. CD45RA+CD25dimCD4+ T cells show evidence of prior TCR 
engagement. (A) Representative staining for CD31 in naive CD25-, CD45RA+CD25dim and 
memory CD4+ T cells and (B) expression of CD31 in the 3 CD45RA+CD4+ T cell subsets 
and memory CD4+ T cells of 29 aged individuals. (C) Mean proportions of CD31+ and 
CD31- cells as well as CD25dim and CD25- cells within the naive CD4+ T cell compartment 
of 11 young and 15 aged individuals. (D) CD31 expression on sorted, CFSE-labelled 
CD31+CD45RA+CCR7+ naive CD4+ T cell upon 6 days culture with anti-CD3/CD28 coated 
beads. Baseline (BL) cells were directly analysed after sorting. Data represent experiments 
with 4 different donors. Bars and whiskers represent mean with SEM. Statistical significance 
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Supplemental Figure 5. Per-cell expression of CD5 by CD45RA+CD25dimCD4+ 
T cells. Mean fluorescence intensity (MFI) is shown for naive CD25-CD4+ T cells and 
CD45RA+CD25dim CD4+ T cells, as well as memory CD4+ T cells of 8 aged individuals. 
Bars and whiskers represent median and interquartile range. Statistical significance is 
indicated as ** p<0.01 by Wilcoxon signed rank test. ns = non-significant.
Supplemental Figure 6. Increased sensitivity for IL-2 in CD45RA+ CD25dimCD4+ T cells. 
(A) Representative flow cytometric staining for CD122 (IL-2RE chain), CD132 (common J 
chain), CD127 (IL-7RD chain) and the IL-15RD chain in naive CD25-, CD45RA+CD25dim and 
memory (mem) CD4+ T cells. (B) MFI for pSTAT5 in naive CD25-, CD45RA+CD25dim and 
memory CD4+ T cells of aged individuals following 15 minutes stimulation with 100 U/mL 
IL-2 (n=9), 100 ng/mL IL-7 (n=8) or 100 ng/mL IL-15 (n=7). Bars and whiskers represent 
mean with SEM. Statistical significance is indicated as * p<0.05, ** and p<0.01 by Wilcoxon 
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Supplemental Figure 7. Acquisition of CD45RO by anti-CD3/CD28 stimulated 
CD45RA+CD25dimCD4+ T cells. Differentiation of sorted naive CD25- and 
CD45RA+CD25dimCD4+ T cells into CD45RO+ memory cells upon 6 day culture with 
anti-CD3/CD28 coated beads. The sorted cells were obtained from 2 healthy, aged individuals.
Supplemental Figure 8. Schematic overview of naive CD4+ T cell maintenance 
in young and aged humans. Left panel: at young age, the naive CD4+ T cell pool is 
continuously replenished by new T cells from the thymus. These naive CD4+ T cells are 
maintained via IL-7. In addition, some naive CD4+ T cells receive TCR-derived signals in 
secondary lymphoid tissues, possibly via engagement with self-peptide/MHC complexes, 
and become CD45RA+CD25dimCD4+ T cells. These naive-like cells acquire enhanced 
sensitivity for IL-2. Right panel: at old age, thymic output has dropped due to thymic 
involution. What is left of the naive CD4+ T cell repertoire is partly maintained by IL-7. In 
addition, a substantial fraction of CD45RA+CD25dimCD4+ T cells accumulate over time, 
partly due to an enhanced sensitivity to IL-2. Of interest, serum levels of IL-2 are retained 
at old age, whereas levels of IL-7 decline.
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Measuring changes of the T cell receptor (TCR) repertoire is important to 
many fields of medicine. Flow cytometry is a popular technique to study 
the TCR repertoire, as it quickly provides insight into the TCR-VE usage 
among well-defined populations of T cells. However, the interpretation of the 
flow cytometric data remains difficult, and subtle TCR repertoire changes 
may go undetected. Here, we introduce a novel means for analysing the 
flow cytometric data on TCR-VE usage. By applying economic statistics, 
we calculated the Gini-TCR skewing index from the flow cytometric TCR-VE 
analysis. The Gini-TCR skewing index, which is a direct measure of TCR-VE 
distribution among T cells, allowed us to track subtle changes of the TCR 
repertoire among distinct populations of T cells. Application of the Gini-TCR 
skewing index to the flow cytometric TCR-VE analysis will greatly help to 





A broad T cell receptor (TCR) repertoire is considered critical for optimal immunity 
against a wide variety of antigens [1,2]. Contraction of the TCR repertoire is 
associated with poor vaccine responses in aged individuals [3], progression to AIDS 
in HIV-infected patients [4], and poor survival in cancer patients [5]. Assessment 
of the T cell receptor (TCR) repertoire is therefore relevant to researchers in 
many fields of medicine. 
Several techniques are currently used to study the TCR repertoire [6]. Moderate 
to high resolution assessment of the TCR repertoire is provided by PCR-based 
methods, such as TCR spectratyping and sequencing. As these methods are 
relatively labour-intensive and preferably require cell-sorting of highly pure 
T cell populations, many researchers turn to flow cytometry [6]. Flow cytometry 
quickly measures the proportional TCR-VE usage in multiple T cell subsets on a 
per-cell basis, without the need for cell-sorting. Although this assessment can 
provide helpful information, an accurate and reliable way for analysing the flow 
cytometric data on the TCR repertoire is currently lacking.
Here, we introduce economic statistics to improve the analysis of flow 
cytometric data on TCR-VE usage. We noticed that the distribution of TCR-VE 
families among T cells resembles the distribution of income among people 
(Fig. 1A-C). Economists typically study the distribution of income by constructing 
Lorenz curves and calculating the Gini index. The Gini index, with scores ranging 
from 0 to 100, is a direct measure of income distribution [7-9]. By applying the 
Gini index to the flow cytometric TCR-VE analysis, we could directly measure the 
distribution of 24 TCR-VE families among multiple, well-defined T cell subsets. In 
this context, low Gini index values indicated equal distribution of TCR-VE families 
(i.e. broad repertoire), whereas high values pointed to unequal distribution of 
TCR-VE families (i.e. repertoire skewing). Although the Gini index has been used 
in TCR sequencing studies [10,11], we here demonstrate that the Gini index, 
hence referred to as the Gini-TCR skewing index, also aids the analysis of flow 
cytometric data on TCR-VE usage. Importantly, the Gini-TCR skewing index allowed 




Heparinized blood samples were acquired from 27 healthy volunteers. Eight men and 19 
women were included (age range 22-81). Samples of 5 children (age 9 years) undergoing 
DTaP-IPV vaccination were also collected. Written informed consent was obtained from 
adult volunteers or from parents on behalf of the children. The study was approved by 
the institutional review board of the UMCG (METc2012/375) and the Central Committee on 
Research Involving Human Subjects in the Netherlands (CCMO; ISRCTN64117538). None of 





Whole blood samples (150 μL) or isolated peripheral blood mononuclear cells were 
incubated with fluorochrome-conjugated antibodies (Table 1 and S1 Fig.) for 45 minutes 
at room temperature. Subsequently, whole blood samples were lysed with 2 mL of 1x 
Lysing solution (BD Biosciences) for 10 minutes at room temperature. Finally, samples 
were washed twice with phosphate buffered saline containing 1% bovine serum albumin. 
Samples were measured immediately on a LSR-II flow cytometer (BD Biosciences). The flow 
cytometric data was obtained with FACS Diva (BD Biosciences) and analysed with Kaluza 
Software (Beckman Coulter). Fluorescence-minus-one (FMO) controls served as negative 
controls for the flow cytometric staining. 
Figure 1. Schematic overview showing the relation between T cell receptor (TCR) 
Vǁ diversity, distribution and percentages. (A) Schematic drawing illustrating broad 
versus contracted TCR-VE diversity. (B) Schematic drawing illustrating distribution and 
proportional usage of TCR VE families when TCR-VE diversity is broad or contracted. (C) 




Table 1. Monoclonal antibodies. Overview of fluorochrome-conjugated monoclonal 
antibodies applied in the study. 
Antibody specificity Fluorochrome Clone Manufacturer
VE1 PE+FITC BL37.2 Beckman Coulter
VE2 PE+FITC MPB2D5 Beckman Coulter
VE3 FITC CH92 Beckman Coulter
VE4 PE+FITC WJF24 Beckman Coulter
VE5.1 PE+FITC IMMU157 Beckman Coulter
VE5.2 PE 36213 Beckman Coulter
VE5.3 PE 3D11 Beckman Coulter
VE7.1 PE+FITC ZOE Beckman Coulter
VE7.2 FITC ZIZOU4 Beckman Coulter
VE8 FITC 56C5.2 Beckman Coulter
VE9 PE FIN9 Beckman Coulter
VE11 PE C21 Beckman Coulter
VE12 FITC VER2.32 Beckman Coulter
VE13.1 PE IMMU222 Beckman Coulter
VE13.2 PE H132 Beckman Coulter
VE13.6 PE+FITC JU74.3 Beckman Coulter
VE14 FITC CAS1.1.3 Beckman Coulter
VE16 FITC TAMAYA1.2 Beckman Coulter
VE17 PE+FITC E17.5F3 Beckman Coulter
VE18 PE BA62.6 Beckman Coulter
VE20 FITC ELL1.4 Beckman Coulter
VE21.3 FITC IG125 Beckman Coulter
VE22 PE+FITC IMMU546 Beckman Coulter
VE23 PE AF23 Beckman Coulter
CD28 APC CD28.2 Beckman Coulter
CD31 Pacific blue 5.6E Beckman Coulter
CD4 APC-AF700 13B8.2 Beckman Coulter
CD45RA APC-AF750 2H4 Beckman Coulter
CD8 Krome orange B9.11 Beckman Coulter
TCRJG PC5.5 IMMU510 Beckman Coulter
CCR7 PE-Cy7 3D12 BD Biosciences
Calculation of Gini-TCR skewing index
Gini-TCR skewing index values were calculated for T cell subsets of individual blood 
donors with use of the Gini index, which is generally used to measure income distribution 




percentages of 24 TCR-VE families is provided in the Supporting Information (S1 File). A 
simplified overview to calculate the Gini-TCR skewing index is provided (S2 Fig.). Briefly, 
proportions of all 24 TCR-VE families within a T cell subset were arranged from small 
to large. To construct Lorentz curves, the cumulative proportions of all TCR-VE family 
proportions were normalized to a total of 100%. Lorenz curves for individual blood donors 
were plotted with the cumulative percentage of the 24 TCR-VE families studied on the 
x-axis, and the cumulative proportion of CD4 or CD8 T cells that were covered by these 
24 TCR-VE families on the y-axis. Next, the surface under the Lorenz curve was subtracted 
from the surface under the equidistribution line (i.e. line of perfectly equal distribution). To 
calculate the Gini-TCR skewing index, the surface between the equidistribution line and the 
Lorenz curve was divided by the total surface under the equidistribution line (100 * 100 / 
0.5 = 5000) and then multiplied by 100. An example of the complete calculation of a 
Gini-TCR skewing index is shown in Table 2. 
Hierarchical clustering analysis
Gini-TCR skewing index values of all T cell subsets from individual donors were plotted 
in a heat map using Microsoft Excel 2007. Colours were appointed based on absolute 
Gini-TCR skewing index values. Subsequently, hierarchical clustering analysis of T cell 
subsets and blood donors was performed in Genesis 1.7.6 (Genomics and Bioinformatics 
Graz) using Euclidean distance and complete linkage clustering. 
CMV ELISA
CMV-specific IgG was determined in serum samples using an in-house ELISA. 96-well ELISA 
plates (Greiner) were coated with lysates of CMV-infected fibroblasts overnight. Lysates of 
non-infected fibroblasts were used as negative controls. Following the coating, dilutions of 
serum samples were incubated for 1 hour. Goat anti-human IgG was added and incubated 
for 1 hour. Samples were incubated with phosphatase for 15 minutes and the reaction 
was stopped with NaOH. The plates were scanned on a Versamax reader (Molecular 
Devices). A pool of sera from 3 CMV-seropositive individuals with known concentrations of 
CMV-specific IgG was used to quantify levels of CMV-specific IgG in the tested samples. 
Vaccination
Nine year old children in good health were vaccinated with a combination vaccine against 
diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV). Peripheral 
blood mononuclear cells were isolated by density centrifugation before vaccination, as 
˙ˇˎˎ˃˕ʔʚˆ˃˛˕˃ːˆʓ˛ˇ˃˔˃ˈ˖ˇ˔˘˃˅˅ˋː˃˖ˋˑːʎʵ˃ˏ˒ˎˇ˕˙ˇ˔ˇ˘ˋ˃˄ˎ˛˕˖ˑ˔ˇˆ˃˖ʐʓʕʗ ͊ʥ˙ˋ˖ˊ
RPMI + 10% FCS and 10% DMSO. To perform flow cytometric staining, the samples were 
thawed in a 37 °C water bath and washed twice with RPMI + 10% FCS. 
Statistics
Gini-TCR skewing index values between two T cell subsets within individuals were compared 
with the Wilcoxon signed rank test. In case multiple T cell subsets were compared, the 
Wilcoxon signed rank test was preceded by the Friedman test. Gini-TCR skewing index 
values in CMV seropositive and seronegative individuals were compared with the Mann 
Whitney U test. Two-sided p values < 0.05 were considered statistically significant. Statistical 





Calculation of the Gini-TCR skewing index
To demonstrate that flow cytometry and economic statistics can be combined, 
we started by calculating Gini-TCR skewing index values for CD4 and CD8 T cells 
Table 2. Example showing calculation of Gini-TCR skewing index from TCR-Vǁ usage 
of an individual blood donor.












1 VE1 3.23 VE23 0.58 0.78 0.78 A 3.25
2 VE2 10.84 VE11 0.77 1.03 1.81 B 5.40
3 VE3 7.62 VE7.2 0.78 1.05 2.86 C 9.74
4 VE4 2.68 VE5.2 0.92 1.24 4.10 D 14.49
5 VE5.1 5.65 VE5.3 0.92 1.24 5.33 E 19.64
6 VE5.2 0.92 VE16 1.18 1.58 6.92 F 25.52
7 VE5.3 0.92 VE20 1.48 1.99 8.90 G 32.96
8 VE7.1 1.97 VE13.6 1.56 2.10 11.00 H 41.47
9 VE7.2 0.78 VE21.3 1.88 2.52 13.52 I 51.09
10 VE8 3.84 VE7.1 1.97 2.65 16.17 J 61.86
11 VE9 4.72 VE13.2 2.13 2.86 19.03 K 73.33
12 VE11 0.77 VE12 2.22 2.98 22.01 L 85.50
13 VE12 2.22 VE4 2.68 3.60 25.61 M 99.21
14 VE13.1 3.34 VE1 3.23 4.34 29.95 N 115.75
15 VE13.2 2.13 VE18 3.33 4.47 34.42 O 134.10
16 VE13.6 1.56 VE13.1 3.34 4.49 38.91 P 152.77
17 VE14 3.41 VE14 3.41 4.58 43.49 Q 171.65
18 VE16 1.18 VE22 3.69 4.96 48.44 R 191.52
19 VE17 5.72 VE8 3.84 5.16 53.60 S 212.59
20 VE18 3.33 VE9 4.72 6.34 59.94 T 236.54
21 VE20 1.48 VE5.1 5.65 7.59 67.53 U 265.55
22 VE21.3 1.88 VE17 5.72 7.68 75.21 V 297.36
23 VE22 3.69 VE3 7.62 10.23 85.44 W 334.69
24 VE23 0.58 VE2 10.84 14.56 100.00 X 386.34
Total 74.46 74.46 100.00 3022.32
First TCR-VEĨĂŵŝůŝĞƐĂƌĞƌĂŶŬĞĚďĂƐĞĚŽŶƚŚĞŝƌƉƌŽƉŽƌƟŽŶĂůƐŝǌĞ͘dŚĞŶǀĂůƵĞƐĂƌĞŶŽƌŵĂůŝǌĞĚƚŽϭϬϬй͘






from healthy individuals. Therefore, we first measured the proportional usage 
of 24 TCR-VE families in CD4 and CD8 T cells with a commercially available 
panel of monoclonal antibodies (S1 Fig.). In accordance with previous reports, 
the antibody panel recognized TCR-VE families on 66 ± 1% (mean ± SEM) of 
CD4 T cells and 60 ± 2% of CD8 T cells [12,13]. At this stage, it was difficult 
to conclude whether the distribution of TCR-VE families differed between CD4 
and CD8 T cells (Fig. 2A). Next, the proportional TCR-VE usage of CD4 and 
CD8 T cells from individual blood donors was plotted in Lorenz curves with 
the cumulative percentage of the 24 TCR-VE families studied on the x-axis, and 
the cumulative proportion of CD4 or CD8 T cells that was covered by these 
24 TCR-VE families on the y-axis (Fig. 2B and S2 Fig.). A Lorenz curve far from 
the equidistribution line refers to unequal distribution and skewing of the TCR 
repertoire. Finally, Gini-TCR skewing index values were calculated for CD4 and 
CD8 T cells of individual blood donors (S2 Fig.). In some individuals, Gini-TCR 
skewing index values were markedly higher for CD8 T cells than CD4 T cells, 
whereas the values were similar in others (Fig. 2C). This difference could be 
explained by cytomegalovirus (CMV) infection, as only CD8 T cells of CMV-
seropositive individuals demonstrated increased Gini-TCR skewing index values 
(Fig. 2D). Furthermore, we noted that variation of Gini-TCR skewing index values 
in CMV-seronegative could be explained by age, as we observed a substantial, 
aging-associated increase in Gini-TCR skewing index values among CD8 T cells 
of CMV-seronegative individuals (Fig. 2E). In contrast, the TCR-VE repertoire of 
CD8 T cells was already skewed in young CMV-seropositive donors and did 
not modulate further with age. In addition, Gini-TCR skewing index values only 
modestly increased with age among CD4 T cells, irrespective of CMV-serostatus. 
With these experiments, we demonstrated that flow cytometry can be combined 
with economic statistics and confirmed previous findings that CMV-infection 
and aging are associated with profound skewing of the TCR repertoire in CD8 
T cells [14-16]. 
Gini-TCR skewing index in T cell differentiation subsets
To further validate our method, we determined Gini-TCR skewing index values 
in well-defined T cell differentiation subsets. T cells were therefore divided into 
naive (TNaive), central memory (TCM), effector memory (TEM) and terminally 
differentiated (TTD) T cells based on CD45RA and CCR7 expression [17] as 
shown in S3 Fig. TCR sequencing and spectratyping studies have shown that 
naive T cells demonstrate the broadest TCR repertoire, whereas the repertoire 
becomes more contracted in memory T cells [18-20]. We indeed observed that 
CD4 TNaive cells show significantly lower Gini-TCR skewing index values than the 
three CD4 memory cells subsets (Fig. 3A). Among the memory cells, CD4 TCM 
cells demonstrated significantly less TCR skewing than CD4 TEM and TTD cells, 
as previously found with TCR sequencing [18]. Further delineation of CD4 TNaive 




that CD31 negative T cells (central naive) have a slightly more skewed TCR 
repertoire than CD31 positive T cells (thymic naive) [21], as demonstrated in 
Fig. 3B. Analysis of TCR-VE distribution in CD8 differentiation subsets (S3 Fig.) 
resulted in similar findings as observed in CD4 T cells, although the TCR 
repertoire skewing was more pronounced in the CD8 TEM and TTD populations 
(Fig. 3C). Taken together, calculation of the Gini-TCR skewing index in naive and 
memory T cell subsets provided similar results as previously reported with TCR 
sequencing and spectratyping [18-21]. 












Hierarchical clustering analysis of Gini-TCR skewing index values
As the distribution of the TCR repertoire was simultaneously measured in a 
large number of distinct CD4 and CD8 T cell subsets, we next determined to 
what extent TCR skewing in one subset is linked to TCR skewing in another 
subset. Hierarchical clustering analysis readily revealed that CD8 TEM and CD8 
TTD cells formed a separate cluster from all other CD4 and CD8 T cell subsets 
(Fig. 3D). This finding indicates that TCR skewing in CD8 TEM and TTD cells occurs 
relatively independently from TCR skewing in the other subsets. An additional 
hierarchical clustering analysis showed that Gini-TCR skewing index values of 
CMV-seropositive and CMV-seronegative individuals largely formed two separate 
clusters. This finding further underscores the impact that CMV has on the TCR 
repertoire in humans [14]. 
Figure 3. T cell receptor (TCR) Vǁ distribution in CD4 and CD8 T cell subsets. (A) 
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Tracking Gini-TCR skewing index changes following an antigenic 
challenge
Finally, we determined whether the Gini-TCR skewing index allowed us to detect 
TCR repertoire changes following an antigenic challenge. Therefore, we studied 
the TCR repertoire of CD4 and CD8 TNaive and TEM cells in 9-year old children 
receiving a combination vaccine against diphtheria, tetanus, acellular pertussis 
and inactivated poliovirus (DTaP-IPV). We hypothesized that DTaP-IPV vaccination 
will recruit naive T cells towards the effector memory T cell pool and thereby 
cause skewing of the naive TCR repertoire. In accordance with our expectations, 
we observed clear skewing of the TCR repertoire among CD8 TNaive cells at 
28 days after vaccination (Fig. 4A, left panel). In parallel, we observed a slight 
decrease in Gini-TCR skewing index values, i.e. broadening of the TCR repertoire, 
among CD8 TEM cells at 28 days (Fig. 4A, right panel). The latter finding was 
only temporary, as Gini-TCR skewing index values of CD8 TEM cells returned to 
baseline levels at 1 year after vaccination. In contrast, Gini-TCR skewing index 
values remained elevated among CD8 TNaive cells after 1 year follow-up. These 
TCR repertoire changes were associated with a stable numerical decrease in 
CD8 TNaive cells (Fig. 4B, left panel) and increase in CD8 TEM cells (Fig. 4B, 
right panel). In essence, we observed comparable modulations within the CD4 
T cell compartment (Fig. 4C and D), albeit substantially less pronounced. These 
findings indeed implied that naive T cells are recruited towards the effector 
memory pool upon DTaP-IPV vaccination. Taken together, our results show that 
the Gini-TCR skewing index provides stable values over time, but is sensitive 
enough to detect TCR repertoire changes following an antigenic challenge. 
Discussion
We here report a novel application of the Gini index for analysing flow cytometric 
data on the TCR-VE repertoire. Flow cytometry is widely used to investigate the 
human TCR repertoire, as it quickly provides insight into the TCR repertoire of 
many different T cell subsets without the need for laborious cell-sorting. Until 
now however, the analysis and interpretation of the flow cytometric data on 
TCR-VE usage was difficult and subtle TCR repertoire changes were easily missed 
[6]. In the current study, we show that economic statistics, which have previously 
been applied in TCR sequencing studies [10,11], allowed us to quantify the flow 
cytometric data on proportional TCR-VE usage into direct measures of TCR-VE 
distribution: the Gini-TCR skewing index. Using the Gini-TCR skewing index, we 
were capable of detecting subtle changes of the TCR repertoire among multiple, 
well-defined populations of T cells. 
We validated the Gini-TCR skewing index by comparing our results to previous 
findings obtained with TCR sequencing and spectratyping [14,18-21]. We confirmed 




of the TCR repertoire in CD8 T cells [14-16]. Moreover, we found that naive and 
memory T cell populations display differences in TCR repertoire skewing. Naive 
T cells are known to have the broadest TCR repertoire, whereas the repertoire 
becomes skewed in memory T cells [18-20]. By calculating the Gini-TCR skewing 
index, we could confirm that naive T cells have a less skewed TCR-VE repertoire 
than memory T cells. In addition, we verified that CD31+ thymic naive CD4+ T cells 
have a broader TCR-VE repertoire than CD31- central naive CD4+ T cells [21]. 
Furthermore, we confirmed that central memory CD4 and CD8 T cells demonstrate 










less TCR repertoire skewing than effector memory and terminally differentiated 
memory T cells [18]. Interestingly, we could even detect changes of the TCR-VE 
repertoire following an antigenic challenge (i.e. DTaP-IPV vaccination). Our findings 
therefore confirm that distinct populations of T cells are characterized by distinct 
skewing of the TCR repertoire, and that these differences can be detected with 
the Gini-TCR skewing index. Furthermore, our data underscore that future TCR 
repertoire studies should take into account that age, antigenic challenges and 
the presence of chronic viral infections (i.e. CMV) have a profound impact on 
the TCR repertoire. 
In summary, we introduce a novel and rapid approach for analysing flow 
cytometric data on TCR-VE usage. By applying economic statistics, we could 
calculate the Gini-TCR skewing index and readily track subtle changes of the 
TCR-VE repertoire among a large number of T cell subsets. Our study therefore 
reveals interesting synergy between economic statistics and the flow cytometric 
analysis of the TCR repertoire. We expect that application of the Gini-TCR 
skewing index to the flow cytometric TCR-VE analysis will contribute to a better 
understanding of the TCR repertoire in health and disease. The development 
of novel monoclonal antibodies for additional TCR-VE families could make the 
flow cytometric assessment of the TCR repertoire also more suitable for use in 
clinical diagnostics [4,5,22].
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S1 Fig. Flow cytometric analysis of T cell receptor (TCR) Vǁ usage. (A) Representative 
flow cytometric plot showing gating of CD4 T cells. Additional negative gating for CD8 
T cells and JG T cells was performed. (B) Representative flow cytometric plot showing gating 
of CD8 T cells. Additional negative gating for CD4 T cells and JG T cells was performed. 
(C) Representative flow cytometric plots showing staining for 24 TCR-VE families in 8 





S2 Fig. Simplified calculation of Gini-TCR skewing index based on the Gini index. A 
step-by-step explanation shows how to calculate Gini-TCR skewing index values. For clarity 




S3 Fig. Flow cytometric analysis of CD4 and CD8 T cell differentiation subsets. (A) 
Representative flow cytometric staining for CD45RA and CCR7 to identify naïve, central 
memory (CM), effector memory (EM) and terminally differentiated (TD) CD4 and CD8 T cells. 
The flow cytometric gates were based on fluorescence-minus-one (FMO) controls. (B) 
Representative flow cytometric staining for CD31 in CD4 T cells and FMO control for CD31. 
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Aging and Treg/Teffector balance
Summary
Healthy aging requires an optimal balance between pro-inflammatory 
and anti-inflammatory immune responses. Although CD4+ T cells play 
an essential role in many immune responses, few studies have directly 
assessed the effect of aging on the balance between effector T (Teff) 
cells and regulatory T (Treg) cells. Here, we determined if and how aging 
affects the ratio between Treg and Teff cells. Percentages of both naive 
Treg (nTreg; CD45RA+CD25intFOXP3low) and memory Treg (memTreg; 
CD45RA-CD25highFOXP3high) cells were determined by flow cytometry 
in peripheral blood samples of healthy individuals of various ages 
(20-84 years). Circulating Th1, Th2 and Th17 effector cells were identified 
by intracellular staining for IFN-J, IL-4 and IL-17, respectively, upon in vitro 
stimulation with PMA and calcium ionophore. Whereas proportions of 
nTreg cells declined with age, memTreg cells increased. Both Th1 and Th2 
cells were largely maintained in the circulation of aged humans, whereas 
Th17 cells were decreased. Similar to memTreg cells, the 3 Teff subsets 
resided primarily in the memory CD4+ T cell compartment. Overall, Treg/
Teff ratios were increased in the memory CD4+ T cell compartment of 
aged individuals when compared to that of young individuals. Finally, the 
relative increase of memTreg cells in elderly individuals was associated 
with poor responses to influenza vaccination. Taken together, our findings 
imply that aging disturbs the balance between Treg cells and Teff cells.
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Introduction
An optimal balance between pro-inflammatory and anti-inflammatory immune 
responses is considered essential to preserve health in the elderly (Franceschi et 
al, 2007). Tilting the balance towards inflammation in aged individuals, sometimes 
referred to as ‘inflammaging’, may contribute to the development of autoimmunity. 
Conversely, when the balance shifts towards anti-inflammation, immunity against 
microbes and tumour cells is hampered (Franceschi et al, 2007).  
The concept of ‘inflammaging’ and ‘anti-inflammaging’ has been mostly 
studied in relation to the innate immune system (Franceschi et al, 2007). Aging, 
however, also has a profound impact on the adaptive immune system (Boraschi 
et al, 2013). The T cell compartment in particular is affected by aging, as thymic 
output dramatically drops early in life (den Braber et al, 2012). Consequently, 
T cell-mediated immunity relies on the maintenance of already existing naive and 
memory T cells. Ample evidence indicates that late stage memory CD8+ T cells, 
which lack CD28 expression, expand with age and promote inflammation in the 
elderly (Weng et al, 2009). In contrast, the CD4+ T cell compartment remains 
more heterogeneous with age and only few CD28 negative memory CD4+ T cells 
develop in most aged individuals (Weng et al, 2009). 
CD4+ T cells play a central role in the development and persistence of 
immune responses. Distinct subpopulations of CD4+ T cells producing specific 
effector cytokines have been reported (Murphy and Stockinger, 2010). T helper 
(Th) 1 cells produce IFN-J, which is important for immunity against intracellular 
pathogens. IL-4 producing Th2 cells promote immune responses to parasites, 
whereas IL-17 producing Th17 cells are involved in protection against extracellular 
bacteria and yeasts. Various studies have shown that these subsets of effector 
T (Teff) cells are either retained or decreased in the circulation of aged humans 
(Alberti et al, 2006; Karanfilov et al, 1999; Lee et al, 2011).
Another subpopulation of CD4+ T cells, termed regulatory T (Treg) cells, 
can potently inhibit immune responses (Sakaguchi et al, 2010). Previous studies 
have shown that both naive (CD45RA+CD25intFOXP3low) and memory (CD45RA-
CD25highFOXP3high) Treg cells can be identified (Miyara et al, 2009). These Treg 
cell subsets express different chemokine receptors and have distinct migratory 
properties (Booth et al, 2010). Naive Treg cells express CCR7 and therefore track 
into lymphoid organs along with naive T cells (Menning et al, 2007). Memory Treg 
cells express chemokine receptors similar to Teff cells and are therefore able to 
home towards sites of inflammation (Duhen et al, 2012). Although few studies 
have directly assessed the impact of aging on the Treg/Teff balance (Schmitt 
et al, 2013), many studies have shown that the number of Treg cells increases 
in the elderly. This could indicate that the balance tilts towards Treg cells in 
the elderly. Although Treg cells may be necessary to suppress ‘inflammaging’, 
studies have shown that Treg cells may hamper immunity against microbes and 
tumour cells in aged mice (Lages et al, 2008; Sharma et al, 2006; Williams-Bey 
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et al, 2011). To date, only scarce data exist suggesting that Treg cells interfere 
with protective immune responses in aged humans (Agius et al, 2009). 
In the current study, we determined if and how aging shifts the balance 
between Treg and Teff cells. Furthermore, we assessed whether the number of 
circulating Treg cells could be related to vaccine responses in a small cohort 
of aged individuals receiving influenza vaccination.
Materials and methods
Study subjects and samples
Blood samples were obtained from 79 healthy individuals (age 20-84). All individuals 
underwent medical history taking, physical examination, blood testing (general blood 
count, renal and liver function, glucose, ESR, urine sediment) and urinalysis. None 
of the subjects had a history of infection, malignancy, autoimmune disease, chronic 
liver or kidney disease, alcohol or drug abuse, diabetes mellitus, current pregnancy or 
immunosuppressive therapy. An elevated blood pressure and the use of anti-hypertensive 
treatment were accepted. Clinical and laboratory data are provided in Table 1. Additional 
blood samples were collected from 14 healthy individuals (median age 63, range 49-82) 
before and after influenza vaccination. Mononuclear cell fractions were isolated by density 
gradient centrifugation with Lymphoprep (Axis-Shield and Nycomed Pharma). Written 
informed consent was obtained from all study participants and the study was approved 
by the Medical Ethical Committee of the UMCG. All procedures were in accordance with 
the Declaration of Helsinki. 
Flow cytometry
Isolated mononuclear cells were stained with the following fluorochrome-conjugated 
monoclonal antibodies: CD4-PcP, CD8-APC-H7, CD31-PE, CD45RO-PE-Cy7, CD45RO-FITC, 
CCR7-PcP-Cy5.5, CCR4-PE-Cy7 (all BD), CCR6-PcP-Cy5.5, CXCR3-PE-Cy5, IL-2-AF700, IL-4-PE, 
IFN-J-PcP-Cy5.5, FOXP3-AF647 (all Biolegend), CD4-ef450, CD25-APC, CD25-PE, CD45RA-PE, 
CD45RA-ef605 and IL-17-AF488 (all eBioscience). Samples were measured on a LSR-II (BD) 
and analysed with Kaluza Analysis Software (Beckman Coulter). 
Intracellular cytokine and transcription factor staining
As previously described (Dolff et al, 2011), whole blood samples were diluted 1:1 with RPMI 
and stimulated with 40 nM PMA and 2 nM Ca2+ ionophore A23187 in the presence of 
3 μM brefeldin A (all Sigma) for 4 hours. After red blood cell lysis with ammonium chloride, 
cells were fixed and permeabilized with FOXP3 Staining Buffer Set (eBioscience) followed 
by intracellular staining for cytokines. Intracellular staining for FOXP3 was performed on 
unstimulated, isolated mononuclear cells with the same FOXP3 Staining Buffer Set.  
Vaccination, anti-H1N1 influenza IgG ELISA and hemagglutination 
inhibition assay 
Healthy individuals received a trivalent inactivated virus vaccine containing A/California/7/2009 
(H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 (Influvac, Solvay Pharmaceuticals) 
between October 2010 and January 2011 as part of the National Vaccination Program in 
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the Netherlands. Peripheral blood samples were obtained prior to vaccination at day 0, 
as well as day 7 and day 28 after vaccination. For detection of anti-H1N1 influenza IgG, 
ELISA plates (Costar) were coated with 1 μg of A/H1N1 subunit and subsequently incubated 
with serum obtained at day 0, 7 and 28. Subsequently, plates were incubated with mouse 
anti-human IgG-HRP (Southern Biotech), followed by incubation with TMB substrate (Sigma). 
Absorbance at 450 nm was read with an Emax microplate reader. Antibody concentrations 
were calculated with SOFTmax PRO software (Molecular Devices). The hemagglutination 
inhibition (HI) assay to A/California/7/2009 (H1N1) was performed according to standard 
techniques with guinea pig erythrocytes and egg-grown influenza viruses as antigens, as 
previously described (WHO Global Influenza Surveillance Network,). 
Statistics
The Mann Whitney U test was used to compare different groups. Wilcoxon signed rank 
test was used to analyse paired data. Correlations were assessed using the Spearman’s 







No. 25 22 32 79
Age, years, mean ± SD 26 ± 5 54 ± 5 70 ± 7 52 ± 20
No. Male (%) 7 (28%) 6 (28%) 9 (28%) 22 (28%)
Haemoglobin, mmol/L,  
mean ± SDa
8.4 ± 0.6 8.5 ± 0.7 8.8 ± 0.6 8.6 ± 0.6
Leukocyte count, 109/L,  
mean ± SDa
5.0 ± 1.6 5.3 ± 1.4 5.7 ± 1.1 5.5 ± 1.3
Thrombocyte count,  
109/L, mean ± SDa
256 ± 48 236 ± 45 239 ± 50 241 ± 48
ESR, mm/hr, mean ± SDa 6 ± 4 8 ± 6 11 ± 6 10 ± 6
CD3+ T cell count,  
109/L, mean ± SD
1.48 ± 0.62 1.45 ± 0.45 1.32 ± 0.42 1.40 ± 0.49
CD4+ T cell count,  
109/L, mean ± SD
0.72 ± 0.50 0.62 ± 0.36 0.97 ± 0.35*† 0.80 ± 0.42
CD8+ T cell count,  
109/L, mean ± SD
0.69 ± 0.26 0.77 ± 0.44 0.34 ± 0.16*† 0.56 ± 0.35
CD4/CD8 ratio, mean ± SD 1.2 ± 0.8 1.4 ± 1.6 3.5 ± 2.6*† 2.2 ± 2.2
CD16/CD56+ NK cell count, 
109/L, mean ± SD
0.25 ± 0.12 0.28 ± 0.14 0.35 ± 0.18 0.30 ± 0.16
CD19+ B cell count,  
109/L, mean ± SD
0.27 ± 0.16 0.24 ± 0.09 0.20 ± 0.10 0.23 ± 0.12
Creatinine, μmol/L,  
mean ± SDa
64 ± 9 74 ± 9 69 ± 13 69 ± 11
No. = number. ESR = erythrocyte sedimentation ration. SD  = standard deviation. * P value < 0.05 versus Age 
18-40, † P value < 0.05 versus Age 41-60;  a performed in 9/25 young individuals, 17/22 intermediate age individuals 
and 32/32 aged individuals. 
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rank correlation coefficient. Analyses were performed with GraphPad Prism 5.0. Two-tailed 
p values less than 0.05 were considered significant.
Results
Characterization of study cohort 
Subject characteristics and general immune parameters are shown in Table 1. 
Most immune parameters were comparable between the different age groups. 
However, CD4 counts were significantly increased in aged individuals when 
compared to young (18-40) and intermediate age (41-60) individuals. In contrast, 
aged individuals (61-90) demonstrated substantially lower CD8 counts than 
observed in the young and intermediate groups. Consequently, CD4/CD8 ratios 
were significantly increased in aged subjects. 
Proportions of naive and memory Treg cells in relation to age
Based on CD45RA and CD25 expression (Miyara et al, 2009), CD45RA+CD25int 
naive Treg cells (nTreg) and CD45RA-CD25high memory Treg cells (memTreg) were 
identified in the peripheral blood of adult humans (Fig. 1A). In addition, 2 subsets 
of conventional naive CD4+ T cells and 3 subsets of conventional memory CD4+ 
T cells were identified. The conventional naive CD4+ T cell populations expressed 
CCR7 and were able to produce some IL-2 after 4 hours of PMA/calcium ionophore 
stimulation (data not shown). The conventional memory CD4+ T cell population 
expressed chemokine receptors of Teff cells, i.e. CXCR3, CCR4 and CCR6, and 
could produce effector cytokines such as IFN-J, IL-4 and IL-17 (data not shown). 
We confirmed that nTreg cells express low levels of FOXP3, whereas memTreg 
cells express high levels of FOXP3 (Fig. 1B). In accordance with prior studies 
(Miyara et al, 2009; Booth et al, 2010), we also found that nTreg and memTreg 
cells equally suppressed the proliferation of anti-CD3/CD28 stimulated CD25-CD4+ 
T cells (Fig. 1C). Next, we analysed the proportions of Treg cells in the peripheral 
blood of healthy individuals of different ages. Whereas the proportion of nTreg 
cells decreased with age (Fig. 1D), the proportions of memTreg cells increased 
(Fig. 1E). When calculating absolute numbers of Treg cells, we observed a relatively 
stable number of nTreg cells, whereas memTreg cells were increased (Supplemental 
Figure 1). Thus, aging was associated with an increase in circulating memTreg cells.
Balance between Treg and Teff cells in young and aged individuals
Subsequently, we identified Th1, Th2 and Th17 effector cells by expression of 
their hall mark cytokines IFN-J, IL-4 and IL-17, respectively, upon short stimulation 
with PMA/calcium ionophore (Fig. 2A). Whereas Th1 and Th2 cells were retained 
within the total CD4+ T cell pool of aged individuals, the number of circulating 
Th17 cells was substantially lower in aged individuals than in young individuals 
(Fig. 2B). Next, naive and memory CD4+ T cells were analysed separately for 
expression of effector cytokines. In essence, the 3 Teff subsets resided within 
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Figure 1. Proportions of naive and memory Treg cells as a function of age. 
(A) Representative CD45RA and CD25 staining in CD4+ T cells of a young and aged 
individuals. Naive Treg cells (I), memory Treg cells (II) and distinct populations of memory 
(III-V) and naive (VI-VII) CD4+ T cells were delineated (Miyara et al, 2009). (B) Representative 
intracellular flow cytometric staining for FOXP3 in the 7 subpopulations of CD4+ T cells. 
(C) Percentage suppression of proliferation in CD25-CD4+ responder T (Tresp) cells by 
naive or memory Treg cells at Treg:Tresp ratio of 2:1. Dose-dependent suppression of 
these Treg subset was confirmed in experiments with lower Treg:Tresp ratios. Experiments 
were performed with cells from 5 different individuals. Bars and whiskers represent mean 
with SEM. (D-E) Proportions of naive (D) and memory (E) Treg cells within the total CD4+ 
T cell population of 79 healthy individuals of different ages (20-84 years). Correlations 
were determined by Spearman’s correlation coefficient. 
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the memory compartment, whereas only few naive cells could produce IFN-J, 
IL-4 or IL-17. The percentage of memory cells producing IFN-J was decreased in 
healthy aged individuals, which was somewhat compensated by a slight increase 
in the percentage of naive cells producing this Th1 cytokine. The latter finding 
could reflect a minor increase of CD45RA re-expressing memory cells in the aged 
individuals (Akbar and Henson, 2011). The percentages of naive and memory 
cells producing the Th2 cytokine IL-4 were similar in young and aged individuals. 
Memory CD4+ T cells of healthy aged individuals less frequently produced IL-17 
than those of young individuals, whereas naive CD4+ T cells did not express IL-17 
in either age group. Thus, Teff cells primarily resided within the memory CD4+ 
T cell compartment and numbers of circulating Teff cells were either retained 
or decreased in aged individuals. 
As memTreg share homing receptors with Teff cells, such as CXCR3, CCR4 
and CCR6 (Supplemental figure 2), memTreg cells are likely more relevant to 
keep Teff cells in check than nTreg cells, which primarily express the naive T cell 
homing receptor CCR7 (Menning et al, 2007; Duhen et al, 2012). Therefore, we 
determined the ratios between memory Treg cells and Teff cells only. The ratio 
between memTreg cells and Th1 cells was approximately 2-fold higher in aged 
individuals than in young individuals (Fig 2C). The ratio between memTreg cells 
and Th2 cells was 1.5-fold higher in aged individuals. In addition, a 3-fold higher 
ratio between memTreg cells and Th17 cells was observed in aged individuals 
when compared to young individuals. Whereas memTreg cells were outnumbered 
by Th17 in the memory compartment of young individuals, memTreg cells slightly 
predominated over Th17 cells in aged individuals (Fig 2C). 
As reciprocal development and plasticity of fully differentiated Teff cells 
and Treg cells has been described (Murphy and Stockinger, 2010; Zhou et al, 
2009), we next determined correlations between the proportions of Treg cells 
and Teff cells within the memory CD4+ T cell compartment. The percentages 
of memTreg cells did not correlate with the percentages of Th1 cells and Th2 
cells (Fig. 2D). In contrast, the percentage of memTreg cells correlated inversely 
with the percentage of Th17 cells. 
Correlation between memory Treg cells and vaccine responses 
Next, we questioned whether the relative increase of memTreg cells in aged 
individuals was associated with worse vaccine responses in the elderly. To that 
end, the pre-vaccination percentages of circulating memTreg cells were determined 
in a small cohort of aged individuals who received a vaccine against H1N1-
influenza as part of the National Vaccination Program. In addition, H1N1-specific 
IgG titres were determined before vaccination, as well as at 7 days and 28 days 
after vaccination. The most optimal rise in virus-specific titres was observed 
28 days after vaccination (Fig. 3A). No correlation was observed between the pre-
vaccination percentages of memTreg cells and the fold increase in virus-specific 
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Figure 2. Effect of age on the balance between Treg and Teff cells. (A) Representative 
flow cytometric staining of intracellular IFN-J, IL-4 and IL-17 in CD4+ T cells after 4 hour 
stimulation with 40 nM PMA and 2 nM calcium ionophore in the presence of 3 μM Brefeldin 
A. (B) Percentage of cells expressing IFN-J, IL-4 and IL-17 within CD4+ T cells, CD45RA-positive 
naive CD4+ T cells and CD45RA-negative memory CD4+ T cells of 20 young and 32 aged 
individuals. (C) Ratio between the percentage of memory Treg cells and Th1, Th2 or Th17 
cells within the memory CD4+ T cell compartment of 13 young and 25 aged individuals. 
The percentage of memory Treg cells was determined in unstimulated samples and the 
percentage of Teff subsets in stimulated samples. Bars and whiskers represent mean with 
SEM. (D) Correlation between the percentage of memory Treg cells and Th1, Th2 or Th17 
cells within the memory CD4+ T cell compartment of the same individuals as shown in 
C. Statistical significance by Mann Whitney U test is indicated as * p < 0.05, ** p < 0.01 
and *** p < 0.001. Correlations were determined by Spearman’s correlation coefficient.
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IgG at day 7 (data not shown). However, an inverse correlation was observed 
between the pre-vaccination percentage of memTreg cells and the fold increase 
in virus-specific IgG at 28 days after vaccination (Fig. 3B). 
In addition, the serological response to influenza vaccination was assessed 
with the hemagglutination inhibition (HI) assay. H1N1-specific HI titres correlated 
closely with the H1N1-specific IgG titres (Fig. 3C; Spearman’s rho 0.67, p < 0.0001). 
Seroprotection was defined as HI titres of t 40 and was present in 2/14 donors 
before vaccination and in 8/14 (57%) donors at 28 days after vaccination. 
However, substantial seroconversion with a 4-fold increase in HI titres was only 
Figure 3. Correlation between Treg cells and vaccine responses in aged individuals. 
Fourteen healthy individuals (median age 63, range 49-82) received a trivalent vaccine 
containing inactivated H1N1-influenza. (A) Serum levels of anti-H1N1 IgG at day 0 (before 
vaccination), as well as 7 days and 28 days after vaccination. (B) Correlation between the 
pre-vaccination percentage of memory Treg cells and the fold increase in serum levels of 
anti-H1N1-influenza IgG at 28 days after vaccination. (C) Relation between serum levels 
of anti-H1N1 IgG and H1N1-specific hemagglutination inhibition (HI) titres. The dashed 
line represents a HI titre of 40 that is considered seroprotective. (D) The percentage 
of memory Treg cells in individuals that seroconverted 28 days after vaccination (n=3) 
and those that did not seroconvert (n=11). Seroconversion was defined as at least a 
4-fold increase in HI titres. Statistical significance by Wilcoxon signed rank test or Mann 
Whitney U test is indicated as * p < 0.05, ** p < 0.01 and *** p < 0.001. Correlations 
were determined by Spearman’s correlation coefficient.
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obtained in 3/14 (21%) donors at 28 days after vaccination. Interestingly, these 
3 donors demonstrated lower percentages of circulating memTreg cells than 
those that did not seroconvert (Fig. 3D).
Discussion
We here demonstrate that aging shifts the balance between Treg cells and Teff 
cells. Ratios between Treg cells and Teff cells were increased in the memory CD4+ 
T cell compartment of healthy aged individuals. To the best of our knowledge, this 
is the first study showing that aging modulates the balance between Treg cells 
and the 3 major subsets of Teff cells. Interestingly, our preliminary data show 
that the increase in memTreg cells is associated with poor vaccine responses 
in elderly individuals. 
Ample evidence shows that aging has a profound effect on the human 
immune system (Boraschi et al, 2013). In the current study with healthy aged 
volunteers, we observed relatively stable numbers of leukocytes and the 3 main 
lymphocyte subsets, i.e. T cells, B cells and NK cells. Although the total number 
of circulating T cells was relatively well-maintained in aged individuals, the ratio 
between CD4 and CD8 T cells tilted markedly towards CD4 T cells. Previously, a 
decreased CD4/CD8 ratio was linked to increased mortality in large cohorts of 
aged individuals and the CD4/CD8 ratio constituted one of the parameters of 
the so-called immune risk phenotype (Boren and Gershwin, 2004). The high CD4/
CD8 ratios found by us further underscore the health of the aged participants 
in our study. 
In accordance with prior reports (Miyara et al, 2009; Booth et al, 2010), the 
proportions of circulating nTreg cells were decreased with age, whereas memTreg 
cells were increased. Due to the rise in total CD4+ T cells counts in aged 
individuals, absolute numbers of nTreg cells were actually well-retained with age, 
whereas the absolute number of memTreg increased. Although we are not aware 
of prior reports on absolute numbers of nTreg and memTreg cells, these data 
underscore the net expansion Treg cells in the elderly. Importantly, we distinguished 
CD45RA+CD25int nTreg and CD45RA-CD25high memTreg cells according to a state 
of the art flow cytometric gating strategy (Miyara et al, 2009) and confirmed their 
expression of the Treg transcription factor FOXP3, as well as their suppressive 
potential in vitro (Miyara et al, 2009; Booth et al, 2010). In earlier studies, aging 
was associated with either an increase or no change of circulating Treg cells 
(Raynor et al, 2012). Notably, a multitude of gating strategies was applied to 
identify Treg cells in earlier studies, without discriminating between nTreg and 
memTreg cells. However, the discrimination between nTreg and memTreg cells is 
biologically relevant, as these cells possess distinct homing receptors that allow 
migration into either lymphoid organs or inflamed tissues, respectively (Menning 
et al, 2007; Duhen et al, 2012). We here confirmed that nTreg cells primarily 
express CCR7, whereas memTreg cells express chemokine receptors similar to 
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Teff cells. Thus, although both suppressive, nTreg and memTreg cells seem to 
be responsible for controlling immune responses at distinct sites in the human 
body (Booth et al, 2010; Menning et al, 2007; Duhen et al, 2012).
Similar to previous studies, we observed that Th1, Th2 and Th17 cell numbers 
are either retained or decreased in the elderly (Alberti et al, 2006; Karanfilov 
et al, 1999; Lee et al, 2011). Both in young and aged individuals, these Teff 
subsets primarily resided within the memory CD4+ T cell compartment. As we 
confirmed that memTreg cells rather than nTreg cells express homing receptors 
of Teff cells (Booth et al, 2010), we concluded that the balance between memTreg 
cells and Teff cells may be more biologically relevant than that between nTreg 
cells and Teff cells. Overall, the balance between memTreg cells and all 3 Teff 
subsets shifted towards the Treg cells in elderly individuals. 
In particular the shift in balance from Th17 to memTreg cells was substantial 
and the numbers of these cells demonstrated an inverse correlation. In contrast 
to our findings, Schmitt et al. recently reported a markedly decreased Treg/
Th17 ratio in elderly individuals, which primarily resulted from a substantial 
increase in Th17 cells (Schmitt et al, 2013). In the latter study, however, the 
number of Th17 cells may have been overestimated, as Th17 cells were solely 
identified by expression of the IL-23 receptor, which is also expressed by cells 
other than Th17 cells (Parham et al, 2002). We and others identified Th17 cells 
by expression of their hallmark cytokine IL-17 and found decreased numbers of 
these cells in elderly individuals (Lee et al, 2011). Our data therefore indicate 
that aging in healthy elderly substantially tilts the Treg/Th17 balance towards 
Treg cells. The cause of the inverse relation between memTreg cells and Th17 
cells remains to be elucidated. One possibility is that the age-associated increase 
in memTreg cells results in more suppression of Th17 cells. The enhanced 
suppression should be specifically directed towards Th17 cells, as we observed 
no decrease in Th1 and Th2 cells. It has been shown, however, that aged Treg 
cells are not efficient in suppressing Th17 cells (Sun et al, 2012). Instead, a 
more plausible explanation would be that the development of Treg and Th17 
cells is tightly linked (Fessler et al, 2013). Indeed, various studies have reported 
on the reciprocal development and plasticity between Treg cells and Th17 cells 
in particular (Koenen et al, 2008; Ye et al, 2011; Valmori et al, 2010). It would 
be interesting to further study whether and how aging favours the development 
of Treg cells over Th17 cells. (Valmori et al, 2010)
An increase in Treg cells may be essential to prevent aging-related autoimmune 
diseases, such as rheumatoid arthritis (Miyara et al, 2011). Indeed, decreased 
numbers of circulating memory Treg cells have been observed in patients with 
rheumatoid arthritis (Van der Geest et al, 2014). In contrast, animal studies have 
shown that the aging-related increase of Treg cells may also hamper effective 
immunity against tumour cells and microbes, such as influenza virus (Lages et 
al, 2008; Sharma et al, 2006; Williams-Bey et al, 2011). Previously, Agius et al. 
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have shown that accumulation of Treg cells in the skin of aged humans interferes 
with local immunity against recall antigens (Agius et al, 2009). We here observed 
that the increase of memTreg cells in a small cohort of aged individuals is 
associated with a decreased humoral response to influenza vaccination. Influenza 
is a major cause of hospitalization and death in aged populations (Thompson et 
al, 2003). However, the efficiency of influenza vaccines in the elderly is limited 
(Goodwin et al, 2006). We obtained modest seroprotection rates (i.e. HI titres 
t 40) and seroconversion rates (i.e. t 4-fold increase in HI titres), which are in 
accordance with prior findings (Goodwin et al, 2006). Interestingly, seroconverted 
individuals demonstrated substantially lower numbers of circulating memTreg cells 
than those that did not seroconvert. Although our findings require confirmation 
in a larger study, they further substantiate the notion that the balance between 
pro- and anti-inflammatory immune responses is important to preserve health 
later in life (Franceschi et al, 2007). 
Conclusions
Circulating numbers of naive Treg cells decline with age, whereas memory Treg 
cells increase. While both Th1 and Th2 are retained, Th17 are decreased in 
aged humans. Consequently, the balance between Treg cells and Teff cells tilts 
towards Treg cells in the elderly. Numbers of circulating memory Treg cells 
correlated inversely with humoral responses to influenza vaccination. Future 
studies should further evaluate the role of Treg cells in the age-related decline 
of immunity in the elderly.
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Supplemental figure 2. Expression of chemokine receptors by Treg cells. The 
percentages of CXCR3, CCR6, CCR4 and CCR7 expressing cells were determined in naive 
Treg cells, total naive CD4+ T cells, memory Treg cells and total memory CD4+ T cells.
Supplemental figure 1. Absolute numbers of naive and memory Treg cells. Absolute 
CD4+ T cell counts were determined according to the TruCount Method (BD). With the 
absolute numbers of CD4+ T cells and proportions of naive and memory Treg cells, 
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B cell cytokine production and autoantibodies in the elderly
Summary
Aging is associated with development of autoimmunity. Loss of B cell 
tolerance in the elderly is suggested by an increased prevalence of anti-
nuclear antibodies (ANAs) and rheumatoid factors (RFs). Accumulating 
evidence indicates that B cells also impact autoimmunity via secretion of 
cytokines. So far, few studies have directly assessed the effect of aging 
on the latter B cell function. Here, we determined if and how human aging 
influences the production of cytokines by B cells. In a cross-sectional 
study, we found that absolute numbers of circulating B cells were similar 
in 31 young (age 19-39) and 73 old (age t60) individuals. Numbers of 
transitional B cells (CD19+CD27-CD38HighCD24High) were decreased in old 
individuals, whereas numbers of naive and memory B cell subsets were 
comparable in young and old individuals. Short-term in vitro stimulation 
of whole blood samples revealed that numbers of B cells capable of 
producing TNF-D were similar in young and old individuals. In contrast, 
B cells capable of IL-10 production were decreased in old subjects. This 
decline of IL-10+ B cells was observed in old individuals that were ANA 
positive, and in those that were negative for both ANAs and RFs. However, 
IL-10+ B cells were remarkably well retained in the circulation of old subjects 
that were RF positive. Thus, pro-inflammatory TNF-D+ B cells are retained 
in the elderly, whereas IL-10+ B cells generally decline. In addition, our 
finding findings indicate that IL-10+ B cells may differentially impact the 
development of ANAs and RFs in the elderly. 
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Introduction
Aging is associated with development of autoimmunity (Boots et al, 2013). 
The incidence of various autoimmune diseases, such as rheumatoid arthritis, 
increases substantially with age (Crowson et al, 2011). Moreover, the prevalence 
of autoantibodies is increased in serum samples of healthy, elderly subjects 
(Nisihara et al, 2013; van Schaardenburg et al, 1993). These findings suggest 
that B cell tolerance may be compromised in the elderly. 
B cells play an important role in systemic autoimmune diseases via production 
of autoantibodies. Prototype autoantibodies are rheumatoid factors and anti-
nuclear antibodies. The seroprevalence of rheumatoid factors and anti-nuclear 
antibodies increases with age (Nisihara et al, 2013; van Schaardenburg et al, 
1993). In recent years, it has become clear that B cells also promote autoimmunity 
via secretion of pro-inflammatory cytokines, such TNF-D and IL-6 (Barr et al, 
2012; van der Geest et al, 2014a). So far, little is known about the impact of 
age on the frequencies of these pro-inflammatory B cells. In addition, various 
authors have described B cells that secrete anti-inflammatory cytokines, such 
as IL-10 and TGF-E (Blair et al, 2010; Iwata et al, 2011). Recently, Duggal et al. 
have convincingly demonstrated that aging compromises the in vitro potential 
of transitional B cells to differentiate into IL-10 producing B cells (Duggal et al, 
2013). Furthermore, this poor differentiation potential was associated with rising 
titres of rheumatoid factors in elderly subjects. It remains to be elucidated, 
however, if aging also influences the actual number of IL-10 producing B cells 
in the circulation of aged individuals, and whether such modulation is indeed 
associated with increased prevalence of rheumatoid factors, and perhaps anti-
nuclear antibodies. 
In the current study, we first investigated the impact of healthy aging on 
the proportions of circulating TNF-D and IL-10 producing B cells. Subsequently, 
we analysed serum samples of healthy young and old subjects for presence of 
rheumatoid factors and anti-nuclear antibodies. Finally, we tested whether the 
presence of these autoantibodies was associated with differential maintenance 
of TNF-D and IL-10 producing B cells in aged individuals. 
Materials and Methods
Study subjects and samples
Peripheral blood was collected from healthy, young (n=31) and old (n=73) individuals. 
Seven young and 26 old individuals were male. Representative characteristics and details 
on recruitment and health assessment of study participants were described previously 
(van der Geest et al, 2014b). Written informed consent was obtained from all study 
participants and the study was approved by the Medical Ethical Committee of the UMCG. 
All procedures were in accordance with the Declaration of Helsinki. 
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Quantification of B cells and B cell differentiation subsets
B cells and B cell differentiation subsets were enumerated as reported previously (van 
der Geest et al, 2014a). In brief, absolute numbers of CD19+ B cells were determined 
according to the MultiTest TruCount method (BD). Mononuclear cells were isolated from 
heparinized blood with Lymphoprep (Axis-Shield) and stained with the following monoclonal 
antibodies: CD19-efluor605, CD24-PcP-efluor710, CD27-APC-efluor780, CD38-PE-Cy7 (all 
eBioscience), IgD-V450 and IgM-APC (BD). Samples were measured on a LSR-II (BD) flow 
cytometer and analysed with Kaluza Flow Analysis Software (Beckman Coulter). 
Intracellular cytokine staining 
Heparinised blood samples were diluted 1:1 with RPMI and stimulated with 40 nM PMA and 
2 nM Ca2+ ionophore A23187 in the presence of 3 μM brefeldin A (BFA, Sigma) during 4 
hours. After red blood cell lysis with ammonium chloride, stimulated cells were treated with 
Fix/Perm reagent A and B (Invitrogen) and stained with the following antibodies: CD19-
APC-efluor780 (eBioscience), CD22-FITC, IL-10-APC (BD) and TNF-D-PcP-Cy5.5 (Biolegend). 
Detection of anti-nuclear antibodies and rheumatoid factors
To measure anti-nuclear antibodies, dilutions of sera (1:40 and 1:80) were incubated 
on slides coated with human epithelioma type 2 cells transfected with SSA/Ro 60 kD 
antigen (Hep2000 cells, BioMedical Diagnostics). Next, slides were incubated with goat-
anti-human IgG-FITC (BioMedical Diagnostics). Subsequently, slides were analysed for the 
presence of ANAs with a Leica DM LB2 fluorescence microscope (Leica Microsystems) by 
an experienced technician. 
Serum levels of IgM rheumatoid factor were determined by ELISA. Costar 96-well plates 
were coated with aggregated human IgG. Following coating, dilutions of serum samples 
were incubated. Next, goat anti-human IgM-HRPO (Southern Biotech) was added. Finally, 
wells were incubated with TMB and the reaction was stopped with H2SO4. Plates were 
scanned on a Versamax reader (Molecular Devices). Sera of rheumatoid factor positive 
individuals with known concentrations of IgM rheumatoid factors were used to quantify 
levels of IgM rheumatoid factors in the tested samples. An ANA titre t 40 and an IgM RF 
level of >15 IU/mL were considered positive. 
Statistics
Young and old subjects were compared with the Mann-Whitney U test. P values less than 
0.05 (2 tailed) were considered statistically significant. Analyses were performed with IBM 
SPSS Statistics 20 (SPSS) and GraphPad Prism 5.0 software.
Results
Limited effect of aging on B cell numbers
To study whether B cells are modulated with age, we first investigated the absolute 
number of CD19+ B cells in the peripheral blood of healthy, young (age 19-39) 
and old (age t 60) individuals. Absolute numbers of circulating B cells were 
comparable in young and old individuals (Figure 1A, left panel). In addition, B cell 
numbers remained stable in longitudinal study of old study subjects (Figure 1A, 
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Figure 1. Effect of age on circulating B cell numbers and B cell differentiation 
subsets. (A) Absolute numbers of CD19+ B cells in peripheral blood of 31 young and 73 old 
individuals (left panel). In addition, absolute B cell numbers were determined in 22 old 
individuals after 2 years of follow up (right panel). (B) Flow cytometric gating strategy for 
distinct B cell differentiation subsets (left panel) and representative CD27/IgD staining in 
peripheral blood CD19+ B cells from a young and an old healthy individual (right panel). 
(C) Absolute numbers of distinct B cell differentiation subsets in 28 young and 45 old 
individuals. Statistical significance by Mann Whitney U test is indicated as ** p < 0.01. 
right panel). Furthermore, no differences were observed between B cell counts 
in male and female donors (Supplemental Figure 1). 
To determine whether particular B cell differentiation subsets were affected 
by aging, we further delineated B cells according to their expression of multiple 
differentiation markers (Figure 1B; Supplemental Figure 2). Whereas the absolute 
numbers of transitional B cells were slightly decreased in aged subjects, the 
absolute numbers of mature-naive, unswitched memory, IgM only memory, switched 
memory and double-negative B cells, as well as plasmablasts, were similar in 
young and old individuals (Figure 1C). Thus, absolute numbers of total B cells 
and most B cell differentiation subsets remained stable with aging.
Decrease of IL-10 producing B cells in aged subjects
To determine whether aging affects cytokine production by B cells, we analysed 
peripheral blood B cells of young and old individuals for production of TNF-D and 
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IL-10 upon short stimulation with PMA and Ca2+ ionophore (Figure 2A). Absolute 
numbers of TNF-D+IL-10- B cells were comparable in young and old subjects 
(Figure 2B). In essence, IL-10 producing B cells showed an aging-associated 
decline, as numbers of both TNF-D+IL-10+ B cells and TNF-D-IL-10+ B cells were 
decreased in old subjects. 
Next, we sought to link production of TNF-D and IL-10 by B cells to particular 
B cell differentiation subsets. Numbers of TNF-D+IL-10- B cells correlated positively 
with numbers of mature-naive, unswitched memory, IgM only memory, switched 
memory and double-negative B cells (Supplemental Figure 3). TNF-D+IL-10+ B 
cells showed a positive correlation with unswitched memory, IgM only memory, 
switched memory and double-negative B cells. Absolute numbers of TNF-D-IL-10+ 
B cells tended to correlate positively with switched memory B cells only. Overall, 
these findings implied that memory are mostly responsible for production of 
TNF-D and IL-10 in B cells. Additional phenotypical analysis indeed confirmed 
that TNF-D and IL-10 were primarily produced by the memory B cell populations 
(Supplemental Figure 4). 
Figure 2. Effect of age on TNF-ǀ and IL-10 production by circulating B cells. (A) 
Representative flow cytometric staining of TNF-D and IL-10 in CD19+CD22+ B cells of 
a young and an old individual. Cells were stimulated with PMA (40 nM) and calcium 
ionophore (2 nM) in the presence of Brefeldin A (3μM) for 4 hours. (B) Absolute numbers 
of TNF-D+IL-10- B cells, TNF-D+IL-10+ B cells and TNF-D-IL-10+ B cells in 16 young and 50 
old individuals. Statistical significance by Mann Whitney U test is indicated as * p < 0.05 
and ** p < 0.01. 
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IL-10 producing B cells are maintained in aged subjects with 
rheumatoid factors
We next investigated the relation between declining numbers of IL-10 producing B 
cells in aged subjects and the prevalence of autoantibodies. Rheumatoid factors 
(RFs) were detected in 6% of young individuals and 12% of old individuals 
(Figure 3A). None of the sera from young individuals contained antinuclear 
Figure 3. Relation between cytokine production in B cells and autoantibody presence. 
(A) Serum levels of IgM rheumatoid factors (RF) in young and old individuals. The dashed 
line at 15 IU/mL represents the normal value for IgM RF. (B) Pie charts showing proportions 
of young and old individuals that were seropositive for anti-nuclear antibodies (ANA+), 
seropositive for RF (RF+) or seronegative for both autoantibody types (AB-). (C) Absolute 
numbers of CD19+ B cells and (D) erythrocyte sedimentation rate (ESR) in 16 young 
individuals, as well as 50 old individuals that were ANA+ (n=5), RF+ (n=6) or AB- (n=39). 
(E) Absolute numbers of TNF-a+IL-10- B cells, TNF-a+IL-10+ B cells and TNF-a-IL-10+ B cells 
in the donors mentioned at (C and D). Statistical significance by Mann Whitney U test is 
indicated as ** p < 0.01 and *** p < 0.001.
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antibodies (ANAs), whereas 10% of old individuals tested positive for ANAs 
(Figure 3B), albeit with lower titres (Supplemental Table 1). In none of the tested 
individuals, a combination of RFs and ANAs was observed. The absolute numbers 
of total CD19+ B cells (Figure 3C), the erythrocyte sedimentation rates (Figure 3D) 
and serum levels of C-reactive protein (data not shown) were comparable in aged 
subjects with and without autoantibodies. Both ANA positive and autoantibody 
negative (AB negative) old subjects showed an aging-associated decrease of 
TNFa+IL-10+ and TNFa-IL-10+ B cells (Figure. 3E). In contrast, absolute numbers of 
these IL-10 producing B cell subsets were retained in RF positive old subjects. 
No aging-associated modulation of TNF-a+IL-10- B cells was observed, irrespective 
of autoantibody presence. 
Discussion
In this study, we show that TNF-D producing B cells are largely retained in 
the circulation of aged individuals, whereas numbers of IL-10 producing B cells 
decline. This aging-dependent decline of IL-10 producing B cells was observed 
in aged subjects without autoantibodies, as well as in those that had developed 
ANAs. In contrast, RF positive aged subjects showed a remarkable preservation 
of IL-10 producing B cells, when compared to other aged individuals. These 
findings imply that the presence of IL-10 producing B cells may differentially 
impact the occurrence of ANAs and RFs in the elderly. 
The incidence of autoimmune diseases, such as rheumatoid arthritis, increases 
with age (Crowson et al, 2011). Furthermore, aging is associated with the 
appearance of circulating autoantibodies in healthy individuals (Nisihara et al, 
2013; van Schaardenburg et al, 1993). We here confirm the increased prevalence 
of RFs and ANAs in aged subjects. RFs are autoantibodies directed to the constant 
region of the IgG heavy chain. We restricted our analysis to IgM RFs only, as IgM 
RFs are commonly measured in clinical practice, whereas IgA and IgG RFs are 
not. Earlier studies have shown that the prevalence of IgM RFs increases with 
age (van Schaardenburg et al, 1993). ANAs are directed towards components of 
the cell nucleus. The specificity of ANAs in healthy, elderly individuals remains 
elusive, as autoantibodies to double stranded DNA or extractable nuclear antigens 
are rarely observed in these individuals (Candore et al, 1997). Development of 
ANAs and RFs in healthy individuals may reflect polyclonal B cell activation and 
can occur during various types of infections (Berlin et al, 2007; Shmerling and 
Delbanco, 1991). Although the clinical significance of RFs and ANAs in healthy 
elderly individuals remains unclear, the development of RFs and ANAs implies 
a subtle increase in autoimmunity. Indeed, longitudinal studies indicate that the 
development of autoantibodies may proceed the onset of autoimmune diseases 
(Nielen et al, 2004). 
TNF-D producing B cells were retained in the circulation of aged individuals. 
Accumulating evidence suggests that B cells not only contribute to autoimmunity 
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via secretion of autoantibodies, but also via production of pro-inflammatory 
cytokines (Lund and Randall, 2010). In general, TNF-D producing B cells are 
thought to promote low grade inflammation in the elderly (Frasca et al, 2014). 
Furthermore, TNF-D and IL-6 producing B cells have been directly linked to 
development of autoimmune diseases, such as multiple sclerosis, large vessel 
vasculitis and polymyalgia rheumatica (Barr et al, 2012; van der Geest et al, 
2014a). Therefore, preservation of pro-inflammatory B cells may represent an 
important risk factor for the development of aging-associated autoimmunity. 
IL-10 producing B cells were decreased in the circulation of aged individuals. 
These B cells may play a dual role during autoimmune responses. IL-10 producing 
B cells not only suppress cellular immune responses by T cells and monocytes 
(Blair et al, 2010; Iwata et al, 2011; Lepse et al, 2014), but may also promote the 
differentiation of antibody secreting cells (Heine et al, 2014). Recently, Duggal et 
al. have reported that transitional B cells of aged individuals show a decreased 
ability to differentiate into IL-10 producing B cells (Duggal et al, 2013). We 
here extend these in vitro findings by showing that the actual number of IL-10 
producing B cells is decreased in the circulation of old subjects. 
Whereas an aging-associated decrease of IL-10 producing B cells was observed 
in autoantibody negative and ANA positive subjects, IL-10 producing B cells were 
remarkably well preserved in RF positive subjects. This latter finding may seem 
in contrast with the prior observation that the potential of transitional B cells 
to differentiate into IL-10 producing B cells correlates inversely with RF levels in 
sera of aged subjects (Duggal et al, 2013). A direct comparison with our data, 
however, remains difficult, as we enumerated actual numbers of IL-10 producing 
B cells in the circulation of aged individuals. So far, it remains to be established 
why the presence of RFs and ANAs is associated with different maintenance of 
IL-10 producing B cells. One explanation would be that IL-10 producing B cells 
differentially impact the development of RFs and ANAs. For instance, IL-10 
producing B cell may supress T helper cells (Blair et al, 2010), which are likely 
more important for the production of IgG ANAs rather than IgM RFs. Of interest, 
various studies imply that IL-10 potently promotes the production of RFs (Perez 
et al, 1995; Van Esch et al, 1997). Further studies are needed to determine if 
IL-10 producing B cells indeed differentially impact the development of RFs and 
ANAs in the elderly. 
Conclusions
We demonstrate that the number of circulating, TNF-D producing B cells is 
maintained in the elderly, whereas IL-10 producing B cells are decreased. This 
decline in IL-10 producing B cells was restricted to aged subjects that were 
anti-nuclear antibody (ANA) positive and to those that were seronegative for 
both ANAs and rheumatoid factors (RFs). Interestingly, the presence of RFs was 
associated with a remarkable maintenance of IL-10 producing B cells in aged 
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subject. These findings imply a differential impact of IL-10 producing B cells on 
the development of ANAs and RFs in the elderly. 
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B cell cytokine production and autoantibodies in the elderly
Supplemental Table 1. Anti-nuclear antibody (ANA) titre and pattern in aged 
individuals. 
ANA titre ANA pattern
Aged donor A 1:40 Speckled
Aged donor B 1:40 Speckled
Aged donor C 1:40 Speckled
Aged donor D 1:80 Nucleolar
Aged donor E 1:80 Speckled
Five out of 51 aged individuals (age ≥ 60) demonstrated slightly elevated ANA titres of 1:40 or 1:80. A titre < 1:40 




B cell cytokine production and autoantibodies in the elderly
Supplemental figure 1. Circulating B cell numbers in male and female donors. (A) 
Absolute numbers of CD19+ B cells in peripheral blood of 31 young (24 female, 7 male) 
and 73 old (47 female, 26 male) individuals.
Supplemental figure 2. CD27 and IgD staining in B cells. Representative CD27/IgD 
staining in peripheral blood CD19+ B cells from a young and an old healthy individual. 
Supplemental figure 3. Spearman’s correlation coefficients of the 3 TNF-ǀ/IL-10 
defined B cell populations and the 7 distinct B cell differentiation subsets. Data 
are representative for 26 individuals (age 19-83). Statistical significance is indicated as 
* p < 0.05 and ** p < 0.01. † represents a p value of 0.07.
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Supplemental figure 4. Production of TNF-ǀ and IL-10 in distinct B cell differentiation 
subsets. Blood samples of 7 healthy, young individuals were stimulated with PMA (50 nM) 
and calcium ionophore (2 nM) in the presence of Brefeldin A (3 μM) for 4 hours. (A) 
Intracellular TNF-D and IL-10 was measured in four distinct CD27/IgD defined B cell 
differentiation subsets. (B) Pie charts represent median proportions of TNF-D+IL-10-, 
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B cells in GCA and PM
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Abstract
Objective: Several lines of evidence indicate that B cells may be involved 
in the immunopathology of giant cell arteritis (GCA) and polymyalgia 
rheumatica (PMR). This study was undertaken to examine the distribution 
of defined B cell subsets, including effector B (Beff) cells and regulatory 
B (Breg) cells, in patients with GCA and patients with PMR before and 
after corticosteroid treatment.
Methods: Circulating B cells were analysed in 34 newly diagnosed, untreated 
patients with GCA or PMR, and in 44 followup samples from patients with 
GCA or PMR who received corticosteroids for 2 weeks or 3 months. For 
comparison, 40 age-matched healthy controls and 11 rheumatoid arthritis 
(RA) patients were included. Serum BAFF levels were determined, and 
temporal arteries were studied by immunohistochemistry.
Results: Patients newly diagnosed as having GCA or PMR, but not patients 
with RA, had decreased numbers of circulating B cells compared to healthy 
controls. B cell numbers recovered rapidly in treated patients with GCA 
and PMR in remission. This recovery was not achieved by compensatory 
hyperproliferation or enhanced bone marrow production. B cell numbers 
inversely correlated with erythrocyte sedimentation rates, C-reactive protein 
levels, and serum BAFF levels. Tumour necrosis factor D–positive Beff cells, 
but not interleukin-10 (IL-10)–positive Breg cells, were decreased in patients 
newly diagnosed as having GCA or PMR. Following treatment, circulating 
numbers of Beff cells normalized. The returning Beff cells demonstrated 
an enhanced capacity to produce IL-6. Few B cells were found in temporal 
artery biopsy specimens from GCA patients.
Conclusion: We show for the first time that the distribution of B cells is 
highly disturbed in GCA and PMR and that B cells likely contribute to the 
enhanced IL-6 response in both diseases.
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Introduction 
Giant cell arteritis (GCA) is the most common type of primary vasculitis in 
Western countries [1]. GCA is characterized by inflammation of medium-sized and 
large arteries, resulting in classic symptoms, such as headache, blindness, and 
stroke [2]. Polymyalgia rheumatica (PMR) is a closely related disorder associated 
with tenderness and stiffness of the hips and shoulders. Corticosteroids are the 
cornerstone of treatment in GCA and PMR, but unfortunately have considerable 
side effects [3]. Insight into the pathogenesis of GCA and PMR is crucial for the 
development of targeted therapies in both diseases. Current evidence suggests 
that dendritic cells, T cells, and macrophages play important roles in GCA and 
PMR [4, 5].
Although B cells are not predominant cells in the inflamed temporal arteries 
of GCA patients or in the affected joints of PMR patients [5-10], several findings 
indicate that B cells are not mere bystanders in GCA and PMR. General 
B cell activation in GCA and PMR is suggested by the increased presence of 
autoantibodies against various endogenous antigens in the sera of patients with 
GCA and patients with PMR [11-15]. Furthermore, early studies have indicated that 
deposits of immunoglobulins are present in the inflamed temporal arteries of GCA 
patients [16, 17]. Scarce data on B cell depletion therapy in GCA suggest that 
this treatment may ameliorate GCA disease activity [18], as previously described 
in small vessel vasculitis and Takayasu arteritis [19, 20]. Currently, little is known 
about B cells and their distribution in GCA and PMR patients.
Emerging data indicate that B cells not only produce antibodies, but also 
modulate T cell responses by secreting pro-inflammatory and anti-inflammatory 
cytokines such as tumour necrosis factor D (TNFD) and interleukin-10 (IL-10), 
respectively [21-23]. Furthermore, effector B (Beff) cells can potentiate T cell–
mediated autoimmunity via secretion of IL-6 [24]. So far, the contributions 
of Beff cells and regulatory B (Breg) cells to GCA and PMR have not been 
studied. We hypothesized that B cells may be involved in the immunopathology 
of GCA and PMR. Therefore, we investigated the distribution of defined B 




In a prospective study, 34 patients who were newly diagnosed as having GCA (n = 
16) or PMR (n = 18) were consecutively enrolled (Supplementary Table 1). None of 
the patients were receiving corticosteroids or disease-modifying anti-rheumatic drugs 
(DMARDs) at the time of blood withdrawal. GCA patients fulfilled the American College 
of Rheumatology criteria ([25]), and PMR patients fulfilled the Chuang and Hunder 
criteria [26]. In GCA patients, an 18F-fluorodeoxyglucose–positron emission tomography/
computed tomography (FDG-PET/CT) scan with similar or enhanced glucose uptake by 
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large vessels in comparison to the liver was considered to be as equally diagnostic as 
a positive temporal artery biopsy. We precluded atherosclerosis as a main cause for this 
glucose uptake by co-examining the vessels for calcifications. In total, 15 of 16 GCA 
patients had positive temporal artery biopsy findings and/or demonstrated evidence of 
GCA on the FDG-PET/CT scan.
We obtained 44 followup samples from patients with GCA or PMR in remission after 
2 weeks of corticosteroid treatment and after 3 months of corticosteroid treatment. 
Remission was defined as the absence of symptoms and a normal erythrocyte 
sedimentation rate (ESR) (<30 mm/hour). We also obtained blood samples from 8 patients 
with GCA or PMR who experienced a relapse during followup. Relapse was defined 
as an increase in ESR from normal to t30 mm/hour, plus at least one symptom of 
active GCA or PMR not attributable to other causes. We obtained blood samples from 
40 age-matched healthy controls who were thoroughly screened for past or current 
morbidities. As inflammatory disease controls, we also included 11 patients who were 
newly diagnosed as having rheumatoid arthritis (RA) and had never been treated with 
corticosteroids or DMARDs. The study was approved by the institutional review board 
of the University Medical Center Groningen, and written informed consent was obtained 
from all study participants.
Treatment
Patients with GCA and patients with PMR were initially treated with 60 mg/day and 
20 mg/day of prednisolone, respectively. Tapering of corticosteroid treatment was 
started after 3–4 weeks and further continued based on clinical and laboratory findings 
during followup. After 3 months, the median prednisolone dosage was 20 mg/day (range 
15–40 mg/day) in GCA patients and 15 mg/day (range 7.5–17.5 mg/day) in PMR patients.
Quantification of B cells and B cell differentiation subsets
Absolute numbers of CD19+ B cells were determined according to the MultiTest TruCount 
method, as described by the manufacturer (Becton Dickinson). Data were acquired 
using a FACSCanto II (Becton Dickinson) and analyzed with FACSCanto Clinical software 
(Becton Dickinson). In addition, mononuclear cells were isolated from heparinized blood 
with Lymphoprep (Axis-Shield). Isolated cells were stained with the following monoclonal 
antibodies: eFluor 605–conjugated CD19, PerCP-eFluor 710–conjugated CD24, phycoerythrin 
(PE)–conjugated CD24, allophycocyanin (APC)–eFluor 780–conjugated CD27, PE-Cy7–
conjugated CD38 (all from eBioscience), and V450-conjugated IgD and APC-conjugated 
IgM (both from Becton Dickinson). To perform intracellular staining with monoclonal 
antibodies PerCP-Cy5.5–conjugated Ki-67 and fluorescein isothiocyanate (FITC)–conjugated 
Bcl-2 (both from Becton Dickinson), the cells were first treated with a FoxP-staining buffer 
set (eBioscience). Samples were measured on an LSRII flow cytometer (Becton Dickinson) 
and analysed with Kaluza Flow Analysis software (Beckman Coulter). B cell differentiation 
subsets were gated as previously described [27-29].
Intracellular cytokine staining
Whole blood samples were diluted 1:1 with RPMI and stimulated with phorbol myristate 
acetate and calcium ionophore A23187 or with different concentrations of recombinant 
human BAFF (Enzo Life Sciences) in the presence of brefeldin A (Sigma) for 4 hours. 
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After red blood cell lysis with ammonium chloride, stimulated cells were treated with Fix 
& Perm reagents A and B (Invitrogen) and stained with the following antibodies: APC-
eFluor 780–conjugated CD19, eFluor 605–conjugated CD3, eFluor 450–conjugated CD4, 
APC-conjugated IL-6 (all from eBioscience), FITC-conjugated CD22, PE-conjugated TNFD, 
APC-conjugated IL-10 (all from Becton Dickinson), and PE-conjugated CD14 and PerCP-
Cy5.5–conjugated TNFD (both from BioLegend).
Enzyme-linked immunosorbent assay (ELISA).
Serum levels of BAFF were measured with an ELISA kit from R&D Systems. Measurements 
were performed with a VersaMax microplate spectrophotometer from Molecular Devices.
Immunohistochemistry
Temporal artery biopsy specimens were obtained from 6 GCA patients not receiving 
corticosteroid treatment and from 3 controls with uninflamed temporal arteries. The tissue 
was fixed in 10% neutral buffered formalin and paraffin embedded. Sections of 5 μm 
thickness were deparaffinised in xylene and rehydrated in graded ethanol. Antigens were 
retrieved, and endogenous peroxidase was blocked. Staining was performed with antibodies 
against CD3 (clone F7.2.38), CD20 (L26), and CD138 (MI15) (all from Dako) and visualized 
with diaminobenzidine. Semiquantitative scoring of CD3-, CD20-, and CD138-expressing 
cells was performed by 2 independent investigators using a 5-point scale (0–4), where 
0 = no positive cells, 1 = occasional positive cells, 2 = a moderate number of positive 
cells, 3 = a large number of positive cells, and 4 = a very large number of positive cells. 
The scores of both investigators were averaged.
Statistical analysis
The data from the healthy controls and patient groups were first analysed by Kruskal-
Wallis test. The Mann-Whitney U test was used to compare the different patient groups 
with the healthy controls. Analyses were performed with GraphPad Prism 5.0 software. 
Correlations were assessed using Spearman’s rank correlation coefficient. P values less 
than 0.05 (2-tailed) were considered significant.
Results
Decreased numbers of circulating B cells in GCA and PMR
To study whether B cells are modulated in GCA and PMR, we first determined 
the absolute numbers of CD19+ B cells in the peripheral blood of untreated 
patients who were newly diagnosed as having GCA or PMR (Figure 1A). Numbers 
of circulating B cells were clearly decreased in patients with newly diagnosed 
GCA or PMR compared to healthy controls. In contrast, peripheral B cell numbers 
were normal in patients who were newly diagnosed as having RA. 
To study the effect of corticosteroid treatment, absolute numbers of CD19+ 
B cells were determined in patients with GCA or PMR in remission after 2 weeks 
and after 3 months of treatment. Intriguingly, normalization of circulating B cell 
numbers occurred in GCA and PMR patients whose disease was in remission 
after 2 weeks of corticosteroid treatment (Figures 1B and C). After 3 months 
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of treatment, B cell numbers were retained in patients with PMR in remission, 
but further increased in patients with GCA in remission. Interestingly, B cell 
numbers decreased again when corticosteroid-treated patients with GCA or PMR 
experienced a relapse (Figure 1A).
Since B cell numbers seemed to correlate inversely with disease activity in 
patients with GCA and patients with PMR, we tested whether circulating B cell 
numbers in these patients also inversely correlated with systemic markers of 
inflammation. Indeed, the numbers of circulating B cells were inversely correlated 
with the ESR (Figure 1D) and C-reactive protein level (Spearman’s Uʟ˵ʒʎʗʕʏ
Figure 1. Absolute numbers of B cells in patients with giant cell arteritis (GCA) 
and patients with polymyalgia rheumatica (PMR) before and after treatment. A, 
Absolute numbers of peripheral blood CD19+ B cells in healthy controls (HCs; n = 40) and 
patients who were newly diagnosed as having GCA (nGCA; n = 16), PMR (nPMR; n = 18), 
or rheumatoid arthritis (nRA; n = 11) and had not received corticosteroids or disease-
modifying antirheumatic drugs, and in the combined group of patients with relapsing GCA 
(n = 4) and patients with relapsing PMR (n = 4) (RLPS GCA/PMR). The relapses occurred 
after 3 months of treatment. B, Absolute numbers of circulating CD19+ B cells in patients 
with newly diagnosed GCA and in patients with GCA in remission after 2 weeks (n = 11) 
and 3 months (n = 12) of corticosteroid treatment. C, Absolute numbers of circulating 
CD19+ B cells in patients with newly diagnosed PMR and in patients with PMR in remission 
after 2 weeks (n = 10) and 3 months (n = 11) of corticosteroid treatment. D, Inverse 
correlation between absolute B cell numbers in the peripheral blood of patients with GCA 
or PMR and the erythrocyte sedimentation rate (ESR), as determined by Spearman’s rank 
correlation coefficient. Bars in A–C show the mean ± SEM.  = P < 0.05;  = P < 0.01 
versus healthy controls, by Mann-Whitney U test.
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P < 0.001) in patients with GCA or PMR. B cell counts in GCA patients did not 
correlate with the number of inflamed large arteries seen on the FDG-PET/CT 
scan (data not shown).
Disturbed numbers of B cell differentiation subsets in GCA and PMR
To identify whether particular B cell differentiation subsets were modulated in 
patients with newly diagnosed GCA or PMR, we further delineated B cells based 
on the expression of B cell differentiation markers, as shown in Figures 2A and 
B. In essence, nearly all B cell differentiation subsets were decreased in patients 
with newly diagnosed GCA or PMR compared to healthy controls (Figure 2C). 
Unswitched memory B cells were an exception, as these cells were increased in 
patients with newly diagnosed GCA but were unchanged in patients with newly 
diagnosed PMR. We did not observe changes in B cell differentiation subsets in 
patients with newly diagnosed RA. 
Figure 2. B cell differentiation subsets in patients with newly diagnosed GCA 
or PMR. A, Flow cytometry gating strategy to distinguish differentiation subsets within 
peripheral blood CD19+ B cells. B, Representative flow cytometry dot plots for CD27 and 
IgD staining in CD19+ B cells from a healthy control and an untreated patient with newly 
diagnosed GCA. Values are the percentages of cells in each subset. C, Absolute numbers 
of B cell differentiation subsets in healthy controls (n = 26), patients who were newly 
diagnosed as having GCA (n = 16), PMR (n = 18), or RA (n = 11) and had not received 
corticosteroids or disease-modifying antirheumatic drugs, and in the combined group of 
patients with relapsing GCA (n = 4) and patients with relapsing PMR (n = 4). Bars show 
the mean ± SEM.  = P < 0.05;  = P < 0.01;  = P < 0.001 versus healthy controls, 
by Mann-Whitney U test. See Figure 1 for definitions.
126
7
B cells in GCA and PM
R
No evidence of B cell repopulation or compensatory 
hyperproliferation
We sought to determine how the numbers of circulating B cells were normalized in 
treated patients with GCA or PMR in remission. To that end, we first investigated 
whether the circulating B cell pool was perhaps replenished by immature, 
transitional B cells from the bone marrow. Since the numbers of transitional B 
cells were even further decreased in the peripheral blood of treated patients 
with GCA or PMR in remission (Figure 3A), it seemed highly unlikely that the 
Figure 3. B cell differentiation subsets in treated GCA and PMR patients whose disease 
was in remission. A, Left, Representative flow cytometry staining of CD24highCD38high 
˖˔˃ː˕ˋ˖ˋˑː˃ˎʤ˅ ˇˎˎ˕ˋ ːʥʦʓʛʍʥʦʔʙ˵ʫˉʦʍʤ˅ ˇˎˎ˕ˈ ˔ˑˏ˃ ʩʥʣ˒ ˃˖ˋˇː˖˄ ˇˈˑ˔ˇ˖ ˔ˇ˃˖ˏˇː˖ʊːʩʥʣʋ
and after 3 months of corticosteroid treatment (GCA in remission [rGCA]). Circled areas show 
CD24highCD38high B cells; values are the percentage of CD24highCD38high B cells. Right, 
Absolute numbers of transitional B cells in healthy controls (n = 26), patients with newly 
diagnosed GCA (n = 16), GCA patients whose disease was in remission after 3 months of 
corticosteroid treatment (n = 12), patients with newly diagnosed PMR (n = 18), and PMR 
patients in remission (rPMR) after 3 months of corticosteroid treatment (n = 11). B, Left, 
Representative flow cytometry staining of Ki-67 in CD19+ B cells from a GCA patient before 
treatment and after 3 months of corticosteroid treatment. Right, Proportions of Ki-67+ cells 
within CD19+ B cells in healthy controls (n = 14), patients with newly diagnosed GCA (n = 
13), patients with GCA in remission (n = 8), patients with newly diagnosed PMR (n = 12), 
and patients with PMR in remission (n = 7). C, Mean fluorescence intensity (MFI) for Bcl-2 
in CD19+ B cells from healthy controls (n = 8), patients with newly diagnosed GCA (n = 
4), patients with GCA in remission (n = 4), patients with newly diagnosed PMR (n = 4), and 
patients with PMR in remission (n = 4). D, Absolute numbers of unswitched memory B cells 
in healthy controls (n = 26), patients with newly diagnosed GCA (n = 16), patients with GCA 
in remission (n = 12), patients with newly diagnosed PMR (n = 18), and patients with PMR 
in remission (n = 11). Bars show the mean ± SEM.  = P < 0.05;  = P < 0.01;  = P < 
0.001 versus healthy controls, by Mann-Whitney U test. See Figure 1 for other definitions.
127
7
B cells in GCA and PM
R
circulating B cell pool was repopulated by newly produced B cells from the 
bone marrow. 
Next, we assessed whether B cell numbers were replenished through 
compensatory hyperproliferation of circulating B cells in patients with GCA or 
PMR in remission. B cells derived from peripheral blood were stained for the 
proliferation marker Ki-67 before and after treatment (Figure 3B). Before treatment, 
the proportions of proliferating B cells in patients with newly diagnosed GCA 
or PMR were similar to those in healthy controls (Figure 3B). Corticosteroid 
treatment, however, led to decreased peripheral B cell proliferation in patients 
with GCA in remission and tended to slightly reduce proliferation in patients 
with PMR in remission. Since B cell numbers did not seem to be replenished via 
compensatory hyperproliferation or enhanced bone marrow output, it seemed 
unlikely that B cells were actually lost in patients with newly diagnosed GCA or 
PMR. To further preclude a prominent role of B cell apoptosis in both diseases, 
we assessed circulating B cells for expression of the antiapoptotic regulator 
Bcl-2. B cells from patients with GCA or PMR indeed demonstrated a normal 
per-cell expression level of Bcl-2 during active disease and remission (Figure 3C).
Next, we further investigated the composition of the peripheral B cell pool in 
treated patients with GCA and PMR in remission. In particular, mature naive B cells 
and memory B cells seemed to return to the circulation in treated patients with 
GCA or PMR in remission. Numbers of mature naive B cells, IgM-only memory B 
cells, and switched memory B cells normalized in patients with GCA or PMR in 
remission (data not shown). Whereas circulating numbers of unswitched memory 
B cells remained normal in patients with PMR in remission, we observed a 
further expansion of unswitched memory B cells in treated patients with GCA 
in remission (Figure 3D). In contrast, the circulating number of double-negative 
B cells tended to remain decreased in patients with PMR in remission, and the 
same was observed for plasmablasts in patients with GCA in remission and in 
patients with PMR in remission (data not shown). Thus, both mature naive and 
memory B cell subsets returned to the circulation in patients with GCA or PMR 
in remission.
Increased serum BAFF levels in newly diagnosed GCA and PMR
Since our results did not provide evidence of enhanced B cell apoptosis during 
active disease or compensatory proliferation of B cells during remission, we 
hypothesized that the mature naive and memory B cells had been either 
marginalized or redistributed during active GCA and PMR. To test this, the 
B cell growth factor BAFF was used as an indirect marker of the presence 
or absence of B cells in the circulation. Serum levels of BAFF highly depend 
on the number of circulating B cells and typically increase when B cells 
are absent from the circulation [30, 31]. Indeed, serum BAFF levels were 
increased in untreated patients with newly diagnosed GCA or PMR (Figure 4A). 
128
7
B cells in GCA and PM
R
Following treatment, serum BAFF levels decreased in patients with GCA or 
PMR in remission (Figure 4B), but increased again during relapse (Figure 4A). 
Serum BAFF levels were inversely correlated with circulating B cell numbers 
in patients with GCA or PMR (Spearman’s Uʟ˵ʒʎʖʕʏP = 0.0015). Overall, our 
data indicated that B cells were redistributed during active GCA and PMR and 
returned during remission. 
Figure 4. Serum BAFF levels in patients with GCA and patients with PMR before 
and after treatment. A, Serum levels of BAFF in healthy controls (n = 16), untreated 
patients with newly diagnosed GCA (n = 14), untreated patients with newly diagnosed PMR 
(n = 13), and the combined group of patients with relapsing GCA (n = 4) and patients 
with relapsing PMR (n = 3). B, Left, Serum levels of BAFF in healthy controls (n = 16), 
patients with newly diagnosed nGCA (n = 14), and treated patients with GCA in remission 
(rGCA; n = 11). Right, Serum levels of BAFF in healthy controls (n = 16), patients with 
newly diagnosed PMR (n = 13), and treated patients with PMR in remission (rPMR; n = 11). 
C, Positive correlation between serum BAFF levels and serum interleukin-6 (IL-6) levels 
in the peripheral blood of patients with GCA or PMR, as determined by Spearman’s rank 
correlation coefficient. D, Left, Representative flow cytometry staining of intracellular IL-6 
in unstimulated CD14+ monocytes (medium plus brefeldin A) and BAFF-stimulated CD14+ 
monocytes (2,000 ng/ml soluble recombinant BAFF plus brefeldin A) from a patient with 
GCA in remission. Boxed areas show gate for IL-6+ cells among CD14+ monocytes; values 
are the percentage of positive cells. Right, Median percentages of IL-6+ CD14+ monocytes 
from healthy controls (n = 4), patients with GCA in remission (n = 4), and patients with PMR 
in remission (n = 4) following 4 hours of in vitro stimulation with different concentrations 
of soluble recombinant BAFF. Bars in A and B show the mean ± SEM.  = P < 0.05;  = 
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Induction of IL-6 in monocytes by nonphysiologic BAFF 
concentrations only
Although serum BAFF levels are primarily influenced by circulating B cell numbers 
[30], soluble BAFF can also activate monocytes to produce IL-6 [32, 33]. Therefore, 
we hypothesized that low B cell counts in GCA and PMR patients may indirectly 
contribute to the production of IL-6 in monocytes via elevated serum BAFF levels. 
Consistent with this hypothesis, we found a strong positive correlation between 
serum levels of BAFF and IL-6 in patients with GCA or PMR (Figure 4C). However, 
high nonphysiologic concentrations of BAFF were required for significant in vitro 
production of IL-6 by monocytes from healthy controls and patients with GCA or 
PMR in remission (Figure 4D). Furthermore, monocytes from patients with GCA 
or PMR in remission seemed to require twice as high concentrations of soluble 
BAFF for induction of IL-6 than did monocytes from healthy controls. In our 
assays, we excluded indirect stimulation of monocytes via other BAFF-induced 
cytokines, since cytokine excretion was blocked by brefeldin A. Soluble BAFF did 
not induce IL-6 production in B cells or T cells (data not shown). Although we 
did not study monocytes from patients with newly diagnosed GCA or PMR, our 
data indicate that significant IL-6 production by monocytes can only occur when 
these cells are exposed to nonphysiologic concentrations of BAFF. Therefore, 
it is unlikely that BAFF-induced activation of peripheral monocytes explains the 
elevated IL-6 levels in patients with GCA or PMR.
Increased potential of Beff cells from patients with GCA or PMR to 
produce IL-6.
Since B cells can modulate autoimmune responses by producing cytokines [34], 
we analyzed whether circulating TNFD+ B cells (Beff cells) or IL-10+ B cells 
(Breg cells) were redistributed in patients with newly diagnosed GCA or PMR 
(Figure 5A). The numbers of circulating Beff cells (TNFDʍʫʮʐʓʒ˵ʋ˙ˇ˔ˇˆˇ˅˔ˇ˃˕ˇˆ
in patients with newly diagnosed GCA or PMR, whereas numbers of circulating 
Breg cells (TNFD˵ʫʮʐʓʒʍʋ˙ˇ˔ˇːˑ˔ˏ˃ˎ ʊʨˋˉ˗˔ˇʗʤʋʎʹˇ˃ˎ˕ˑˑ˄˕ˇ˔˘ˇˆ˃˕ˏ˃ˎˎ
fraction of TNFD+IL-10+ B cells, but their numbers were similar in patients with 
newly diagnosed GCA or PMR and healthy controls (data not shown). Additional 
phenotypic analysis of Beff cells and Breg cells showed that production of TNFD 
and IL-10 varied among B cell differentiation subsets. Whereas Beff cells were 
found among all memory B cell subsets, Breg cells resided in the unswitched 
memory B cell population only (Supplementary Figure 1).
Since Beff cells may produce the proinflammatory cytokine IL-6 [34], we 
analyzed the returning Beff cells in patients with GCA or PMR in remission for 
the production of IL-6 (Figure 5C). As expected, TNFD+ Beff cells produced 
more IL-6 than did TNFD˵ʤ˅ˇˎˎ˕ʊʨˋˉ˗˔ˇʗʦʋʎʫː˖ˇ˔ˇ˕˖ˋːˉˎ˛ʏ˖ˊˇ˒ˇ˔˅ˇː˖˃ˉˇˑˈ
IL-6–producing cells was significantly expanded among Beff cells from patients 
with GCA or PMR in remission compared to healthy controls. We also observed 
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a slight increase in IL-6–producing cells among TNFD˵ʤ˅ˇˎˎ˕ ˈ˔ˑˏ˒˃˖ˋˇː˖˕
with GCA or PMR in remission. The enhanced potential to produce IL-6 was also 
noted when patients with GCA in remission and patients with PMR in remission 
were analysed separately (data not shown).
B cells in the temporal arteries of GCA patients
To determine whether B cells can be detected in the inflamed arteries of GCA 
patients, we performed immunohistochemistry for CD20+ B cells on temporal 
artery biopsy specimens from GCA patients (Figure 6A). Low- to-moderate numbers 
of CD20+ B cells were found in the adventitia of all inflamed temporal artery 
biopsy specimens studied, but rarely in the media and intima (Figure 6B). CD20+ 
Figure 5. Effector B (Beff) cells and regulatory B (Breg) cells in patients with GCA 
and patients with PMR before and after treatment. A, Representative flow cytometry 
dot plots for intracellular tumour necrosis factor D (TNFD) and interleukin-10 (IL-10) 
staining in peripheral blood CD19+CD22+ B cells from a healthy control, a patient with 
newly diagnosed GCA, and the same patient with GCA in remission after corticosteroid 
treatment. Whole blood samples were stimulated with phorbol myristate acetate and 
calcium ionophore in the presence of brefeldin A for 4 hours. Values are the percentage 
of cells in each subset. B, Absolute numbers of TNFDʍʫʮʐʓʒ˵ʤˇˈˈ˅ˇˎˎ˕˃ːˆʶʰʨD˵ʫʮʐʓʒʍ
Breg cells in healthy controls (n = 36), patients with newly diagnosed GCA (n = 8), treated 
patients with GCA in remission (rGCA; n = 7), patients with newly diagnosed PMR (n = 7), 
and treated patients with PMR in remission (rPMR; n = 6). C, Representative flow cytometry 
dot plots for intracellular TNFD and IL-6 staining in peripheral blood CD19+CD22+ B cells 
from a healthy control and a patient with GCA in remission. Cells were stimulated as 
described in A. Values are the percentage of cells in each subset. D, Percentage of TNFD+ 
Beff cells and TNFD˵ʤ˅ˇˎˎ˕˒˔ˑˆ˗˅ˋːˉʫʮʐʘˋːˊˇ˃ˎ˖ˊ˛˅ˑː˖˔ˑˎ˕ʊːʟʓʔʋ˃ːˆ˒˃˖ˋˇː˖˕
with GCA or PMR in remission (n = 11). Bars in B and D show the mean ± SEM.  = P 
< 0.05;  = P < 0.01;  = P < 0.001 versus healthy controls, by Mann-Whitney U test. 
See Figure 1 for other definitions.
131
7
B cells in GCA and PM
R
B cells were mostly confined to areas that were also infiltrated by CD3+ T cells. 
In some temporal artery biopsy specimens, low-to-moderate numbers of CD138+ 
plasma cells were detected, primarily in the adventitia. Although B cells were 
readily detected in temporal artery biopsy specimens from GCA patients, both 
CD20+ B cells and CD138+ plasma cells were outnumbered by CD3+ T cells. 
Discussion
Our findings indicate that the distribution of B cells is highly disturbed in patients 
with newly diagnosed GCA and PMR. A longitudinal analysis of B cells and serum 
BAFF levels suggested that circulating B cells were redistributed during active 
GCA and PMR, but quickly returned during remission. More specifically, Beff cells 
rather than Breg cells were redistributed during active disease. Beff cells that 
returned during remission in GCA and PMR patients demonstrated an enhanced 
potential to produce the proinflammatory cytokine IL-6.
Figure 6. B cells in temporal artery biopsy specimens from patients with giant cell 
arteritis (GCA). A, Immunohistochemistry staining for CD20+ B cells, CD138+ plasma cells, 
and CD3+ T cells in a representative inflamed temporal artery biopsy specimen from a GCA 
patient. B, Semiquantitative scoring for B cells, plasma cells, and T cells in inflamed temporal 
artery biopsy specimens from 6 GCA patients. Semiquantitative scoring was performed by 2 
independent investigators on a 5-point scale (0–4), where 0 = no positive cells, 1 = occasional 
positive cells, 2 = a moderate number of positive cells, 3 = a large number of positive 
cells, and 4 = a very large number of positive cells. The scores from the 2 investigators 
were averaged. Bars show the mean ± SEM. Adv = adventitia; med = media; int = intima.
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Both patients with newly diagnosed GCA and patients with newly diagnosed 
PMR showed a marked decrease in circulating B cells before corticosteroid 
treatment. It is well known that GCA and PMR frequently overlap in individual 
patients [2], and similarities in autoantibody production in patients with GCA and 
patients with PMR have been reported [12, 14]. Our findings further underline 
the close relationship between GCA and PMR. The decreased B cell numbers 
seemed characteristic of both diseases, as we found normal B cell numbers in 
patients with newly diagnosed, untreated RA. In addition, normal or even increased 
total B cell numbers have been found in antineutrophil cytoplasmic antibody 
(ANCA)–associated vasculitis and in other systemic inflammatory diseases [19, 
20, 27, 35, 36]. Disturbances in B cell homeostasis were also noted in Takayasu 
arteritis, although the absolute numbers of B cells were normal [20]. A direct 
comparison, however, with our data from untreated patients with newly diagnosed 
GCA or PMR remains difficult, because the patients with Takayasu arteritis had 
long-standing disease and had been treated with immunosuppressive drugs [20].
The decrease in circulating B cells in patients with newly diagnosed GCA or 
PMR could not be explained by a loss of B cells. Expression of antiapoptotic 
Bcl-2 suggested that circulating B cells were not more susceptible to apoptosis 
during active disease. Moreover, to correct for an actual loss of B cells (e.g., 
due to apoptosis), the circulating B cell pool would have to be replenished by 
newly produced B cells from the bone marrow or by hyperproliferation of already 
existing B cells. We provide evidence against both of these mechanisms. First, 
bone marrow production of new B cells was unlikely, since transitional B cells were 
nearly ablated by corticosteroid treatment. Instead, mature-naive and memory B 
cell subsets appeared in the circulation of treated patients with GCA or PMR in 
remission. Although we cannot fully exclude the possibility that some transitional 
B cells are released from the bone marrow early after initiation of treatment, 
our findings are consistent with previous studies indicating that corticosteroids 
induce apoptosis of precursor B cells [37, 38]. Second, circulating B cells are 
usually in a relatively quiescent state and have a low proliferation rate in healthy 
individuals [39]. Our data on Ki-67 expression in circulating B cells suggest that 
this is also true for circulating B cells in GCA and PMR patients before and 
during treatment. Moreover, proliferation of circulating B cells was even decreased 
in treated GCA patients, which is a known effect of corticosteroids [40]. Thus, 
we did not find evidence of either B cell replenishment from the bone marrow 
or compensatory hyperproliferation of circulating B cells. Taken together, these 
findings indicate that it is highly unlikely that the decrease in circulating B cells 
in patients with newly diagnosed GCA and PMR resulted from an actual loss of B 
cells. Instead, our data pointed at redistribution or intravascular marginalization 
of B cells during active disease.
Modulated serum levels of BAFF suggested that B cells were redistributed 
rather than marginalized in patients with newly diagnosed GCA or PMR. A recent 
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study indicated that the serum level of BAFF in humans is highly dependent 
on the number of circulating B cells [30]. This observation is further supported 
by findings from clinical trials of B cell depletion therapy [31, 41]. Intravascular 
marginalized B cells would probably still consume BAFF, as they remain in 
contact with the blood. Interestingly, serum BAFF levels were initially increased 
in patients with newly diagnosed GCA or PMR, but readily decreased upon the 
return of B cells during remission. Overall, serum BAFF levels showed a strong 
inverse correlation with circulating B cell numbers in patients with GCA or PMR. 
Although we cannot exclude the possibility that corticosteroids directly suppressed 
BAFF production to some extent [42], the increased serum levels of BAFF in 
corticosteroid-treated patients experiencing a relapse does not support such 
an effect. High levels of BAFF may favour selection of autoreactive B cells in 
autoimmune diseases [43]. Therefore, it would be interesting to study whether 
BAFF plays a role in the development of the various autoantibodies observed 
in GCA and PMR [11-15]. Although BAFF may also induce IL-6 production by 
monocytes [32, 33], we demonstrated that this process requires nonphysiologic 
BAFF concentrations that are much higher than the BAFF levels measured in the 
serum of patients with newly diagnosed GCA and PMR.
Of note, the return of B cells to the circulation in treated patients with GCA or 
PMR in remission was not an effect of corticosteroid treatment per se. Although 
corticosteroids can influence the homing of B cells in healthy humans, they usually 
direct B cells toward the tissues instead of the circulation [38]. Furthermore, B 
cells only returned in treated patients whose disease was in remission, and not 
in treated patients experiencing a relapse. Thus, the redistribution and return 
of B cells toward the circulation seemed to be associated with disease activity 
rather than corticosteroid treatment.
Although lymphocytes can be redistributed toward peripheral sites of 
inflammation, inflamed arteries and joints are likely not the most important 
homing sites for B cells during active GCA and PMR, respectively. Consistent 
with previous studies [6-10], we observed low-to-moderate numbers of B cells in 
the temporal arteries of GCA patients. Since B cells were not the predominant 
cells in the inflamed arteries, it seems unlikely that the decrease in circulating B 
cells in patients with active GCA was solely the effect of B cell migration toward 
inflamed arteries. Moreover, circulating numbers of B cells did not correlate 
with the number of inflamed arteries on the FDG-PET/CT scan in GCA patients 
with large vessel involvement. In addition, others have shown that very few B 
cells are present in the inflamed synovial tissue of PMR patients [5]. Therefore, 
we conclude that peripheral sites of inflammation, i.e., arteries and joints, are 
unlikely the primary homing sites for B cells during active GCA and PMR.
The exact reservoir for B cells during active GCA and PMR remains to be 
established, but secondary lymphoid tissues likely represent important homing 
sites for redistributed B cells in both diseases. Here, activated B cells can undergo 
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isotype-switching under the influence of T cell help [44]. Indeed, several findings 
indicate that enhanced B cell activation and isotype-switching occur in GCA and 
PMR patients. The prevalence of various IgG autoantibodies is increased in both 
GCA and PMR [11-14]. In GCA patients, we also noted a profound expansion of 
circulating unswitched memory B cells. This finding may suggest that B cells 
in the secondary lymphoid tissues of GCA patients are also activated in the 
absence of T cell help [45]. Interestingly, unswitched memory B cells are induced 
and maintained by the signalling of Toll-like receptors that are also implicated 
in the pathogenesis of GCA, such as Toll-like receptor 4 [46].
Ample evidence indicates that B cells produce not only antibodies, but also 
cytokines that modulate immune responses [34]. Intriguingly, inflammatory Beff 
cells rather than suppressive Breg cells seemed to be redistributed in patients with 
newly diagnosed GCA or PMR. Recently, decreased numbers of IL-10–producing Breg 
cells were found in ANCA-associated vasculitis [47], whereas normal numbers of 
Breg cells were found in other autoimmune diseases [22]. Our findings indicated 
that circulating Breg cells may not be subject to redistribution in patients with 
newly diagnosed GCA or PMR. Only TNFD-producing Beff cells [34] seemed to 
leave the circulation during active disease. Interestingly, returning Beff cells 
in patients with GCA or PMR demonstrated an enhanced potential to produce 
IL-6. This finding is relevant, since IL-6–producing B cells may potentiate T cell–
mediated autoimmunity in humans [24]. More specifically, IL-6 is currently thought 
to promote the pathogenic Th17 response in GCA and PMR [4, 48]. Since IL-6 
production by B cells is promoted by T cell help [24], and IL-6 is important for 
the development of Th17 cells [4], our findings point toward a delicate interplay 
between B cells and T cells in GCA and PMR. It would be interesting to evaluate 
whether IL-6 receptor blockade or B cell depletion therapy ameliorates disease 
activity in patients with GCA or PMR.
In conclusion, we demonstrate for the first time that the homeostasis of B cells 
is highly disturbed in patients with newly diagnosed GCA or PMR. B cells, including 
Beff cells, are decreased in the circulation during active disease, but return during 
corticosteroid-induced remission. B cells likely contribute to the enhanced IL-6 
response of patients with GCA or PMR. Our results justify further studies into B 
cells as biomarkers and possible targets for treatment in GCA and PMR.
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Supplemental table 1. Patient characteristics.
HC nGCA nPMR nRA
No. of subjects 40 16 18 11
Age, mean (SEM) 70 (±1.2) 69 (±2.0) 71 (±2.1) 70 (±1.8)
Sex, no. female (%) 27 (68%) 12 (75%) 12 (67%) 11 (100%)
TAB or FDG-PET-CT scan, no. 
positive for LVV (%)
NA 15 (94%) NA NA
Associated PMR, no. NA 3 NA NA
Leukocyte number, mean 
(SEM) 109 cells/L
6.2 (±0.2) 9.1 (±0.6) 9.1 (±0.6) 7.7 (±1.0)
ESR, median (range) mm/hr 11 (3-26) 61 (31-116) 52 (30-107) 29 (2-96)
CRP, median (range) mg/L 2.5 (2.5-7) 43 (11-116) 46 (16-186) 25 (2.5-108)
DAS28, median (range) NA NA NA 5.5 (3.2-7.8)
Characteristics of newly-diagnosed, corticosteroid/DMARD-free GCA patients (nGCA), PMR patients (nPMR) 
and RA patients (nRA) and healthy controls (HCs). No. = number. LVV = large vessel vasculitis. TAB = temporal 
artery biopsy. ESR = erythrocyte sedimentation rate. CRP = C-reactive protein. SEM = standard error of the 
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Supplemental figure 1. TNF-ǀand IL-10 production in B cell differentiation subsets. 
Whole blood samples of rGCA (n=5) and rPMR (n=5) patients were stimulation with PMA 
and Ca2+ ionophore in the presence of brefeldin A for 4 hours. Data are shown for 
GCA and PMR patients combined. (A) Intracellular TNF-D and IL-10 was measured in four 
distinct CD27/IgD defined B cell differentiation subsets. (B) Pie charts represent median 
proportions of TNF-D+IL-10-, TNF-D+IL-10+, TNF-D-IL-10+ and TNF-D-IL-10- cells among the 
four CD27/IgD defined B cell differentiation subsets.
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Abstract
Objectives: To investigate cellular makers of T cell activation, proliferation 
and differentiation for their ability to detect active disease in giant cell 
arteritis (GCA) and polymyalgia rheumatica (PMR) patients. 
Methods: CD4 counts, CD8 counts and absolute numbers of CD4 and 
CD8 T cell differentiation subsets were determined by flow cytometry in 
peripheral blood of 28 newly-diagnosed, untreated GCA/PMR patients, 
16 corticosteroid treated GCA/PMR patients in remission and 25 healthy 
controls. Expression of the activation marker HLA-DR and proliferation 
marker Ki-67 was determined. Receiver operating characteristic (ROC) 
analysis with area under the curve (AUC) and Spearman’s correlation 
coefficients were performed. 
Results: CD4 T cell counts were decreased in newly-diagnosed GCA 
and PMR patients. Central memory CD4 T cells were decreased in GCA 
patients only, and terminally differentiated CD4 T cells in PMR patients 
only. Percentages of HLA-DR+ and Ki-67+ CD4 T cells were increased in 
GCA patients, but not PMR patients. In essence, no modulation of the CD8 
T cell compartment was observed in GCA and PMR patients. Ten CD4 T cell 
parameters provided moderate discrimination between newly-diagnosed 
GCA/PMR patients and healthy controls, as indicated by AUCs of 0.7-0.8. 
Of these markers, only the percentage of Ki-67+ terminally differentiated 
CD4 T cells in GCA patients normalized upon remission and correlated 
with the ESR and CRP. 
Conclusions: Although CD4 T cells were modulated in GCA and PMR 
patients, cellular markers of T cell activation, proliferation and differentiation 
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Introduction
Giant cell arteritis (GCA) is a common form of primary, systemic vasculitis and 
affects large- and medium-sized arteries [1]. GCA patients may present with 
classic symptoms such as headache, jaw claudication and blindness, as well as 
less-specific symptoms including general malaise and weight loss. Polymyalgia 
rheumatica (PMR) is a closely related rheumatic disease associated with pain 
and stiffness of shoulders and hips due to synovitis, bursitis and enthesitis [1]. 
As the vast majority of GCA and PMR patients presents with an increased 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level, these 
markers play an important role in the diagnosis of both diseases [1]. However, 
the ESR and CRP remain normal in a subset of newly-diagnosed patients [2, 3]. 
Furthermore, these inflammatory markers are not always increased in GCA and 
PMR patients who suffer from relapse during tapering of their corticosteroid 
treatment [4]. The ESR and CRP also become less reliable markers of disease 
activity upon treatment with anti-IL-6R therapy, which is currently under 
investigation in trials with GCA and PMR patients. Thus, identifying novel markers 
for disease activity would not only be relevant for daily clinical care of GCA 
and PMR patients, but also for the growing number of clinical trials with these 
patients [5, 6]. 
As T cells play a critical role in GCA and PMR [7], we performed a 
comprehensive analysis of T cells and their expression of activation, proliferation 
and differentiation markers in well-defined cohorts of GCA and PMR patients. 
Subsequently, we investigated the utility of T cells as markers for disease 
activity in GCA and PMR. We aimed to identify T cell parameters that (1) 
discriminate newly-diagnosed patients from healthy controls, (2) normalize upon 
remission and (3) correlate well with the ESR and CRP. The latter requirement 
was proposed, as a novel biomarker should modulate along with the ESR and 




Twenty-eight patients with newly-diagnosed GCA (n=14) or PMR (n=14) were enrolled 
before start of treatment (supplementary Table S1). GCA patients fulfilled the ACR criteria 
and PMR patients the Chuang/Hunder criteria [8, 9]. Follow-up samples were obtained 
from 16 patients with GCA (n=9) or PMR (n=7) that were in remission after 3 months of 
corticosteroid treatment. Remission was defined as absence of signs/symptoms of active 
GCA or PMR and a normal ESR (<30 mm/hr). Control samples were collected from 25 age-
matched healthy individuals. All procedures were in compliance with the declaration of 
Helsinki. Written informed consent was obtained from all study participants and the study 
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Treatment
As previously described [10], patients with GCA and patients with PMR were initially treated 
with 60 mg/day and 20 mg/day of prednisolone, respectively. Tapering of corticosteroid 
treatment started after 3-4 weeks and further continued based on clinical and laboratory 
findings during follow up. After 3 months the median prednisolone dosage was 20 mg/
day (range 10-40) in GCA patients and 15 mg/day (range 12.5-17.5) in PMR patients. 
Flow cytometry
Absolute numbers of CD3, CD4 and CD8 T cells were determined according to the MultiTest 
TruCount method (BD). Peripheral blood mononuclear cells were isolated by density 
gradient centrifugation with Lymphoprep (Axis-Shield). Cells were stained with the following 
monoclonal antibodies: CD3-efluor605, CD4-efluor450, HLA-DR-APC-efluor780, CD8-alexa-
fluor700 (eBioscience), CCR7-PE-Cy7 and CD45RO-FITC (BD). Subsequently, cells were fixed 
and permeabilized with FOXP3 Staining Buffer Set (eBioscience) followed by intracellular 
staining with Ki-67-PerCP-Cy5.5 antibody (BD). Samples were measured on a LSR-II flow 
cytometer (BD) and analyzed with Kaluza Flow Analysis software (Beckman Coulter). 
Statistical analysis
The Mann Whitney U test was used to compare newly-diagnosed patients and healthy 
controls. The Wilcoxon Signed Rank test was used to compare the same patients over 
time. Receiver operating characteristic (ROC) analysis with area under the curve (AUC) 
was performed. Optimal cut-off points were identified according to the Youden Index. 
Correlations were determined with Spearman’s correlation coefficient. Two-tailed p values 
<0.05 were considered statistically significant. Statistics were performed in IBM SPSS 
Statistics 20 and Graphpad Prism 5.0. 
Results
CD4 T cells are modulated in newly-diagnosed GCA and PMR 
patients
Total CD3 counts were decreased in newly-diagnosed GCA (nGCA) and PMR 
(nPMR) patients when compared to healthy controls (Table 1). This decrease 
was caused by a decline in CD4 T cell counts, but not CD8 T cell counts, 
in nGCA and nPMR patients. Next, distinct CD4 T cell differentiation subsets 
were identif ied based on CD45RO and CCR7 expression (supplementary 
Figure S1). Although CD4 TNaive cell counts tended to be lower in nGCA and 
nPMR patients than in healthy controls, these differences did not reach 
statistical significance (Table 1). In contrast, CD4 TCM cells were significantly 
decreased in nGCA patients only, whereas CD4 TTD were decreased in nPMR 
patients only. No differences were observed between CD4 TEM cell counts of 
newly-diagnosed patients and healthy controls. In essence, absolute numbers 
of CD8 T cell differentiation subsets were not modulated in nGCA and nPMR 
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Table 1. T cell parameters in GCA/PMR patients. 
T cell parameters Area under the curve









1.47 (0.77-2.04) 1.01 (0.72-2.23)* 1.04 (0.53-1.88)* 0.73 0.71
CD4
counta
1.00 (0.42-1.61) 0.69 (0.42-1.71)* 0.77 (0.40-1.39)* 0.75 0.71
CD8 
counta
0.31 (0.09-0.68) 0.31 (0.14-0.68) 0.27 (0.10-0.65) 0.61 0.62
CD4 TNaive 
counta
0.47 (0.09-1.10) 0.31 (0.08-1.05) 0.28 (0.10-0.85) 0.64 0.60
CD4 TCM 
counta
0.22 (0.10-0.54) 0.16 (0.06-0.42)* 0.21 (0.07-0.42) 0.71 0.53
CD4 TEM 
counta
0.22 (0.07-0.95) 0.20 (0.06-0.63) 0.15 (0.04-0.49) 0.53 0.69
CD4 TTD 
counta
0.03 (0.01-0.19) 0.02 (0.01-0.21) 0.01 (0.01-0.08)* 0.68 0.72
CD4   
%HLA-DR+
3.3 (1.2) 7.0 (2.0-17.4)* 4.7 (2.3-10.1) 0.74 0.63
CD4 TNaive 
%HLA-DR+
0.21 (0.07-1.28) 0.21 (0.06-1.06) 0.23 (0.10-0.59) 0.59 0.56
CD4 TCM 
%HLA-DR+
3.1 (1.2-10.2) 3.6 (2.2-9.2) 3.6 (1.5-7.0) 0.62 0.56
CD4 TEM 
%HLA-DR+
12.4 (2.5-38.5) 22.4 (2.5-35.6)** 15.5 (8.7-31.3) 0.77 0.68
CD4 TTD 
%HLA-DR+
2.7 (1.2-30.1) 6.0 (1.9-18.7)* 5.5 (2.4-17.7) 0.69 0.68
CD4      
%Ki-67+
1.1 (0.4-7.8) 2.0 (0.7-3.7)* 1.6 (0.6-2.7) 0.72 0.63
CD4 TNaive 
%Ki-67+
0.13 (0.04-6.03) 0.10 (0.4-0.21)* 0.12 (0.02-0.34) 0.71 0.62
CD4 TCM 
%Ki-67+
1.7 (0.5-10.9) 1.7 (1.0-4.7) 1.6 (0.4-3.7) 0.53 0.55
CD4 TEM 
%Ki-67+
2.9 (0.7-9.9) 5.8 (1.1-10.1)** 4.1 (1.5-14.8) 0.78 0.68
CD4 TTD 
%Ki-67+
0.9 (0.2-7.5) 1.5 (0.9-4.2)* 1.5 (0.3-4.9)* 0.74 0.71
T cell parameters were determined in 14 newly-diagnosed GCA patients, 14-newly-diagnosed PMR patients and 
25 age-matched healthy controls. The following CD45RO/CCR7 deﬁned CD4 T cell diﬀerentiation subsets were 
identiﬁed: CD4 T
Naive
 (CD45RO-CCR7+) cells, CD4 T
CM
 (CD45RO+CCR7+) cells, CD4 T
EM
 (CD45RO+CCR7-) cells 
and CD4 T
TD
 (CD45RO-CCR7-) cells. Statistical signiﬁcance of patients versus healthy controls was tested by 
Mann Whitney U test and is indicated as * p < 0.05 and ** p < 0.01. Percentages of HLA-DR+ and Ki-67+ cells were 
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Enhanced activation and proliferation of CD4 TEM cells in newly-
diagnosed GCA patients 
The percentage of HLA-DR+ (i.e. activated) CD4 T cells was significantly higher 
in nGCA patients than healthy controls (Table 1 and supplemental Figure S2A). 
This increase resulted from an increase in HLA-DR+ CD4 TEM cells and HLA-DR+ 
CD4 TTD cells in nGCA patients. In contrast, no increase of HLA-DR+ CD4 T cells 
was observed in PMR patients. CD8 T cells and CD8 T cell differentiation subsets 
of nGCA and nPMR patients showed similar expression of HLA-DR as those of 
healthy controls (Supplementary Table S2). 
In addition, T cells were evaluated for expression of the proliferation marker 
Ki-67 (supplemental Figure S2B). The percentage of Ki-67+ cells was increased 
among CD4 T cells, CD4 TEM cells and CD4 TTD cells of nGCA patients. In 
contrast, the percentage of Ki-67+ cells was decreased among CD4 TNaive cells of 
nGCA patients (Table 1). Ki-67+ CD4 TTD cells were increased in nPMR patients, 
whereas normal percentages of Ki-67+ cells were observed in other CD4 T cell 
subsets of nPMR patients. Although Ki-67+ CD8 TEM cells were increased in nGCA 
patients, the percentage of Ki-67+ cells was not modulated among other CD8 
T cell differentiation subsets of nGCA or nPMR patients (supplemental Table S2). 
T cell markers provide limited discrimination between newly-
diagnosed patients and healthy controls 
In a ROC analysis, we next investigated the diagnostic accuracy of the T cell 
parameters for distinguishing nGCA and nPMR patients from healthy controls. 
None of the T cell parameters provided acceptable AUCs >0.80. Nine T cell 
parameters provided moderate discrimination between nGCA patients and healthy 
controls, as indicated by AUCs 0.70-0.80 (Table 1): CD3 counts, CD4 counts, CD4 
TCM counts, the percentages of HLA-DR+ CD4 T cells and HLA-DR+ CD4 TEM cells, 
the percentages of Ki-67+ CD4 T cells, Ki-67+ CD4 TNaive cells, Ki-67+ CD4 TEM 
cells and Ki-67+ CD4 TTD cells. Only four T cell parameters distinguished nPMR 
patients from healthy controls with AUCs >0.70: CD3 counts, CD4 counts, CD4 
TTD counts and the percentage of Ki-67+ CD4 TTD cells. None of these T cell 
parameters provided a combination of high sensitivity and high specificity at 
their optimal cut-off points (supplementary Tables S3 and S4). 
Modulation of T cell markers upon corticosteroid-induced remission 
Next, we assessed the T cell parameters that were significantly modulated in 
newly-diagnosed patients for changes upon corticosteroid-induced remission. 
Although the percentages of Ki-67+ CD4 T cells, Ki-67+ CD4 TNaive cells and 
Ki-67+ CD4 TTD cells showed a decline in GCA patients that were in remission 
(Figure 1A), no significant modulation of other T cell parameters was observed 
in GCA or PMR patients in remission (rGCA and rPMR). Notably, the modulation 
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a normalization, whereas the modulation of Ki-67+ CD4 TNaive cells patients 
represented a further deviation from normal values. 
Finally, we studied the relation between the three T cell parameters that 
were modulating in rGCA patients and the classic markers of inflammation, the 
ESR and CRP. The percentages of Ki-67+ CD4 TNaive and Ki-67+ CD4 TTD cells 
showed a moderate, positive correlation with the ESR and CRP in GCA patients 
(Figure 1B). In contrast, the percentage of Ki-67+ CD4 T cells did not correlate 
significantly with the ESR or CRP in GCA patients. 
Figure 1. Modulation of T cell parameters upon corticosteroid-induced remission. 
(A) T cell parameters that were significantly modulated in newly-diagnosed GCA (nGCA) 
and newly-diagosed PMR (nPMR) patients are shown in combination with values obtained 
from the same patients in remission (rGCA and rPMR) after 3 months of corticosteroid 
treatment. Statistical significance by Wilcoxon Signed Rank test is indicated as * p < 0.05. 
(B) Correlation of the three T cell parameters that were modulated upon corticosteroid-
remission in GCA patients and the ESR and CRP. Statistical significance by Spearman’s 
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Discussion
This is the first study evaluating cellular T cell markers for their ability to detect 
active disease in GCA and PMR patients. Numbers of CD4 T cells and CD4 T cell 
differentiation subsets were modulated in newly-diagnosed GCA and PMR patients 
when compared to healthy controls. Increased activation and proliferation of 
CD4 T cells was observed in newly-diagnosed GCA patients. Cellular markers 
of T cell activation, proliferation and differentiation provided limited diagnostic 
accuracy for detecting active GCA and PMR. Furthermore, cellular T cell markers 
demonstrated limited modulation upon corticosteroid-induced remission and only 
correlated moderately with the ESR and CRP. 
Novel markers for active GCA and PMR are needed, as the ESR and CRP are 
not always increased during active disease [2-4]. In this early phase of biomarker 
identification, we aimed to identify markers that: (1) show high diagnostic accuracy 
in discriminating newly-diagnosed patients from healthy controls, (2) normalize 
upon remission and (3) correlate well with the ESR and CRP. Neither of the T cells 
parameters studied here fulfilled the first criterion in GCA and PMR patients. 
None of the T cell parameters fulfilled the second criterion in PMR patients, 
whereas only two parameters normalized during remission in GCA patients. Out 
of these two parameters, only one correlated moderately with the ESR and CRP. 
Taken together, none of the T cell parameters represented a promising marker 
for active disease in GCA and PMR patients. Hence, future studies should rather 
focus on biomarkers with more promising diagnostic profiles, such as serum 
IL-6 and BAFF [11-13]. 
Whereas CD4 T cells showed enhanced expression of activation and proliferation 
markers in GCA patients, we observed little modulation of CD8 T cells in these 
patients. Our findings therefore suggest that GCA is a CD4 T cell driven rather 
than CD8 T cell driven disease [7]. Indeed, development of GCA is associated with 
the presence of certain amino acids in the peptide binding groove of HLA-DR4, 
which is involved in antigen presentation to CD4 T cells [14]. Furthermore, CD4 
T cells secreting Th1 and Th17 cytokines predominate in vascular infiltrates of 
GCA patients [7], whereas CD8 T cells are rarely found in affected arteries [15]. 
Early studies suggested that CD8 T cell counts are decreased during active 
GCA, but this observation could neither be confirmed by others [16], nor by us 
in the current study. In contrast, little activation and proliferation was observed 
among CD4 T cells of PMR patients. Although the circulating pool of Th1 and 
Th17 cells may be expanded in PMR patients [17], it has been suggested that 
activation of CD4 T cells is limited in PMR [18]. Our findings would support this 
notion. Alternatively, it is possible that few activated and proliferating CD4 T cells 
are present in the circulation of PMR patients, as these cell might be homing 
extensively towards inflamed joints of these patients [19]. 
A limitation of our study is its small sample size. Consequently, small but 
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have gone unnoticed. Furthermore, it is possible that the observed changes in 
T cell parameters during remission may reflect corticosteroid treatment rather 
than a decline of disease activity. Nevertheless, our data are robust enough to 
conclude that the T cell parameters studied here are not suitable biomarkers 
for disease activity in GCA and PMR patients. 
In conclusion, we show that the CD4 T cell compartment is modulated in 
GCA and PMR patients. However, markers of T cell activation, proliferation and 
differentiation are not useful for detecting active disease in GCA and PMR patients. 
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Supplementary materials
Supplementary Table S1. Patient characteristics. 
HC
GCA PMR
New Remission New Remission
No. of subjects 25 14 9 14 7
Age, mean (SD) 70 (7) 69 (8) 68 (10) 71 (10) 70 (11)
Sex, no. female 20 12 8 8 3
TAB or FDG-PET-CT scan, 
no. positive for LVV 
NA 12 8 NA NA
No. of GCA patients with 
associated PMR
NA 2 2 NA NA
ESR, median (range) mm/hr 11 (3-24) 62 (31-116) 13 (6-24) 50 (30-107) 6 (3-11)
CRP, median (range) mg/L 3 (3-3) 40 (11-112) 3 (3-8) 44 (16-186) 6 (3-7)
Samples of GCA/PMR patients in remission were collected 3 months after initiation of prednisolone treatment. 
None of the patients were treated with disease-modifying antirheumatic drugs at time of blood withdrawal. 
HC = healthy control. No. = number. SD = standard deviation. TAB = temporal artery biopsy. LVV = large vessel 
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Supplementary Table S2. CD8 T cell parameters in GCA/PMR patients.
CD8 T cell parameters Area under the curve









0.04 (0.00-0.11) 0.04 (0.01-0.23) 0.04 (0.01-0.12) 0.51 0.53
CD8 TCM 
counta
0.01 (0.00-0.03) 0.01 (0.00-0.07) 0.01 (0.01-0.03) 0.62 0.51
CD8 TEM 
counta
0.14 (0.02-0.30) 0.11 (0.04-0.28) 0.08 (0.3-0.29) 0.61 0.68
CD8 TTD 
counta
0.14 (0.03-0.49) 0.11 (0.02-0.39) 0.12 (0.01-0.34) 0.57 0.52
CD8  
%HLA-DR+
6.2 (1.2-24.4) 9.2 (1.8-25.3) 8.8 (1.6-24.5) 0.60 0.54
CD8 TNaive 
%HLA-DR+
0.54 (0.14-5.12) 0.57 (0.09-1.47) 0.54 (0.06-3.04) 0.55 0.57
CD8 TCM 
%HLA-DR+
6.5 (1.8-32.4) 8.0 (2.0-28.1) 5.5 (0.9-16.8) 0.51 0.57
CD8 TEM 
%HLA-DR+
11.9 (2.8-42.1) 16.3 (4.9-34.7) 15.0 (2.5-27.6) 0.64 0.61
CD8 TTD 
%HLA-DR+
6.1 (0.5-23.1) 7.9 (1.4-25.9) 6.8 (0.5-23.7) 0.62 0.55
CD8      
%Ki-67+
1.2 (0.5-4.5) 1.5 (0.6-5.9) 1.6 (0.2-5.8) 0.67 0.65
CD8 TNaive 
%Ki-67+
0.37 (0.06-3.47) 0.18 (0.08-0.91) 0.21 (0.02-0.65) 0.58 0.56
CD8 TCM 
%Ki-67+
2.8 (0.4-14.6) 2.3 (0.4-16.1) 2.3 (0.0-6.1) 0.57 0.63
CD8 TEM 
%Ki-67+
1.9 (0.6-7.7) 2.8 (1.2-14.8)* 3.1 (0.4-16.5) 0.72 0.68
CD8 TTD 
%Ki-67+
0.7 (0.3-2.0) 0.9 (0.5-2.0) 1.1 (0.1-3.7) 0.68 0.68
T cell parameters were determined in 14 newly-diagnosed GCA patients, 14-newly-diagnosed PMR patients and 
25 age-matched healthy controls. The following CD45RO/CCR7 deﬁned CD8 T cell diﬀerentiation subsets were 
identiﬁed: CD8 T
Naive
 (CD45RO-CCR7+) cells, CD8 T
CM
 (CD45RO+CCR7+) cells, CD8 T
EM
 (CD45RO+CCR7-) cells and 
CD8 T
TD
 (CD45RO-CCR7-) cells. Statistical signiﬁcance of patients versus healthy controls was tested by Mann 
Whitney U test and is indicated as * p < 0.05. Percentages of HLA-DR+ and Ki-67+ cells were enumerated within 
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Supplementary Table S3. Diagnostic accuracy of T cell parameters in discriminating 
newly-diagnosed GCA patients from healthy controls.
nGCA vs. HC
AUC (95%CI) Optimal cut-off Sensitivity (%) Specificity (%)
CD3 count (109/L) 0.73 (0.56-0.90) 1.36 93 60
CD4 count (109/L) 0.75 (0.58-0.92) 0.85 71 72
CD4 TCM count 
(109/L)
0.71 (0.54-0.89) 0.19 79 60
CD4  
(%HLA-DR+)
0.74 (0.57-0.90) 3.4 86 52
CD4 TEM  
(%HLA-DR+)
0.77 (0.61-0.94) 15.1 86 68
CD4 
(%Ki-67+)
0.72 (0.55-0.89) 1.7 64 80
CD4 TNaive 
(%Ki-67+)
0.71 (0.55-0.88) 0.13 79 56
CD4 TEM 
(%Ki-67+)
0.78 (0.62-0.94) 3.4 86 68
CD4 TTD 
(%Ki-67+)
0.74 (0.58-0.89) 0.86 100 52
Areas under the curves (AUC) and the optimal cut-oﬀ points with corresponding sensitivity and speciﬁcity were 
calculated.
Supplementary Table S4. Diagnostic accuracy of T cell parameters in discriminating 
newly-diagnosed PMR patients from healthy controls.
nPMR vs. HC
AUC (95%CI) Optimal cut-off Sensitivity (%) Specificity (%)
CD3 count (109/L) 0.71 (0.53-0.88) 1.43 86 56
CD4 count (109/L) 0.71 (0.53-0.90) 0.91 79 64
CD4 TTD count 
(109/L)
0.72 (0.54-0.90) 0.02 57 84
CD4 TTD         
(%Ki-67+)
0.71 (0.53-0.88) 0.9 86 56
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Supplementary Figure S1. Representative flow cytometric staining for CD4 T cell 
differentiation subsets. CD4 TNaive (CD45RO-CCR7+), CD4 TCM (CD45RO+CCR7+), CD4 TEM 
(CD45RO+CCR7-) and CD4 TTD (CD45RO-CCR7-) cells were identified in peripheral blood 
of healthy controls, GCA patients and PMR patients. Representative flow cytometric plots 
are shown. 
Supplementary Figure S2. Representative flow cytometric staining for HLA-DR and 
Ki-67. (A) Percentages of HLA-DR expressing cells and (B) percentages of Ki-67 expressing 
cells were determined among CD4 T cell differentiation subsets of healthy controls, GCA 
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Abstract
Objective. To compare multiple serum markers for their ability to detect 
active disease in patients with GCA and in those with PMR.
Methods. Twenty-six markers related to immune cells that may be 
involved in GCA and PMR were determined by ELISA and multiplex assay 
in the serum of 24 newly diagnosed, untreated GCA/PMR patients, 14 
corticosteroid (CS)-treated GCA/PMR patients in remission and 13 healthy 
controls. Receiver operating characteristic analysis with area under the 
curve and Spearman’s correlation coefficients were performed.
Results. Serum B-cell activating factor (BAFF), CXCL9 and IL-6 were 
increased in newly diagnosed GCA and PMR patients. Serum CCL2, CCL11, 
IL-10 and sIL-2R were modulated in GCA patients only and CXCL10 in 
PMR patients only. BAFF, CXCL9 and IL-6 accurately distinguished newly 
diagnosed GCA and PMR patients from healthy controls, as shown by an 
area under the curve > 0.80. Upon CS-induced remission, serum BAFF 
and IL-6 decreased significantly in both GCA and PMR patients, whereas 
CXCL9 remained high. Serum BAFF and IL-6 correlated strongly with the 
ESR and CRP in GCA and PMR patients.
Conclusion. Among the serum markers tested, BAFF and IL-6 showed 
the strongest association with disease activity in both GCA and PMR 
patients. The diagnostic value of these markers should be evaluated in 
larger, longitudinal studies with GCA and PMR patients, and in patients 
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Introduction
GCA and PMR are closely related inflammatory diseases that frequently co-occur 
[1]. GCA involves inflammation of large- and medium-sized arteries and gives 
rise to classic symptoms such as headache, blindness and stroke. PMR is a 
rheumatic disease characterized by pain and stiffness of shoulders and hips.
Besides careful examination of clinical signs and symptoms, the assessment 
of GCA and PMR patients typically relies on measurement of the ESR and serum 
levels of CRP. The ESR has been considered the gold standard inflammation marker 
in GCA and PMR for many years, and is also part of the classification criteria 
for GCA and PMR [1]. Although the ESR and CRP are increased in the majority 
of GCA and PMR patients with active disease [2, 3], these inflammatory markers 
remain normal in a subpopulation of patients [2, 3]. As objective measures for 
disease activity are important not only for daily clinical practice, but also for 
evaluating treatment outcomes in clinical trials, novel markers for active GCA 
and PMR are needed [4, 5].
As a first step towards identifying alternative markers for active GCA and PMR, 
we performed a comprehensive analysis of 26 serum markers in well-defined 
cohorts of GCA and PMR patients. These markers, which were related to immune 
cells that may be involved in the immunopathology of GCA and PMR [6, 7], 
were studied both before and after initiation of corticosteroid (CS) treatment. In 
essence, we searched for markers that not only discriminated newly diagnosed 




In a prospective study [7], 24 patients with newly diagnosed GCA (n = 12) or PMR (n = 12) 
were enrolled (supplementary Table S1). None of these patients received CSs or DMARDs 
at the time of blood withdrawal. GCA patients fulfilled the ACR criteria and PMR patients 
the Chuang/Hunder criteria [8, 9]. An 18F-fluorodeoxyglucose-PET/CT scan with similar 
or enhanced glucose uptake by large vessels in comparison with the liver was considered 
equal as a diagnostic criterion to a positive temporal artery biopsy. Follow-up samples 
were obtained from 14 patients with GCA (n = 7) or PMR (n = 7) who were in remission 
after 3 months of CS treatment. Remission was defined as absence of symptoms and a 
normal ESR (<30 mm/h). Control samples were collected from 13 age-matched healthy 
individuals. All procedures were in compliance with the Declaration of Helsinki. Written 
informed consent was obtained from all study participants, and the study was approved 
by the medical ethics committee of the University Medical Center Groningen (UMCG).
Measurement of serum markers
ʵˇ˔˗ˏ˕˃ˏ˒ˎˇ˕˙ˇ˔ˇ˕˖ˑ˔ˇˆ˃˖˵ʖʒ˲ʥ˃ːˆ˗˕ˇˆˈˑ˔˃ː˃ˎ˛˕ˋ˕ˋˏˏˇˆˋ˃˖ˇˎ˛˃ˈ˖ˇ˔˖ˊ˃˙ˋːˉʎ
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The other 25 serum markers were measured with the Human Cytokine 25-plex (Life 
Technologies). The limits of detection of all measurements are provided in supplementary 
Table S2. All procedures were performed according to the manufacturer’s instructions.
Statistical analysis
The Mann–Whitney U-test was used to compare serum markers between groups. The 
Wilcoxon Signed Rank test was used to compare serum markers within groups over time. 
Receiver operating characteristic (ROC) analysis with area under the curve (AUC) was 
performed for non-paired samples only, i.e. patients vs healthy controls. Optimal cut-off 
points were identified by assessing the maximum of the sum of sensitivity and specificity, 
according to the Youden Index. Correlations were determined with Spearman’s rho correlation 
coefficient. Two-tailed P-values <0.05 were considered statistically significant. Statistics 
were performed in IBM SPSS Statistics 20 and Graphpad Prism 5.0.
Results
Serum markers discriminating newly diagnosed GCA and PMR 
patients from healthy controls
Eight out of 26 serum markers were significantly modulated in newly diagnosed 
GCA and/or PMR patients vs healthy controls (Table 1). Serum BAFF, CXCL9 
and IL-6 were increased in both newly diagnosed GCA and newly diagnosed 
PMR patients. Serum CCL2 and CCL11 were decreased in GCA patients only, 
whereas serum IL-10 and sIL-2R were increased. In contrast, serum CXCL10 was 
increased in PMR patients only. Thus, both overlapping and specific changes in 
serum markers were observed in GCA and PMR patients (supplementary Fig. S1). 
In a ROC analysis, we next determined the diagnostic accuracy of individual 
markers in distinguishing newly diagnosed patients from healthy controls. Serum 
CXCL9 and IL-6 provided excellent discrimination of newly diagnosed GCA and 
PMR patients from healthy controls, as indicated by AUCs > 0.90 (Table 1 
and supplementary Table S3). Serum BAFF also accurately distinguished newly 
diagnosed GCA and PMR patients from healthy controls, with AUCs > 0.80. 
Serum CXCL10, which was not modulated in GCA, could discriminate between 
PMR patients and healthy controls, as shown by an AUC > 0.80. None of the 
other markers provided an AUC > 0.80. Taken together, CXCL9, IL-6 and BAFF 
were the most accurate markers for discriminating newly diagnosed GCA and 
PMR patients from healthy controls. Of interest, these three serum markers were 
increased in most GCA and PMR patients in whom ESR levels did not fulfil the 
classification criteria for GCA or PMR [1], respectively (supplementary Table S4).
Serum markers modulating upon CS-induced remission in GCA and PMR
Next, we evaluated the eight serum markers that were significantly modulated in 
patients at baseline, for changes upon remission after 3 months of CS treatment. 
Serum levels of BAFF and IL-6 were significantly decreased in GCA and PMR patients 
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Table 1. Serum marker levels in newly-diagnosed GCA and PMR patients.
Serum marker levels (pg/mL)a Area under the curve 







BAFF 1013 (765-3794) 1321 (1019-1578)*** 1204 (912-2064)** 0.90 0.83
CCL2 612 (445-924) 461 (295-960)* 634 (274-912) 0.74 0.56
CCL3 74 (61-85) 74 (60-135) 73 (58-82) 0.51 0.57
CCL4 77 (48-149) 77 (29-191) 75 (40-106) 0.51 0.61
CCL5a 6.6 (4.9-6.6) 6.6 (2.6-6.6) 6.6 (6.6-6.6) 0.55 0.51
CCL11 164 (88-414) 118 (49-463)* 132 (60-296) 0.76 0.71
CXCL9 35 (18-51) 88 (21-704)*** 64 (39-333)*** 0.93 0.97
CXCL10 65 (38-99) 68 (48-114) 95 (36-204)** 0.67 0.85
GM-CSF 11 (7-29) 11 (5-2457) 9 (5-17) 0.60 0.64
IFN-D 39 (35-51) 39 (35-51) 39 (31-43) 0.57 0.63
IFN-J 131 (87-153) 142 (114-170) 123 (103-182) 0.63 0.56
IL-1E 5.2 (0.1-56.6) 2.0 (0.1-84.2) 2.9 (0.3-85.5) 0.55 0.54
IL-2 5 (1.3-11.4) 3,5 (2.0-51.2) 4.6 (2.7-23.6) 0.62 0.57
IL-4 183 (142-236) 178 (146-346) 188 (133-236) 0.52 0.51
IL-5 7.1 (5.3-10.9) 7.1 (5.3-9.0) 6.2 (3.4-9.0) 0.53 0.64
IL-6 2 (1-6) 15 (4-494)*** 35 (11-175)*** 0.98 1.00
IL-7 13 (1-48) 13 (1-257) 14 (4-51) 0.51 0.60
IL-8 20 (8-239) 19 (0-41) 27 (0-597) 0.65 0.51
IL-10 0.7 (0.4-1.7) 2.1 (0.7-29.0)* 0.7 (0.4-4.7) 0.80 0.59
IL-12 796 (574-964) 804 (634-1094) 857 (576-1396) 0.51 0.55
IL-13 4.2 (0.0-11.0) 7.7 (4.2-11.0) 4.2 (0.0-17.3) 0.64 0.54
IL-15 22 (17-34) 23 (15-31) 23 (17-29) 0.61 0.60
IL-17 65 (61-76) 72 (61080) 72 (57-80) 0.67 0.67
TNF-a 10 (7-12) 11 (8-12) 10 (9-12) 0.68 0.60
sIL-1Ra 163 (125-305) 182 (107-1140) 192 (107-326) 0.51 0.52
sIL-2R 773 (638-980) 911 (722-1085)* 851 (756-1085) 0.80 0.70
Serum levels of 26 markers were measured in 12 newly-diagnosed GCA patients, 12 newly-diagnosed PMR 
patients and 13 age-matched healthy controls. Values are presented as median (range). Statistical signiﬁcance 
of patients versus healthy controls is indicated as * p < 0.05, ** p < 0.01, *** p < 0.001. a ng/mL.
addition, serum CCL2 was increased in GCA patients in remission, but not in PMR 
patients. No significant modulation of CXCL9, CXCL10, IL-10 or sIL-2R was observed 
upon CS-induced remission. Among the serum markers that were not modulated at 
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Figure 1. Correlation of serum markers with disease activity in GCA and PMR. (A) 
Serum levels of the 8 markers that were initially modulated in newly-diagnosed GCA and 
PMR patients (nGCA and nPMR) are shown in combination with the serum levels of the 
same patients in remission (rGCA and rPMR) after 3 months of corticosteroid treatment. 
Statistical significance is indicated as * p < 0.05. (B) Correlation coefficients between 
these 8 serum markers and the ESR and CRP. Cell colours indicate the strength of the 





arkers in GCA and PM
R
Serum markers correlating with the ESR and CRP in GCA and PMR
Finally, we studied the serum markers that were initially modulated in newly 
diagnosed GCA and PMR patients for correlations with the ESR and CRP. Serum 
BAFF provided correlation coefficients of >0.75 with the ESR and CRP in both 
GCA and PMR patients (Fig. 1B and supplementary Fig. S2). Serum IL-6 correlated 
strongly with the ESR and CRP in PMR patients and moderately in GCA patients, 
as indicated by correlation coefficients of >0.75 and >0.50, respectively. Serum 
CCL2 and CCL11 showed a moderate to strong inverse correlation with the ESR 
and CRP in GCA patients, but not in PMR patients. Serum CXCL9 correlated 
moderately with the ESR and CRP in PMR patients only. Serum CXCL10, IL-10 
and sIL-2R, which were modulated at baseline, did not correlate with ESR and 
CRP in patients with GCA or PMR. Taken together, serum BAFF and IL-6 showed 
stronger correlations with ESR and CRP in GCA and PMR patients than any other 
serum marker studied.
Discussion
This is the first study to compare serum levels of 26 markers in GCA and PMR 
patients with those in healthy controls. Three serum markers (i.e. BAFF, CXCL9 
and IL-6) were increased in both newly diagnosed GCA and newly diagnosed 
PMR patients. Moreover, these markers discriminated well between patients and 
healthy controls. Serum BAFF and IL-6, but not CXCL9, were attenuated upon 
CS-induced remission and showed the strongest association with disease activity 
in both GCA and PMR patients.
Objective markers that reflect active inflammation in GCA and PMR patients 
are important not only for daily clinical practice, but also for therapeutic trials 
with these patients [4, 5]. The ESR and CRP, which are the most commonly 
used markers in the diagnosis of active GCA and PMR [1], remain normal in a 
subgroup of GCA and PMR patients with active disease [2, 3]. Consequently, active 
disease may go undetected in these patients and disease-related complications 
can arise [10]. Among the serum markers tested here, serum BAFF and L-6 
showed the strongest association with disease activity in GCA and PMR patients. 
Markers that are modulated in both diseases are attractive, because GCA and 
PMR frequently co-occur [1]. In addition, other serum markers were modulated 
either in newly diagnosed GCA patients (i.e. CCL2, CCL11, IL-10 and sIL-2R) or 
in newly diagnosed PMR patients (i.e. CXCL10). Although none of these markers 
showed diagnostic potential comparable to that of BAFF and IL-6, the differential 
modulation of these serum proteins would suggest that distinct pathological 
processes may be involved in GCA and PMR.
As in other inflammatory conditions [11], serum IL-6 is increased in active 
GCA and PMR [12, 13]. IL-6 has been linked to the enhanced Th17 response in 
GCA and PMR and is locally expressed in inflamed arteries of GCA patients [6]. 





arkers in GCA and PM
R
in GCA and PMR than the ESR and CRP [1, 13]. We here confirm that serum IL-6 
is increased in newly diagnosed GCA and PMR patients and decreases upon 
remission. Serum IL-6 accurately discriminated GCA and PMR patients from healthy 
controls and correlated strongly with the ESR and CRP in both patient groups. 
Thus, our findings confirm that IL-6 may be a valuable marker for diagnosing 
active GCA and PMR [1, 13].
Serum BAFF also distinguished newly diagnosed GCA and PMR patients from 
healthy controls and correlated strongly with disease activity in both diseases. 
BAFF is an important regulator of B cell responses and has been linked to the 
development of many autoimmune diseases [14]. Serum BAFF is constitutively 
produced by stromal cells, but this cytokine can also be produced by monocytes 
upon exposure to pro-inflammatory cytokines such as IFN-J [14]. BAFF is therefore 
regulated in a different way from IL-6 and CRP. It remains to be elucidated to 
what extent BAFF is expressed in inflamed arteries of GCA patients. In addition, 
serum BAFF levels are influenced by the presence of circulating B cells, which 
are decreased during active GCA and PMR [7]. Although elevated serum levels 
of BAFF have also been observed in patients with infectious diseases or cancer 
[14], our findings indicate that serum BAFF is a promising marker for active 
GCA and PMR.
To the best of our knowledge, we are the first to show that serum CXCL9 is 
increased in GCA and PMR, and may provide excellent discrimination between 
newly diagnosed patients and healthy controls. CXCL9 is involved in the migration 
of Th1 cells, which are abundant in inflamed arteries of GCA patients [15–17]. 
Interestingly, we observed that serum levels of CXCL9 remained relatively high 
during remission. CXCL10, a Th1 cell chemoattractant that was increased in PMR 
patients only, also remained high during remission. Although were are not aware 
of prior studies on local expression of CXCL9 and CXCL10 in inflamed tissues 
of GCA and PMR patients, the persistently high serum levels of these Th1 cell 
chemokines during CS-induced remission seem in accordance with the prior 
observation that Th1 responses are resistant to CS-mediated suppression [16].
We here observed decreased serum levels of CCL2 and CCL11 in newly diagnosed 
GCA patients. Although we are not aware of prior studies on CCL11 in GCA, Cid 
et al. [18] have also found decreased serum levels of CCL2 in GCA patients. In 
contrast, Ellingsen et al. [19] reported higher serum levels of CCL2 in GCA and 
PMR patients when compared with healthy controls. However, the healthy controls 
in the latter study were markedly younger than the patients, and CCL2 serum 
levels are known to increase with age [20]. Interestingly, both Cid et al. [18] and 
Ellingsen et al. [19] observed substantial expression of CCL2 in temporal arteries 
of GCA patients. In our study, both CCL2 and CCL11 were markedly increased in 
serum of GCA patients that were in CS-induced remission. Consequently, CCL2 
and CCL11 showed a moderate to strong association with disease activity in GCA. 
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by activated monocytes. To what extent the numbers of activated monocytes are 
altered in the circulation of GCA and PMR remains unknown.
A limitation of our study is the relatively small number of patients that were 
included. As a result, subtle changes in serum markers may have gone unnoticed. 
However, biomarkers should clearly modulate with disease activity in order to 
be useful in daily clinical practice. We here identified markers that would fit this 
profile. In addition, CS treatment may have directly affected serum markers of 
patients in remission. It would therefore be interesting to study serum markers in 
relapsing and non-relapsing patients using similar doses of CS during follow-up.
In conclusion, our study shows that serum levels of BAFF and IL-6 are strongly 
associated with disease activity in GCA and PMR patients. The diagnostic value of 
BAFF and IL-6, both separately and in combination, should be further evaluated 
in larger cohorts of GCA and PMR patients, as well as in patients with infections 
or other inflammatory conditions.
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New Remission New Remission
No. of subjects 13 12 7 12 7
Age, mean (SD) 68 (6) 68 (8) 65 (9) 68 (9) 68 (8)
Sex, no. female (%) 9 (69) 9 (75) 5 (71) 8 (67) 5 (71)
TAB or FDG-PET-CT scan, 
no. positive for LVV (%)
NA 11 (92) 7 (100) NA NA
No. of GCA patients with 
associated PMR (%) 
NA 1 (8) 0 (0) NA NA
ESR, median (range) mm/hr 12 (2-21) 56 (31-116) 13 (7-24) 52 (30-104) 11 (4-16)
CRP, median (range) mg/L 3 43 (13-116) 5 (3-8) 46 (26-162) 3 (3-9)
Prednisolon dose, median 
(range) mg/day
0 0 20 (15-40) 0 15 (7.5-17.5)
Paired samples of GCA/PMR patients in remission were collected 3 months after initiation of prednisolone 
treatment. Nine out of 12 GCA patients showed enhanced glucose uptake by large arteries. None of the patients 
were treated with corticosteroids or disease-modifying antirheumatic drugs at time of blood withdrawal. HC 
= healthy control. No. = number. SD = standard deviation. TAB = temporal artery biopsy. LVV = large vessel 
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Values above the ULOQ were equalized to the ULOQ. Due to linearity between 0 and the LLOQ, values from the 
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Supplemental table 3. Diagnostic accuracy of serum markers in discriminating GCA 
and PMR patients from healthy controls. 
Serum 
marker
































7 92 100 1.00
(1.00-1.00)
8 100 100
Receiver operating characteristic (ROC) curves were constructed for serum markers that were signiﬁcantly 
modulated in both GCA and PMR patients when compared to healthy controls. Areas under the curves (AUC) and 
the optimal cut-oﬀ points with corresponding sensitivity and speciﬁcity were calculated. 
Supplemental table 4. Serum levels of BAFF, CXCL9 and IL-6 in newly-diagnosed GCA 
and PMR patients with ESR values not fulfilling classification criteria for either disease. 
Patient no. Diagnosis ESR* CRP BAFF CXCL9 IL-6
1 GCA 37 36 1367 73 74
2 GCA 31 22 1165 64 8
3 GCA 43 13 1110 704 9
4 GCA 43 21 1019 21 4
5 PMR 30 75 1210 39 34
6 PMR 40 65 1009 51 26
7 PMR 32 27 912 39 82
The optimal cut-oﬀ point for discriminating newly-diagnosed patients from healthy controls for serum BAFF, 
CXCL9 and IL-6 are provided in supplemental table 3. Serum BAFF, CXCL9 and IL-6 values above the respective 
optimal cut-oﬀ points are highlighted in bold. Note that the classiﬁcation criteria for GCA include an ESR ≥ 50 mm/
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Supplemental figure 2. Correlation of serum BAFF and IL-6 with ESR in GCA and 
PMR patients. (A) Plotted correlation between serum BAFF and ESR in GCA and PMR 
patients. (B) Plotted correlation between serum IL-6 and ESR in GCA and PMR patients.
Supplemental figure 1. Venn diagram showing overlap in serum markers that are 
modulated in newly-diagnosed GCA patients and PMR patients versus healthy 
controls. An upward arrow indicates that the marker is increased in patients and a 
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Aging of the immune system may contribute to the development of aging-
associated autoimmune diseases, such as giant cell arteritis, polymyalgia 
rheumatica and rheumatoid arthritis. The aim of this thesis was to identify 
aging-dependent changes of the adaptive immune system that promote 
autoimmunity in the elderly. The first chapters of this thesis describe 
changes of the adaptive immune system occurring during healthy aging 
(chapters 2 to 6). Furthermore, we link maintenance of particular T and 
B cell populations to risk factors for aging-associated autoimmune diseases 
and development of circulating autoantibodies (chapters 2 and 6). The 
final chapters of this thesis focus on changes of the adaptive immune 
system in patients with aging-associated autoimmune diseases, i.e. giant 
cell arteritis and polymyalgia rheumatica (chapters 7 to 9). Furthermore, 
the diagnostic potential of cellular and soluble immune parameters is 






‘Immunological tolerance may be described as a state of indifference or non-
reactivity towards a substance that would normally be expected to excite an 
immunological response’ – Peter Medewar (1960)
Aging of the adaptive immune system
The adaptive immune system, with T and B cells as key representatives, 
is characterized by two fundamental principles: antigen-specificity and the 
development of immunological memory. Whereas B cells recognize soluble 
antigens via their B cell receptors, T cells are equipped with T cell receptors 
(TCR) recognizing antigens presented by major histocompatibility complex (MHC) 
molecules on antigen presenting cells. As every T cell and B cell expresses 
antigen receptors specific to one particular antigen, the ability of the adaptive 
immune system to respond to novel antigens is highly dependent on the size 
and diversity of the antigen receptor repertoires within the naive T and B cell 
pools. Following antigenic recognition, T and B cells become activated and start 
to proliferate. Eventually, part of these cells will differentiate into memory T 
and B cells. These memory cells directly provide the effector functions of the 
adaptive immune system (e.g. cytokine production, cytotoxicity) or differentiate 
even further (i.e. antibody-secreting plasma cells). Development of immunological 
memory allows the adaptive immune system to respond faster and more efficient 
to subsequent challenges with the same antigens. 
Impact of aging on the T cell receptor repertoire
T cells are critical players in the immune system, as CD4+ T cells provide help to 
other immune cells, while CD8+ T cells kill virally-infected host cells and tumour 
cells. A large and diverse naive TCR repertoire is required in order to develop 
T cell immunity against a wide array of microbial and tumour antigens [1]. In 
chapter 4, we combined flow cytometric TCR analysis with economic statistics 
and demonstrated that aging is associated with skewing of the TCR repertoire of 
CD4+ and CD8+ T cells. In addition, we found that naive T cells demonstrate the 
broadest TCR repertoire, whereas progressive repertoire skewing was observed 
among central memory, effector memory and terminally differentiated T cells. 
Furthermore, we confirmed that cytomegalovirus (CMV) skews the TCR repertoire in 
otherwise healthy individuals. Two studies applying TCR sequencing have recently 
shown that the actual number of T cell clones, i.e. TCR diversity, is decreased 
in the elderly [2,3]. One of these studies, however, measured TCR diversity in 
peripheral blood mononuclear cell fractions, rather than within well-defined 
populations of T cells and did not account for CMV serostatus [2]. Therefore, 
the results from this study may have been influenced not only by alterations in 
the cellular composition of the peripheral blood mononuclear cell fractions, but 
also by differences in CMV serostatus between young and old individuals. In 






CD8+ T cell fractions of CMV seronegative individuals [3]. These authors showed 
that clonal diversity within these T cell fractions declines with age, whereas the 
size of distinct clones becomes more unequal (i.e. skewed distribution). Taken 
together, both aging and CMV infection may compromise the diversity of TCR 
repertoire. These findings are relevant, as contractions of the TCR repertoire 
have been associated with poor responses to vaccination, viral infections and 
cancer [4-6]. 
Decline of thymic output with aging
Naive CD4+ and CD8+ T cells show the broadest TCR repertoire (chapter 4). 
The production of these cells, however, dramatically declines with aging [7], 
as adipocytes progressively replace thymic epithelial cells in the thymus [8]. 
This process of thymic involution alters the daily thymic output from 16 million 
cells per day in young subjects to less than 1 million cells per day in aged 
subjects [9]. 
Early T cell precursors are created in the bone marrow. Unlike other immune 
cells, T cells require maturation in another primary lymphoid organ, i.e. the 
thymus [10]. In the thymus, T cells undergo recombination of TCR genes, which 
eventually results in expression of a unique TCR. Eventually, precursor T cells with 
functional TCR proceed their maturation, whereas T cells with non-functioning TCR 
go into apoptosis. This process of positive selection requires the newly-created 
TCR to recognize self-peptide/MHC complexes in the thymus. Subsequently, the 
positively selected, precursor T cells will undergo negative selection to prevent 
the maturation of T cells with high affinity for self-peptide/MHC complexes. 
Eventually, only naive T cells carrying a TCR with low affinity for self-peptide/
MHC complexes are allowed to enter the circulation. As mentioned further on, 
aging-associated disruption of the thymic selection process could be involved 
in the development of aging-associated autoimmune diseases. 
Peripheral maintenance of naive CD4+ T cells in the elderly 
As thymic output declines, homeostatic maintenance of already existing T cells 
is critical to preserve the T cell pool in aged individuals [7]. An estimated 100 
million T cells per day are currently thought to be produced in the periphery 
of healthy adults [9]. Animal studies have shown that peripheral maintenance 
of naive T cells requires low affinity recognition of self-peptide/MHC complexes 
and stimulation by interleukin-7 (IL-7) [11]. An important role for IL-7 in the 
homeostatic maintenance of naive T cells in humans is supported by findings in 
a phase I trial with recombinant IL-7 [12]. In chapter 3, we provide evidence that 
naive CD4+ T cells in elderly humans become responsive to another homeostatic 
cytokine, i.e. interleukin-2 (IL-2). These IL-2 responsive cells are characterized by 
dim expression of the IL-2 receptor D chain (IL-2RD; CD25), and their numbers 
expand substantially with aging. Interestingly, these CD45RA+CD25dim CD4+ 






tissues. These findings are remarkable, as IL-2 was considered important for the 
homeostasis of memory T cells and regulatory T cells only [11]. The enhanced 
sensitivity to IL-2 may be an important adaptation of naive CD4+ T cells to the 
changing cytokine milieu in the elderly, since serum levels of IL-2 remain stable 
with aging, whereas IL-7 levels decline [13-15]. Interestingly, no increase in IL-2 
responsive CD8+ T cells was observed in aged subjects, thereby implying that 
the maintenance of naive CD4+ and CD8+ T cells is differentially regulated. 
Overall, our findings indicate that TCR engagement and homeostatic cytokines 
jointly promote the maintenance of a broad, naive T cell repertoire in the 
elderly (Figure 1).
Both heritable and non-heritable factors appear to influence the maintenance 
of distinct population of T cells. Recently, Brodin et al. showed that inter-individual 
variation in naive CD4+ T cell numbers is mostly explained by heritable factors, 
whereas that of naive CD8+ T cells is mostly determined by non-heritable factors 
[16]. In chapter 2, we identify two heritable factors that may partly explain inter-
individual variation in naive CD4+ T cell numbers. The first factor is gender. In 
accordance with prior studies, we observed that females maintain higher numbers 
of CD4+ T cells than males [17,18]. We demonstrate that this difference results 
from higher numbers of naive CD4+ T cells in women (chapter 2). Hormonal 
effects on the proliferation of naive T cells may contribute to this gender difference 
Figure 1. Schematic representation of naive CD4+ T cell maintenance in humans of 
young and old age. At young age thymic output is substantial and contributes heavily 
to maintenance of the naive CD4+ T cell pool. In contrast, thymic output is limited at 
old age and peripheral maintenance mechanisms become more important to preserve 
the naive CD4+ T cell pool. Interleukin-2 contributes to the homeostasis of naive CD4+ 






[19,20]. The second factor is HLA-DR4 carriage. We observed that naive CD4+ 
T cells were substantially better maintained in HLA-DR4 positive individuals than 
in HLA-DR4 negative individuals. This finding is interesting, as HLA-DR4 positivity 
has been associated with premature aging of the immune system, i.e. shortening 
of telomeres in immune cells [21]. Although the exact relation between HLA-DR4 
positivity and enhanced naive CD4+ T cell maintenance remains to be elucidated, 
it might be possible that HLA-DR4 promotes the homeostatic proliferation of 
naive CD4+ T cells recognizing self-peptides presented by HLA-DR4. This would 
also explain the observation of telomere shortening in CD4+ T cells of HLA-DR4 
positive individuals [21]. 
CMV infection, which represents a non-heritable factor shaping the memory 
T cell compartment of humans, had no effect on the maintenance of naive 
CD8+ T cells (chapter 2). In contrast, latent CMV infection was associated with 
slightly decreased numbers of naive CD4+ T cells in aged individuals but not 
in young individuals. Recently, Wertheimer et al. also observed that CMV only 
affects naive CD4+ T cell numbers in aged subjects [22]. Although the impact 
of CMV on the naive CD4+ T cell compartment of aged subjects may seem 
subtle, a recent study suggests that it is associated with declining CD4+ T cell 
responses to influenza vaccination in the elderly [23]. 
Effect of aging on balance between T helper cells and regulatory 
T cells
Although the concept of ‘inflammaging and anti-inflammaging’ has been mostly 
studied in the context of the innate immune system [24,25], a similar paradigm 
may be present in the memory T cell compartment of humans. The memory 
CD4+ T cell compartment encompasses distinct populations of pro-inflammatory 
T helper (Th) cells. In chapter 5, we show that Th17 cells are decreased in the 
circulation of aged humans, whereas Th1 and Th2 cells are largely retained. In 
contrast, we found that memory regulatory T (Treg) cells are increased in the 
elderly. Consequently, the overall balance between Th cells and memory Treg 
cells shifted towards the latter in healthy, elderly subjects. The balance between 
Th cells and memory Treg cells is important, as these cell populations share 
similar homing receptors (chapter 5) and likely meet in vivo during immune 
responses [26]. 
An aging-associated increase in Treg cells, however, may come at the 
expense of immunity to microbes and tumour cells, as evidenced by animal 
studies [27-29]. One human study has shown that Treg cells compromise anti-
microbial immunity in the skin of aged subjects [30]. We extended this finding 
in chapter 5, by showing that aged subjects with the most pronounced increase 
in Treg cells demonstrated poor responses to influenza vaccination. Thus, the 
balance between pro-inflammatory and anti-inflammatory memory CD4+ T cells 






Aging of the CD8+ T cell compartment
CD8+ T cells are critical for immunity against viruses and cancer. In chapter 2, 
we show that memory CD8+ T cell populations are well-retained with age, 
whereas naive CD8+ T cells dramatically decline. The decline in naive CD8+ 
T cells may result from insufficient adaptation to the changing cytokine milieu, 
as naive CD8+ T cells of elderly subjects are not responsive to IL-2 (chapter 3). 
Alternatively, other studies indicate that naive CD8+ T cells display lower 
thresholds for acquiring a memory phenotype than naive CD4+ T cells, and are 
therefore recruited more extensively towards the memory compartment. Indeed, 
we observed that a single shot of DTaP-IPV vaccine (diphtheria, tetanus, acellular 
pertussis, inactivated poliovirus) results in a more substantial decrease of naive 
CD8+ T cells than naive CD4+ T cells (chapter 4). 
Earlier studies suggested that naive CD8+ T cells decline with aging due 
to progressive occupation of ‘immunological space’ by memory CD8+ T cells. 
This notion, however, was solely based on proportional data. Absolute numbers 
of memory CD8+ T cell populations did not increase with age in our study 
(chapter 2). Our findings are in agreement with those from two recent studies 
[22,31]. As the increased proportions of memory CD8+ T cells in aged subjects 
reflect an absolute decrease in naive CD8+ T cells rather than a true increase of 
memory CD8+ T cells, the original ‘immunological space’ theory seems incorrect. 
It is also difficult to understand how memory CD8+ T cells would compete with 
naive CD8+ T cell for ‘immunological space’, since these cells thrive in different 
niches and respond to different homeostatic cytokines [11]. Instead, it is more 
likely that different clonal specificities of memory CD8+ T cells compete for 
‘immunological space’ amongst each other. As maintenance of T cell memory 
is an active process requiring constant proliferation of short-lived memory cells 
[32], substantial outgrowth of memory CD8+ T cells directed to one pathogen 
could compromise memory to other pathogens. A particular pathogen that is 
associated with substantial clonal expansions is CMV [33]. In accordance with prior 
studies, we observed that CMV infection is associated with a strong increase in 
memory CD8+ T cells and profound skewing of the TCR repertoire among CD8+ 
T cells (chapters 2 and 4). Interestingly, CMV infection compromises long-term 
CD8+ T cell immunity to Epstein-Barr virus [34]. It remains to be elucidated 
whether CMV also affects immunity to other viruses, such as varicella zoster 
virus and influenza virus. 
Impact of aging on cytokine production in B cells
Accumulating evidence indicates that B cells are not only precursors for antibody-
secreting cells, but also actively influence immune responses by providing T cell 
help and secreting cytokines [35]. Previously, B cells have been divided into 
effector B cells producing pro-inflammatory cytokines, such as TNF-D and IL-6, 






[35]. It has been postulated that these B cell populations are truly distinct B cell 
lineages, analogous to Th cells and Treg cells in the CD4+ T cell compartment 
[35]. However, recent data indicate that production of pro-inflammatory and 
anti-inflammatory cytokines represents a transient functional program in B cells 
rather than a true lineage program [36]. 
Only few studies have assessed the impact of aging on the production of 
cytokines by B cells. Frasca et al. have demonstrated that B cells of aged subjects 
contain more mRNA transcripts for TNF-D than those from young subjects [37]. 
Duggal et al. have reported that transitional B cells of aged subjects less efficiently 
differentiate into IL-10 producing B cells than those from young subjects [38]. In 
chapter 6, we studied the actual number of TNF-D and IL-10 producing B cells 
in the circulation of aged humans by shortly stimulating B cells with phorbol 
12-myristate 13-acetate (PMA) and calcium ionophore. We observed that TNF-D 
producing B cells are retained in the circulation of aged subjects, whereas IL-10 
producing B cells are decreased. Recently, Khoder et al. found that transitional B 
cells and unswitched memory B cells show the highest potential to differentiate 
into IL-10 producing cells [39]. Using our direct stimulation approach, we observed 
that IL-10 producing B cells are primarily found among the unswitched, and to 
some extent, switched memory B cell compartments (chapters 6 and 7). TNF-D 
producing cells were observed among all memory B cell populations. Our findings 
therefore suggest that cytokine production in human B cells primarily depends 
on the differentiation stage of these cells. 
Immune-aging and autoimmunity
Aging is associated with development of autoimmunity [25]. Giant cell arteritis 
(GCA) and polymyalgia rheumatica (PMR) solely develop in individuals of 50 years 
and older, whereas rheumatoid arthritis (RA) shows a peak incidence around 
the age of 60 [40]. Furthermore, the prevalence of circulating auto-antibodies 
is increased in otherwise healthy, elderly subjects (chapter 6). Besides cells 
of the innate immune system, CD4+ T cells and B cells are critical players in 
development of aging-associated autoimmunity. 
CD4+ T cell maintenance and autoimmunity 
GCA and RA, and to some extent PMR, are considered CD4+ T cell driven diseases 
[41,42]. Pro-inflammatory T helper cells are increased in these diseases and found 
at local sites of inflammation. The importance of CD4+ T cells in these aging-
associated autoimmune diseases is further suggested by their association with 
the MHC class II molecule, HLA-DR4. This disease association can be attributed 
to amino acids in the peptide binding groove of HLA-DR4, which is involved in 
antigen presentation to CD4+ T cells [43-45]. The importance of CD4+ T cells 
in aging-associated autoimmune disease is intriguing, as these diseases develop 






autoreactive CD4+ T cells are created by the aged thymus, or already early in 
life as are most circulating CD4+ T cells in aged subjects. If autoreactive CD4+ 
T cells are already produced in early life, mechanisms promoting the long-term 
maintenance of these T cells may be critical for development of aging-associated 
autoimmune diseases. This scenario is supported by the observation that the T cell 
pool of aged individuals is maintained via peripheral proliferation (approximately 
100 million cells per day) rather than thymic output (estimated 1 million cells 
per day) [32]. Furthermore, we show in chapter 2 that important risk factors 
for aging-associated autoimmune diseases, i.e. HLA-DR4 positivity and female 
gender, are indeed associated with enhanced maintenance of the naive CD4+ 
T cell repertoire. Although no increase in naive CD4+ T cells was observed in 
GCA and PMR patients (chapter 8), we recently observed increased numbers of 
naive CD4+ T cells in RA patients [46]. Furthermore, patients with seropositive 
arthralgia, who are at risk for development of RA, also tended to show higher 
numbers of circulating, naive CD4+ T cells when compared to healthy controls 
[46]. Animal studies by Busser et al. also support the notion that a diverse 
T cell repertoire is required to develop autoimmunity [47]. Thus, maintenance 
of a broad and diverse T cell repertoire in the elderly may be beneficial for 
immunity against microbes and tumour cells, but at the same time increase 
vulnerability for development of autoimmunity. 
Alternatively, it is possible that aging-associated autoimmunity develops as 
the aged thymus produces highly self-reactive CD4+ T cells due to defects in 
negative selection. Indeed, central tolerance is disturbed in the thymus of aged 
mice, as thymic epithelial cells show less autoimmune regulator (AIRE) gene 
expression with aging [48]. Consequently, the negative selection of autoreactive 
T cells is disturbed in the thymus of aged animals. Although direct translation 
of these findings to humans is difficult, it is likely that the thymus of aged 
humans also exhibits defects in central tolerance, as the gradual replacement 
of thymic epithelial cells by adipocytes will limit the negative selection process 
of precursor T cells. 
B cell maintenance and autoimmunity
Our findings in chapter 6 indicate that the balance between pro-inflammatory 
B cells and anti-inflammatory B cells shifts towards the first. Pro-inflammatory 
B cells producing TNF-D were retained in aged subjects while B cells producing 
IL-10 were decreased. In chapter 7, we show that these pro-inflammatory B 
cells may contribute to the immunopathology of GCA and PMR via enhanced 
production of IL-6. As IL-10 producing B cells may exert regulatory functions, 
their decrease could render aged subjects at risk for autoimmunity. Indeed, we 
observed an association between declining numbers of IL-10 producing B cells 
and development of anti-nuclear antibodies in elderly subjects. However, IL-10 






seropositive for rheumatoid factors. The latter finding is interesting, as IL-10 
is known to promote rheumatoid factor production in B cells of RA patients 
[49]. Furthermore, IL-10 producing B cells are increased in the circulation of RA 
patients [50]. These findings could indicate that IL-10 producing B cells promote 
the development of rheumatoid factors in the elderly. Thus, IL-10 producing B 
cells may have a dual role in aging-associated autoimmunity. 
Giant cell arteritis and polymyalgia rheumatica
Pathogenesis 
GCA and PMR are common, aging-associated autoimmune diseases [40]. GCA 
is a systemic vasculitis affecting large and medium-sized arteries [42], whereas 
PMR is characterized by mild synovitis, enthesitis and bursitis [51]. Interestingly, 
these diseases frequently co-occur [42]. 
The current pathogenic model for GCA is primarily focused on dendritic cells 
(DCs), T cells and monocytes/macrophages [52], as shown in Figure 2. DCs residing 
in the arterial wall are thought to initiate vascular inflammation in GCA patients. 
These resident DCs express distinct Toll-like receptors in different arteries, which 
Figure 2. Schematic model of the pathogenesis of giant cell arteritis. The inflammatory 
response in the arterial wall is initiated when Toll-like receptors (TLRs) on resident dendritic 
cells are activated by TLR ligands. Activated dendritic cells attract Th1 and Th17 cells, 
which cause vascular inflammation. Eventually, monocytes enter the vascular wall and 
differentiate into macrophages promoting vascular inflammation via secretion of cytokines 






could explain why certain vascular beds are affected in some GCA patients but 
spared in others [53]. Vascular DCs may become activated upon exposure to 
microbial (or perhaps endogenous) ligands for Toll-like receptors. Subsequently, 
these DCs attract Th1 and Th17 cells which in turn promote vascular inflammation 
and attract monocytes. Various studies have shown that Th1 cells and Th17 
cells are abundant in the inflamed arteries of GCA patients [54,55]. In addition, 
Th1 and Th17 cells are also expanded in the circulation of GCA patients [54,56]. 
In accordance with the notion that CD4+ T cells are key players in GCA, we 
observed enhanced activation and proliferation of memory CD4+ T cells in GCA 
(chapter 8). Once in the vascular wall, monocytes differentiate into macrophages 
that further promote inflammation and vascular damage [57-59]. In essence, less 
is known about immunopathology of PMR. Samson et al. observed increased 
numbers of Th1 and Th17 cells in the circulation of PMR patients. However, we 
observed little activation and proliferation of circulating CD4+ T cells in PMR 
patients (chapter 8). It might be possible though that activated CD4+ T cells 
migrate extensively from the circulation towards inflamed joints of PMR patients 
(Figure 3). Even less is known about the local inflammatory process in patients 
with PMR. Although Meliconi et al. have shown that T cells and macrophages 
predominate in inflamed synovium of PMR patients [60], the functional properties 
of these infiltrating cells remain to be elucidated. 
Figure 3. Paired peripheral blood and synovial fluid analysis of a polymyalgia 
rheumatica patient. (A) FDG-PET-CT scan showing enhanced glucose uptake around the 
shoulders, hips and knees of the patient. (B) No clear signs of osteoarthritis on knee 
X-ray of the patient. (C) Analysis of CD45RO and CCR7 defined CD4+ T cell subsets in 
peripheral blood and synovial fluid of the patient. CD45RO+CCR7- effector memory CD4+ 






In chapter 7, we extend the pathogenic models for GCA and PMR by showing 
that pro-inflammatory B cells, identified by TNF-D production, are redistributed 
during active disease and return to the circulation upon corticosteroid-induced 
remission. As we confirmed that B cells are not pre-dominant cells in temporal 
arteries of GCA patients [57], and others have observed few B cells in synovial 
tissue of PMR patients [60], we presume that B cells are redistributed towards 
lymphoid organs during active disease. Indeed, profound activation of B cells in 
secondary lymphoid organs of GCA and PMR patients is also suggested by the 
increased prevalence of various types of auto-antibodies in sera of these patients 
[61,62]. Furthermore, enhanced production of IL-6 by pro-inflammatory B cells 
in GCA and PMR patients suggests interaction between B cells and T cells in 
secondary lymphoid organs, as Barr et al. have shown that B cells require T cell 
help in order to produce IL-6 [63]. Interestingly, clinical studies with B cell depletion 
therapy and in vitro experiments have shown that B cells are critical for Th17 cell 
expansion [64]. Therefore, we propose that B cells might promote the expansion 
of Th17 cells in secondary lymphoid organs of GCA and PMR patients (Figure 4). 
Figure 4. Proposed role of B cells in giant cell arteritis and polymyalgia rheumatica. 
Interaction between B cells and T cells in secondary lymphoid tissues promotes IL-6 






Little is known about the role of other immune cells in GCA and PMR. 
Recently, Nadkarni et al. reported that neutrophils may play a role in GCA [65]. 
Indeed, neutrophils are sometimes observed in arterial walls of GCA patients [66]. 
Absence of neutrophils in most temporal artery biopsies might indicate that most 
patients are diagnosed during the chronic phase of GCA, rather than the acute 
phase. In contrast to CD4+ T cells, CD8+ T cells are likely of little importance 
in GCA and PMR. CD8+ T cells are hardly present in inflamed temporal arteries 
of GCA patients [54], and we observed no substantial modulation in circulating 
CD8+ T cells subsets (chapter 8).
Symptoms and diagnosis 
GCA patients with inflammation of cranial arteries may present with typical 
symptoms such as headache, blindness, jaw claudication and stroke [42]. In 
contrast, GCA with involvement of systemic arteries (i.e. aortic arch, subclavian 
arteries) primarily show general symptoms of systemic inflammation, such as 
malaise, weight loss and fever. PMR patients typically present with pain and 
stiffness of shoulders, neck, back and hips [51]. A diagnosis of GCA or PMR is 
suspected, if patients demonstrate symptoms suggestive of GCA or PMR and 
elevations in systemic inflammatory markers.  
The erythrocyte sedimentation rate (ESR) and serum levels of C-reactive 
protein (CRP) are increased in 90% of biopsy-proven GCA patients, whereas 
both these inflammatory markers remain normal in 4% of biopsy-proven patients 
[67]. Notably, during follow-up of corticosteroid treated patients the sensitivity 
of the ESR and CRP are further compromised [68]. Novel biomarkers for active 
GCA and PMR are therefore needed. In chapters 8 and 9 we explored the 
utility of T cells and a large panel of serum markers for diagnosing active GCA 
and PMR. Although we observed significant changes of T cell differentiation 
subsets, activation markers and proliferation markers in GCA and PMR patients, 
these perhaps biologically relevant modulations provided limited diagnostic 
accuracy for diagnosing active GCA and PMR. Among a panel of 26 serum 
markers, all of which related to immune cells involved in the pathogenesis of 
GCA and PMR, we identified serum IL-6 and B cell activating factor (BAFF; also 
termed Blys) as promising markers for active GCA and PMR. Larger longitudinal 
studies are required to determine the diagnostic value of these markers for 
clinical practice. In addition, measuring IL-6 and BAFF in inflammatory control 
subjects, such as patients with infections, will be required to obtain insight 
into their specificity. 
So far, temporal artery biopsy has remained the gold standard test for 
diagnosing GCA. Recent studies have described the spectrum of vascular 
inflammation that might be observed in GCA patients [66]. Imaging techniques, 
i.e. ultrasound and FDG-PET-CT scanning, have become an important tool in 
the diagnostic workup of suspected GCA patients [69]. In clinical trials, imaging 






Ultrasound of temporal, carotid, axillary and subclavian arteries is a promising 
technique to detect active GCA. Ultrasound has a high sensitivity and specificity 
in the hands of experienced investigators [70]. FDG-PET-CT scanning may reveal 
extensive inflammation of large, systemic arteries in 83% of temporal artery 
biopsy-proven GCA patients [71]. Furthermore, FDG-PET-CT scanning is the test 
of choice in patients with systemic symptoms suspected of having inflammation 
of the aorta and its direct branches. In addition, ultrasound and FDG-PET-CT 
scanning may also aid the diagnosis of PMR [51]. It remains an important 
challenge to identify biomarkers separating PMR patients with and without large 
vessel vasculitis. 
Treatment and prognosis
Corticosteroids currently remain the cornerstone of treatment in GCA and 
PMR, despite efforts to identify additional therapies. A meta-analysis of 10 
randomised controlled trials has shown that addition of low dose methotrexate 
to the corticosteroid treatment only slightly reduces relapses and cumulative 
corticosteroid doses in GCA patients [72]. In addition, mixed efficacy of 
methotrexate has been observed in PMR patients [51]. Randomized controlled 
trials have shown that TNF-D blocking therapy is not effective in GCA and PMR 
patients [73,74]. Currently, trials with IL-6 receptor blocking therapy, IL-1R blocking 
therapy and anti-CD80/CD86 therapy are in progress. Our findings in chapter 
7 would also justify studying B cell depletion therapy in GCA and PMR. Most 
PMR patients are withdrawn from corticosteroids after 1-2 years of therapy [51]. 
In contrast, only 50% of GCA patients can be fully tapered after 2 years of 
treatment [75]. Identifying prognostic biomarkers will be important to develop 
therapeutic strategies based on relapse risks. An important long-term complication 
in GCA patients is the development of aortic aneurysms [76]. Further studies 
on the pathogenesis, prevention and clinical management of these aneurysms 
are highly needed. 
Concluding remarks
Development of autoimmunity in the elderly is intriguing, as it implies that aging 
impairs the control of autoreactive immune cells. Understanding the mechanisms 
facilitating the generation and maintenance of autoreactive immune cells may 
therefore greatly help to determine how aging-associated autoimmune diseases 
eventually develop. This thesis describes how certain T and B cell populations 
modulate with age, whereas others remain stable. We show that preservation 
or modulation of certain T and B cell populations in the elderly may be linked 
to risk factors for autoimmunity (i.e. HLA-DR4, female gender) or development 
of autoantibodies (i.e. rheumatoid factors, anti-nuclear antibodies), respectively. 
Furthermore, this thesis offers mechanistic insight into the maintenance of the 






are involved in this process. Studying both young and old healthy individuals 
enabled us to better understand the development of aging-associated autoimmune 
diseases. For instance, we observed that pro-inflammatory B cells are maintained 
until high age and that these B cells likely contribute to the immunopathology of 
GCA and PMR. A key challenge for the future will be to longitudinally study elderly 
individuals before and after onset of aging-associated autoimmune diseases. 
Finally, we describe promising biomarkers for disease activity in GCA and PMR 
patients, which require further validation in large-scale, longitudinal studies. 
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De wereldbevolking vergrijst in een rap tempo, zowel in ontwikkelde 
landen als Nederland, als in minder ontwikkelde landen. Helaas worden 
de extra levensjaren niet altijd doorgebracht in goede gezondheid. 
Veroudering gaat niet zelden gepaard met het ontstaan van infecties, 
kanker en auto-immuunziekten (zoals reuma). Om de toekomstige druk 
op de gezondheidszorg te verminderen is het van groot belang te 
begrijpen hoe deze ouderdoms-gerelateerde ziekten ontstaan en aangepakt 
kunnen worden. 
Nederlandse samenvatting
Veroudering van het afweersysteem in gezonde 






Veroudering van het afweersysteem
Net als andere orgaansystemen in het menselijk lichaam wordt ook het 
afweersysteem beïnvloed door veroudering. In jonge mensen doet het afweersysteem 
doorgaans wat het moet doen: ziekteverwekkers en kankercellen uit de weg 
ruimen. Tegelijkertijd komen auto-immuunziekten weinig voor. Op oude leeftijd 
kan het afweersysteem echter uit balans raken waardoor de beschermende 
functie van het afweersysteem afneemt, terwijl de kans op auto-immuunziekten 
juist toeneemt. Om te begrijpen waarom sommige ouderen auto-immuunziekten 
ontwikkelen, terwijl anderen tot op hoge leeftijd gezond blijven, werd in dit 
proefschrift gekeken hoe het afweersysteem van gezonde ouderen verschilt van 
het afweersysteem van ouderen met auto-immuunziekten. Hierbij werden vooral 
de zogenaamde T-cellen en B-cellen van het afweersysteem bestudeerd. 
Algemene beschrijving van het afweersysteem
Er zijn in het menselijk lichaam vele verschillende soorten afweercellen aanwezig. 
Deze afweercellen hebben allemaal een eigen taak in de verdediging tegen 
ziekteverwekkers en kankercellen. Er zijn twee soorten T-cellen. Zo zijn er helper 
T-cellen, die andere afweercellen aansturen. Deze helper T-cellen zijn als het 
ware de dirigenten van het afweersysteem. Daarnaast zijn er celdodende 
T-cellen die kankercellen en met virus geïnfecteerde cellen vernietigen. Verder 
zijn er B-cellen die antistoffen kunnen maken. Deze antistoffen kunnen aan 
ziekteverwekkers binden, waarna deze opgeruimd worden door andere cellen van 
het afweersysteem. De verschillende afweercellen in het lichaam dienen goed 
met elkaar te communiceren om samen ziekteverwekkers aan te kunnen pakken 
en te elimineren. Deze communicatie tussen afweercellen gebeurt onder andere 
met behulp van signaalstoffen, ook wel cytokines genoemd. 
Zowel de afweercellen zelf als de signaalstoffen die deze cellen aanmaken, 
kunnen een activerende werking of remmende werking hebben op afweerreacties 
in het lichaam. In een goed functionerend afweersysteem zijn activering en 
remming in balans. Een verstoorde balans van het afweersysteem leidt vaak tot 
ziekte. Teveel activiteit van het afweersysteem kan leiden tot ziektes waarbij het 
lichaam zichzelf aanvalt, zoals gebeurt bij een auto-immuun ziekte. Aan de andere 
kant kan te veel onderdrukking van het afweersysteem leiden tot vatbaarheid 
voor infecties of het ontstaan van kanker. 
Specificiteit van het afweersysteem 
Elke T-cel en B-cel beschikt over een unieke herkenningsreceptor waarmee deze 
cellen een specifiek eiwit –of suikerfragment (antigeen) kunnen herkennen. 
Dit kunnen antigenen van ziekteverwekkers zijn, maar ook van kankercellen. In 
principe kan iedere T-cel of B-cel slechts één type ziekteverwekker of kankercel 






kanker beschermd te zijn, is het van groot belang om heel veel verschillende 
T-cellen en B-cellen te hebben met ieder een unieke herkenningsreceptor 
(antigeenreceptor). Het afweersysteem moet dus zo divers mogelijk zijn. In 
sommige gevallen herkennen T-cellen en B-cellen niet alleen antigenen van 
ziekteverwekkers of kankercellen, maar ook van gezonde lichaamscellen. Dit leidt 
er toe dat het afweersysteem deze gezonde cellen gaat aanvallen. Een dergelijk 
afweerreactie wordt ook wel een auto-immuunreactie genoemd en kan leiden 
tot ernstige schade aan weefsels in patiënten met auto-immuunziekten, zoals 
reuscelarteriitis en reumatoïde artritis. 
Geheugenvorming in het afweersysteem
Nieuwgevormde T-cellen en B-cellen kunnen niet gelijk goed reageren op een 
ziekteverwekker of kankercel. Dergelijke cellen, ook wel naïeve T-cellen en B-cellen 
genoemd, hebben eerst nog een vorm van ‘training’ nodig voordat ze efficiënt 
ziekteverwekkers en kankercellen kunnen bestrijden. Deze ‘training’ wordt in gang 
gezet zodra naïeve cellen voor het eerst hun specifieke antigeen herkennen 
met hun antigeenreceptor. Tijdens deze training veranderen de naïeve cellen in 
zogenaamde geheugen T-cellen en B-cellen. Deze geheugencellen zijn in staat 
om snel en efficiënt ziekteverwekkers en kankercellen te bestrijden. Belangrijk 
is dat deze geheugencellen jarenlang kunnen blijven bestaan, waardoor het 
afweersysteem ‘geheugen’ kan opbouwen. Dit principe van geheugenvorming 
wordt ook gebruikt in vaccinaties. 
Veroudering van het afweersysteem en auto-immuniteit 
Behoud van naïeve T-cellen in ouderen
Het behoud van naïeve T-cellen is van groot belang voor gezonde veroudering. 
Mensen met een kleine en weinig diverse naïeve T-celpopulatie zijn slecht 
beschermd tegen nieuwe infecties en kanker. Zoals beschreven in hoofdstuk 4, 
hebben naïeve T-cellen een breed repertoire aan herkenningsreceptoren. Helaas 
krimpt gedurende het ouderen worden het orgaan waarin naïeve T-cellen worden 
aangemaakt: de thymus (oftewel zwezerik). Hierdoor neemt de aanmaak van 
naïeve T-cellen drastisch af. Het is dan ook niet verwonderlijk dat het aantal 
naïeve T-cellen afneemt met het ouder worden. Opvallend is echter dat dit 
voornamelijk geldt voor naïeve celdodende T-cellen en niet voor naïeve helper 
T-cellen (hoofdstuk 2). In hoofdstuk 3 hebben we een verklaring gevonden 
voor dit verschil. Onder invloed van zwakke herkenning van lichaamseigen 
antigenen worden naïeve helper T-cellen in ouderen gevoelig voor signaalstoffen 
(interleukine-2) die de overleving en deling van deze cellen bevorderen. In dit 
geval is de herkenning van lichaamseigen antigenen waarschijnlijk zo zwak, dat 
er geen auto-immuunziekte ontstaat. In tegenstelling tot naïeve helper T-cellen 






kunnen verklaren waarom het aantal naïeve celdodende T-cellen wel sterk afneemt 
met het ouder worden. 
In hoofdstuk 2 hebben we aangetoond dat aangeboren factoren ook van 
invloed zijn op het behoud van naïeve, helper T-cellen. De eerst aangeboren 
factor was geslacht. Oudere vrouwen behielden een grotere populatie aan naïeve, 
helper T-celen dan oudere mannen. Eerdere onderzoeken suggereren dat dit 
te maken kan hebben met een effect van geslachtshormonen op celdeling van 
naïeve T-cellen. Daarnaast vonden we dat de aan -of afwezigheid van HLA-DR4 
gepaard gaat met een grote of respectievelijk kleine populatie naïeve helper 
T-cellen in ouderen. HLA-DR4 behoort tot een groep van moleculen waarmee 
antigenen worden gepresenteerd aan helper T-cellen. Terwijl sommige mensen 
geboren worden met HLA-DR4, beschikken andere mensen over varianten 
zoals HLA-DR1 of HLA-DR6. Interessant is dat aanwezigheid van HLA-DR4 de 
belangrijkste erfelijke risicofactor is voor auto-immuunziekten op oude leeftijd, 
zoals reuscelarteriitis en reumatoïde artritis. Het is niet ondenkbaar dat behoud 
van een grote populatie van naïeve, helper T-cellen in HLA-DR4 dragers niet 
alleen een voordeel is voor het ontwikkelen van goede afweerreacties tegen 
nieuwe ziekteverwekkers of kankercellen, maar uiteindelijk ook de kans verhoogd 
op reacties tegen lichaamseigen antigenen in ouderen. 
Veranderde balans tussen activerende en remmende geheugen 
T-cellen
Na herkenning van hun specifieke antigenen kunnen naïeve, helper T-cellen 
uitgroeien tot geheugen helper T-cellen met vele verschillende functies. Type 1 
helper T-cellen stimuleren afweerreacties tegen virussen. Type 2 helper T-cellen 
bevorderen de afweer tegen parasieten en wormen, terwijl type 17 helper 
T-cellen van belang zijn in de afweer tegen bacteriën en schimmels. Naast 
deze activerende helper T-cellen zijn er echter ook geheugen T-cellen met een 
remmende werking op afweerreacties: regulerende T-cellen. In hoofdstuk 5 
werd onderzocht of de balans tussen de activerende en remmende T-cellen 
verandert gedurende het ouder worden. Dit bleek inderdaad zo te zijn. Het aantal 
regulerende T-cellen nam toe met het ouderen worden, terwijl het aantal type 
1, 2 en 17 helper T-cellen constant bleef of verminderde. In ouderen sloeg de 
balans daardoor meer over naar regulerende T-cellen. De toename van regulerende 
T-cellen kan een belangrijke aanpassing zijn in ouderen, aangezien ouderdom 
gepaard kan gaan met toegenomen ontstekingsactiviteit in het lichaam. Deze 
toegenomen ontsteking zou geremd kunnen worden door een toename van 
regulerende T-cellen. Daarnaast vonden we echter ook dat een té grote toename 
van regulerende T-cellen in ouderen gepaard gaat met een verminderde reactie 
op griepvaccinatie. Of dit ook geldt voor afweerreacties tegen kankercellen is 
nog niet bekend. Desalniettemin is de balans tussen activerende en remmende 






Afgifte signaalstoffen door B-cellen 
B-cellen zijn voorlopers van de cellen die antistoffen maken, de zogenaamde 
plasmacellen. Al langere tijd is bekend dat de B-cellen in ouderen zich minder 
goed kunnen ontwikkelen tot plasmacellen dan in jongeren. De laatste jaren blijkt 
meer en meer dat B-cellen ook nog andere functies hebben. Zo kunnen B-cellen 
afweerreacties beïnvloeden door het afscheiden van activerende signaalstoffen 
(bijv. TNF-D en interleukine-6) of remmende signaalstoffen (bijv. IL-10 en TGF-E). 
Tot nu toe was er weinig bekend in hoeverre veroudering de afgifte van deze 
signaalstoffen door B-cellen beïnvloedt. In hoofdstuk 6 tonen we aan dat het 
aantal B-cellen dat activerende signaalstoffen (TNF-D) kan maken niet verandert 
met het ouder worden. Daarentegen maken B-cellen in ouderen minder remmende 
signaalstoffen (IL-10) dan B-cellen in jongeren. Deze afname van IL-10 producerende 
B-cellen in gezonde ouderen viel samen met de ontwikkeling van bepaalde type 
autoantistoffen, zogenaamde antinucleaire antistoffen. Autoantistoffen zijn 
antistoffen die lichaamseigen structuren herkennen en spelen mogelijk een rol 
in het ontstaan van auto-immuunziekten. Al langer was bekend dat gezonde 
ouderen meer autoantistoffen hebben dan jongeren. Dit geldt niet alleen 
voor antinucleaire antistoffen, maar ook voor een ander type autoantistoffen 
genaamd reumafactoren. Opvallend was echter dat ouderen die reumafactoren 
aanmaakten, juist geen leeftijdsafhankelijke afname van IL-10 producerende B-cellen 
vertoonden in hun bloed. Dit wijst erop dat IL-10 producerende B-cellen mogelijk 
een verschillend effect hebben op het ontstaan van antinucleaire antistoffen en 
reumafactoren in ouderen. 
Reuscelarteriitis en polymyalgia rheumatica
In de laatste hoofdstukken van het proefschrift hebben we T-cellen, B-cellen 
en signaalstoffen bestudeerd in auto-immuunziekten die alleen voorkomen in 
ouderen: reuscelarteriitis (vaatreuma) en polymyalgia rheumatica (spierreuma). 
Symptomen 
Reuscelarteriitis (RCA) is een ziekte waarbij grote en middelgrote slagaders 
in het lichaam ontstoken raken. Door de ontsteking in de slagaders kan de 
doorbloeding naar weefsels, zoals ogen, hersenen, kauwspieren en hoofdhuid 
verminderen. Hierdoor kunnen typerende klachten optreden zoals blindheid, 
ernstige beroertes, pijnlijke kauwspieren tijdens het eten en afsterven van de 
hoofdhuid. Polymyalgia rheumatica (PMR) kan geïsoleerd voorkomen, maar 
ook in combinatie met reuscelarteriitis. Hoewel PMR ook wel spierreuma wordt 
genoemd, betreft het vooral een ontstekingsziekte van gewrichten, slijmbeurzen 
en peesaanhechtingen. Door deze ontstekingen ervaren patiënten hevige pijn en 






Nieuw inzicht in ontstaan van RCA en PMR
Eerdere studies hebben aangetoond dat helper T-cellen een belangrijke rol 
spelen in het ontstaan van RCA en PMR. Met name Th1 en Th17 cellen lijken 
van belang door hun afgifte van activerende en ontstekingsbevorderende 
signaalstoffen. Over de rol van B-cellen in RCA en PMR was tot nu toe weinig 
bekend. In hoofdstuk 7 leveren we het eerste bewijs dat B-cellen bijdragen 
aan het ontstaan van deze ziekten. Tijdens actieve ziekte verdween een groot 
deel van de B-cellen uit het bloed van RCA en PMR patiënten. Zodra de ziekte 
tot rust kwam gedurende behandeling met ontstekingsremmende medicijnen, 
kwamen de B-cellen snel weer terug in het bloed. Opvallend hierbij was dat deze 
terugkerende B-cellen veel interleukine-6 (een activerende signaalstof) konden 
aanmaken in vergelijking met B-cellen in gezonde ouderen. Interessant is dat 
eerdere studies hebben aangetoond dat B-cellen interleukine-6 kunnen maken 
nadat ze gestimuleerd zijn door helper T-cellen, terwijl Th17 cellen zich kunnen 
vermenigvuldigen onder invloed van interleukine-6 producerende B-cellen. Dit 
wijst er dus op dat B-cellen en T-cellen elkaar beïnvloeden in patiënten met RCA 
en PMR en samen bijdragen aan het ontstaan van deze ziekten. 
Nieuwe diagnostische testen
Voor de dagelijkse praktijk is het van belang dat artsen bij hun patiënten kunnen 
vaststellen of de RCA en PMR rustig zijn of dat er sprake is van actieve ziekte. 
Naast het beoordelen of er sprake is van klachten, kunnen artsen momenteel 
twee ontstekingswaarden in het bloed meten: de bloedbezinking en het CRP. 
Een probleem is echter dat deze twee waarden normaal kunnen blijven in 
een (klein) deel van de patiënten ten tijde van actieve ziekte. In hoofdstuk 8 
en 9 zijn we op zoek gegaan naar nieuwe diagnostische testen die gebruikt 
zouden kunnen worden bij het inschatten van de ziekteactiviteit in RCA en PMR 
patiënten. Hoewel T-cellen een belangrijke rol spelen in RCA en PMR, vonden we 
in hoofdstuk 8 dat het meten van T-cel parameters weinig bijdraagt aan het 
bepalen van ziekteactiviteit in RCA en PMR patiënten. Daarentegen vonden we in 
hoofdstuk 9 twee bloedtesten, d.w.z. meting van interleukine-6 en BAFF spiegels 
in het bloed, die mogelijk kunnen helpen bij het vaststellen van ziekteactiviteit. 
De diagnostische waarde van deze veelbelovende bloedtesten zal in grotere 
groepen met RCA en PMR patiënten getest gaan worden. 
Behandeling
Tot dusver worden RCA en PMR patiënten voornamelijk behandeld met het 
ontstekingsremmende middel prednisolon. Hoewel dit middel buitengewoon effectief 
is in het verminderen van de ontsteking en bijbehorende klachten, treden er ook 
vaak bijwerkingen op. Suikerziekte, hoge bloeddruk en botontkalking zijn schadelijke 
effecten die helaas vaak optreden bij gebruik van prednisolon. Hoewel er geen 






ontwikkelingen op dit gebied. Een nieuwe veelbelovende therapie is een middel 
dat de werking van de activerende signaalstof interleukine-6 remt. Dit middel 
is inmiddels getest in kleine groepen RCA en PMR patiënten en zou in theorie 
de ontstekingsbevorderende effecten van de in hoofdstuk 7 beschreven IL-6 
producerende B-cellen kunnen remmen. Daarnaast suggereren de bevindingen 
in hoofdstuk 7 ook dat B-cel remmende therapieën wellicht ook van waarde 
kunnen zijn in RCA en PMR patiënten. 
Conclusies
In dit proefschrift wordt beschreven hoe verschillende typen T-cellen en B-cellen 
beïnvloedt worden door veroudering en kunnen bijdragen aan het ontstaan van 
auto-immuunziekten op oude leeftijd. Het behoud of verlies van bepaalde soorten 
T-cellen en B-cellen lijkt hand in hand te gaan met risicofactoren voor auto-
immuunziekten (HLA-DR4, vrouwelijk geslacht) of ontwikkeling van autoantistoffen 
in ouderen. In dit proefschrift wordt ook een mechanistische verklaring gegeven 
voor de waarneming dat naïeve CD4+ T cellen behouden blijven in ouderen, 
terwijl de aanmaak van deze cellen al stokt op jonge leeftijd. Het onderzoek 
naar het afweersysteem in gezonde jongeren en ouderen stelde ons ook in 
staat om de ontwikkeling van auto-immuunziekten op hoge leeftijd te begrijpen. 
Zo bleken B-cellen die activerende signaalstoffen maken, behouden te blijven 
tot op hoge leeftijd. Met name deze ontstekingsbevorderende B-cellen leken 
bij te dragen aan het ontstaan van RCA en PMR in ouderen. Daarom zouden 
deze B-cellen een nieuw aangrijpingspunt voor behandeling kunnen vormen in 
patiënten met RCA en PMR. Tenslotte beschrijven we veelbelovende diagnostische 
testen waarmee actieve ziekte in RCA en PMR patiënten opgespoord zou kunnen 
worden. Een uitdaging voor de toekomst zal zijn om het afweersysteem van 
ouderen te bestuderen voordat deze auto-immuunziekten zich ontwikkelen. Dit 
zal uiteindelijk de weg openen naar vroegtijdig ingrijpen waardoor deze ziekten 
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